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ABSTRACT 
 
 
Injury to the spinal cord is marked by the disruption of ascending and descending axonal 
pathways, interrupting the communication between the brain and other parts of the body. The 
primary lesion, which essentially leads to cell death, is followed by a cascade of secondary events 
that include inflammation, activation of myelin associated-inhibitory pathways, and glutamate 
excitotoxicity. In this inhibitory environment regeneration fails to occur and the process ends up 
with the formation of a cavity delimited by a glial scar. Developing a therapeutic strategy to 
address a spinal cord lesion demands a multi-target approach that can counteract the inhibitory 
signalling process that is triggered upon injury and also bridge the interrupted connectivity. 
The main aim of this thesis was to design a scaffold that combines multiple cues to assist and 
enhance nerve regeneration in the context of the spinal cord, providing physical support, guidance 
and the delivery of therapeutic molecules constituting, ultimately, a permissive substrate for 
axonal regrowth. 
In the present work, poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] was applied as 
starting material for building up such a structure. The preparation of fibrous structures based on 
this polymer by electrospinning is described. Taking into consideration that microglia is in the front 
line of the central nervous system (CNS) response to injury, we investigated the effect of the 
fibrous topography on the behaviour of primary microglia, in comparison to P(TMC-CL) solvent 
cast films. Microglia was found to organize their cytoskeleton according to the topography of the 
substrate, being an elongated shape favoured when cells are cultured on P(TMC-CL) fibres, 
where an increased release of the pro-inflammatory cytokine tumour necrosis factor-α (TNFα) was 
also observed. This study highlighted the importance of specifically address microglia response in 
the context of tissue engineering for CNS regeneration. Moreover, we showed that microglia 
cultured on P(TMC-CL) surfaces can actively contribute for myelin phagocytosis and conditioned 
medium from microglia cultured on these substrates does not trigger astrogliosis markers in 
astrocytes. These results suggest that P(TMC-CL) scaffolds can actively contribute to modulate 
microglia towards a pro-regenerative phenotype.  
An alternative to modulate cellular response at the lesion site is to combine the scaffolds with the 
delivery of an anti-inflammatory drug. We tested the incorporation of ibuprofen (a non-steroidal 
anti-inflammatory drug) in P(TMC-CL) fibres by single solution electrospinning. Ibuprofen-loaded 
fibres were successfully prepared and, by changing the solvent composition, we showed that 
fibres of different diameter could be obtained. When the loaded fibres were incubated in 
physiological medium in sink conditions, the drug was released in 24 hrs. The secretion of 
prostaglandin E2 by human monocyte-derived macrophages was found to be reduced when cells 
were in the presence of ibuprofen-loaded fibres, confirming the bioactivity of the released drug. 
xiv 
Apart from its anti-inflammatory properties, the selection of ibuprofen to load on P(TMC-CL) 
scaffolds relied also on the recent evidence that this drug can inhibit Ras homolog gene family, 
member A (RhoA) activation, a convergence effector to several inhibitory pathways triggered after 
a lesion in the CNS. Envisaging an application in vivo, in a spinal cord injury scenario, a bilayer 
P(TMC-CL) scaffold was prepared. A solvent cast film was used as outer layer and preferentially 
longitudinally aligned fibres composed the inner layer. Both layers were loaded with ibuprofen. It 
was demonstrated that the drug released from the scaffolds limits RhoA activation in ND7/23 cells 
(a neuronal cell line) when these are stimulated with lysophosphatidic acid. Additionally, the 
scaffolds were tested in vivo, in a dorsal hemisection model of spinal cord injury. The preliminary 
results showed that the scaffold can be implanted at the lesion site and the implantation of 
ibuprofen-loaded scaffolds had no impact on animal survival. 
An alternative to provide scaffolds with biochemical cues is to combine gene therapy approaches 
that can assure the in situ expression of proteins of interest. Chitosan has been under 
investigation as a promising alternative non-viral gene delivery vector due to its biodegradability 
and biocompatibility. In order to understand how chitosan-mediated gene delivery can be 
modulated, an in vitro study on transfection, intracellular trafficking and degradation was firstly 
conducted. Chitosan-based vectors were found to be able to mediate a long-term gene expression 
that can be tuned by adjusting the polymer degradation rate. In order to translate this knowledge 
into a 3D scaffold, chitosan-based nanoparticles were mixed with P(TMC-CL) solutions prior to 
electrospinning. Following this approach it was not possible to obtain a homogeneous mixture that 
one would be able to electrospun. Due to the better solubility and nanoparticle stability of 
trimethylated-chitosan, the use of quaternized chitosan was explored. By freeze-drying and 
subsequent resuspension in organic solvents, the nanoparticles based on trimethyl-chitosan were 
electrospun along with a P(TMC-CL) solution. In this manner, fibres with a homogeneous 
morphology were prepared opening new avenues for the design of a scaffold combining 
electrospun fibres and nanoparticle-based gene delivery. 
 
Overall, the results presented in this thesis point out P(TMC-CL)-based scaffolds as a promising 
platform for building up a multi-target strategy, combining different cues that, as a whole, can 
contribute for nerve regeneration after SCI. 
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RESUMO 
 
 
Uma lesão na medula espinhal caracteriza-se pela interrupção de tratos axonais ascendentes e 
descendentes, suspendendo a comunicação entre o cérebro e as outras partes do corpo. A lesão 
primária, que leva essencialmente a morte celular, é seguida por uma cascata de eventos 
secundários que incluem inflamação, ativação de mecanismos inibidores associados à mielina e 
excitotoxicidade mediada pelo glutamato. Neste ambiente inibitório, a regeneração falha e o 
processo culmina com a formação de uma cavidade delimitada por uma cicatriz glial. Para 
desenvolver uma estratégia adequada ao tratamento de uma lesão na medula espinhal é 
necessária uma terapêutica multi-direcionada que consiga contrariar o processo inibitório ativado 
pela lesão, ao mesmo tempo que reestabelece a conectividade interrompida. 
O objetivo do trabalho desta tese foi desenvolver uma estrutura tridimensional (3D) que 
combinasse múltiplos sinais com vista a assegurar e favorecer a regeneração nervosa no 
contexto da medula espinhal, fornecendo suporte físico, orientação espacial e entrega de 
moléculas terapêuticas, e constituindo, como um todo, um substrato permissivo para o 
crescimento axonal. 
Neste trabalho, o poli(carbonato de trimetileno-co-ε-caprolactona) [P(TMC-CL)] foi usado como 
material inicial para desenvolver essa estrutura, e a técnica de electrospinning foi utilizada para o 
processar sobre a forma de micro/nanofibras. Tendo em consideração que a microglia está na 
linha da frente da resposta do sistema nervoso central (CNS) à injúria, foi investigado o efeito da 
topografia de substratos fibrosos no comportamento de culturas primárias de microglia, em 
comparação com filmes de P(TMC-CL) obtidos por evaporação do solvente. Observou-se que a 
microglia organiza o seu citoesqueleto de acordo com a topografia do substrato, sendo a forma 
alongada favorecida quando as células são cultivadas sobre fibras de P(TMC-CL), onde se 
verifica também um aumento da libertação de uma citoquina pro-inflamatória, o fator de necrose 
tumoral-α (TNFα). Este estudo realça a importância de estudar especificamente a resposta da 
microglia no contexto da engenharia de tecidos para o CNS. Adicionalmente, foi demonstrado 
que microglia cultivada sobre superfícies de P(TMC-CL) pode contribuir ativamente para a 
fagocitose da mielina e que os meios condicionados de microglia cultivada nestes substratos não 
induzem um aumento de marcadores de astrogliose em astrócitos. Estes resultados sugerem que 
as estruturas 3D à base de P(TMC-CL) podem contribuir ativamente para modular a reposta da 
microglia, direcionando-a para um fenótipo de pro-regeneração.    
Uma alternativa para modular a resposta celular no local da lesão é combinar as estruturas 3D 
com a libertação de um fármaco anti-inflamatório. Neste trabalho, foi testada a incorporação de 
ibuprofeno (um fármaco anti-inflamatório não esteroide) nas fibras de P(TMC-CL) por 
electrospinning a partir de uma solução única. Fibras com diferentes diâmetros podem ser 
xvi 
obtidas, ajustando a composição do solvente. Quando as fibras com ibuprofeno são incubadas 
em meio fisiológico (condições “sink”), o fármaco é libertado em 24 hrs. A secreção de 
prostaglandina E2 mediada por macrófagos derivados de monócitos humanos diminuiu quando as 
células foram incubadas com fibras de P(TMC-CL) contendo ibuprofeno, confirmando a atividade 
biológica do fármaco. 
Além das suas propriedades anti-inflamatórias, foi recentemente descrito que o iburpofeno está 
envolvido na inibição da via de sinalização do RhoA (Ras homolog gene family, member A), uma 
molécula de convergência de vários mecanismos inibitórios despoletados pela lesão medular. 
Com vista a uma aplicação in vivo, num cenário de lesão, foi criada uma estrutura tridimensional 
de P(TMC-CL) com ibuprofeno constituída por duas camadas. Um filme preparado por 
evaporação do solvente foi usado para constituir a camada externa, sendo a camada interna 
composta por fibras longitudinalmente alinhadas. Demonstrou-se que o fármaco libertado da 
estrutura 3D de P(TMC-CL) reduz a ativação do RhoA em células neuronais (ND7/23) quando 
estas são estimuladas com ácido lisofosfatídico. As estruturas 3D foram testadas in vivo num 
modelo de lesão da medula espinhal, a hemi-secção dorsal sendo que foi demonstrado que a 
estrutura 3D desenvolvida pode ser implantada no local da lesão e que a implantação destas 
estruturas com ibuprofeno não afeta a sobrevivência dos animais operados.  
Uma forma para prover as estruturas 3D com sinais bioquímicos é combinar estratégias de 
terapia génica que possam garantir uma expressão prolongada de proteínas de interesse no local 
da lesão da medula espinhal. O quitosano tem sido investigado como uma alternativa promissora 
na mediação não-viral de genes devido à sua biodegradabilidade e biocompatibilidade. De forma 
a compreender como é que sistemas de entrega de genes à base de nanopartículas de quitosano 
podem ser modulados, foi elaborado um estudo in vitro abordando a transfeção, o tráfego 
intracelular e a degradação. Foi detetada uma expressão prologada do gene de interesse, sendo 
que esta pode ser modulada ajustando a taxa de degradação do quitosano. Com o objetivo de 
traduzir esse conhecimento para uma estrutura 3D, foi testada a possibilidade de incorporar as 
nanopartículas de quitosano nas fibras através da sua mistura com soluções de P(TMC-CL) antes 
do processo electrospinning. No entanto, este método não permitiu obter uma mistura 
homogénea nem a formação de fibras. A aplicabilidade de nanopartículas à base de quitosano 
trimetilado foi alternativamente investigada, uma vez que estas apresentam maior solubilidade e 
estabilidade. Após liofilização e posterior re-suspensão em solventes orgânicos, as 
nanopartículas de quitosano quaternizado foram processadas por electrospinning juntamente 
com uma solução de P(TMC-CL). Desta forma foram preparadas fibras de morfologia 
homogénea, abrindo caminho para o desenvolvimento de uma estrutura 3D que combine fibras 
obtidas por electrospinning e sistemas de entrega de genes baseados em nanopartículas. 
 
Em resumo, os resultados apresentados nesta tese apontam as estruturas tridimensionais 
baseadas em P(TMC-CL) como promissoras para o desenvolvimento de estratégias multi-
direcionadas, combinando diferentes sinais que, como um todo, podem contribuir para a 
regeneração nervosa depois de uma lesão na medula espinhal. 
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It is estimated that lesions in the spinal cord affect around 2.5 million people worldwide, being the 
annual incidence in the order of 22 per million [1, 2]. Spinal cord injury (SCI) is characterized by 
the loss of sensorial, motor and involuntary functions below the site of lesion, resulting in severe 
psychological, social and economic burdens for patients [3]. Furthermore, the majority of SCI 
patients require lifelong medical care and physical therapy, representing high costs for the health 
systems, particularly because SCI affects more frequently individuals before the age of 40 [3]. 
Notwithstanding the need, currently there is no treatment for SCI.  
The development of therapies for this multi-faced condition resulted to be a tremendous 
challenge. SCI is frequently caused by a mechanical impact on the spinal cord that leads to 
cellular damage and death. However, the injury is not limited to the loss of cells. The physical 
support for axonal growth is also interrupted and a number of inhibitory mechanisms are triggered, 
turning the lesion site into a hostile environment for axonal regrowth. These mechanisms 
constitute the secondary injury and include the recruitment of inflammatory cells, cytokine release, 
activation of myelin-associated inhibitory pathways and release of inhibitory molecules. This 
process ends up with the formation of a glial scar that constitutes, ultimately, a physical barrier 
thwarting the re-wiring of the central nervous system (CNS) [4].  
 
The ultimate goal of the work described in this thesis is to design a scaffold that gathers physical 
and chemical cues, providing a permissive substrate for nerve regeneration after a lesion in the 
spinal cord. 
 
Significant progress was achieved in the last few years in the understanding of the mechanisms 
associated with the secondary injury and identifying potential targets for new therapies. This 
knowledge constitutes the basis for a number of strategies presently being investigated for 
promoting regeneration in the aftermath of SCI. These are reviewed in Chapter II, giving particular 
emphasis to the most recent innovations on biomaterials-based regenerative therapies for SCI.  
There is agreement in the current field supporting the need of a multi-target approach in order to 
create a therapeutic strategy that can support regeneration after SCI [5]. This should assure 
physical support for axonal re-growth, and also physical/chemical signals that can counteract the 
inhibitory environment. Taking this into account, the work presented in this thesis focused on the 
design of a scaffold that provides physical cues to support and guide axonal regrowth, while 
modulating cells present at the lesion site into a pro-regenerative activity and serving as platform 
for the in situ delivery of molecules known to contribute to the nerve regeneration process. 
Previous studies using poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] showed that 
this synthetic copolymer owns appropriate properties to serve as nerve conduit [6, 7], being able 
to support peripheral nerve regeneration in vivo [8]. In the context of the CNS, P(TMC-CL) showed 
to stimulate cortical neuron polarization and promote axonal elongation. Moreover, even in the 
presence of myelin, cortical neurons cultured on P(TMC-CL) films were found to extend more 
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neurites, showing P(TMC-CL)'s ability to tame myelin inhibition in a CNS lesion scenario [9]. 
These results motivated the use of this polymer as the starting material for building up a scaffold 
to promote regeneration at the spinal cord. 
Electrospinning has been attracting an ample interest in the tissue-engineering field for the 
preparation of scaffolds, as fibrous structures can be obtained at the nano/micrometer scale, 
emulating the structure of the extracellular matrix [10, 11]. The topographic signals provided by 
electrospun fibres have previously showed to promote axonal guidance and growth [12-14] and 
stem cell differentiation into the neuronal lineage [15, 16], as well as to modulate astrocytic cell 
phenotype [17].  
In view of an application in the CNS regeneration, we investigated the impact of the topography of 
P(TMC-CL) fibres on microglia cells. Microglia are the immune cells from the CNS and they are in 
the front line of the response to an injury. Even so, studies concerning microglia-biomaterials 
interaction are still very limited, being the effect of electrospun fibres on microglia behaviour 
described for the first time in this thesis. In the Chapter III, it is reported the effect of P(TMC-CL) 
fibrous surface on primary microglia cells in comparison to solvent cast (flat) films. This study was 
conducted in view of the impact of topography on key processes that occur at the lesion site and 
involving microglia, namely assessing myelin phagocytosis by microglia and evaluating the effect 
of these cells on astrogliosis. This study shows that P(TMC-CL) surfaces can favour the activation 
of a pro-regenerative program on microglia, putting forward these structures for an application in a 
SCI scenario.  
To combine topographic cues with the delivery of a molecule with a role on the nerve regeneration 
process, we pursued to the preparation of P(TMC-CL) electrospun fibres loaded with ibuprofen, a 
non-steroidal anti-inflammatory drug used worldwide. The anti-inflammatory effect of ibuprofen 
has been attributed to the inhibition of the cyclooxygenases (COX), enzymes responsible for the 
formation of prostaglandins, associated with fever and pain [18, 19]. Recently, it has been 
highlighted that ibuprofen can also inhibit RhoA [20, 21]. RhoA is a small GTPase protein, and its 
activation has been associated with regeneration failure after SCI, since it leads to actin 
depolymerisation and growth cone collapse, hindering axonal outgrowth [22, 23].  
In Chapter IV, the incorporation of ibuprofen on P(TMC-CL) fibres during the electrospinning 
process is described. The preparation of the fibres was optimized and we show that the drug 
released from the fibres was able to reduce the amount of prostaglandin E2 produced by human 
monocyte-derived macrophages. This result indicates that ibuprofen remains bioactive and the 
preparation of P(TMC-CL) fibres with anti-inflammatory properties was achieved. 
As the use of ibuprofen-loaded P(TMC-CL) fibres envisaged a double target strategy, the 
subsequent step was to evaluate the impact of ibuprofen released from the fibres on the RhoA 
pathway. A bilayer ibuprofen-loaded scaffold has been developed foreseeing its implantation in a 
SCI animal model. The scaffold was composed by an outer layer based on a P(TMC-CL) solvent 
cast film, and, taking advantage of the electrospinning technique, the inner layer was made up of 
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longitudinally aligned fibres. In Chapter V it is reported the characterization of the bilayer scaffolds, 
loaded- or non-loaded with ibuprofen, as well as their performance in vitro and in vivo. It is 
demonstrated that the released ibuprofen can limit RhoA activation in a neuronal cell line, 
confirming the drug bioactivity. In this chapter the preliminary results of the in vivo assessment 
conducted with the developed scaffolds in a dorsal hemisection SCI animal model (rat) is also 
reported. So far, no harmful effect on animal survival was observed, but further analysis is needed 
to evaluate whether this strategy is influencing the RhoA pathway. 
To combine gene delivery with the proposed drug loaded scaffolds would constitute a step forward 
in the design of a multiple strategy to address the challenge of promoting CNS regeneration. 
Implantable devices have previously been explored as vehicles of nanoparticles carrying genes 
encoding for proteins with a therapeutic effect in the context of a SCI [24, 25]. Chitosan is a 
natural polymer previously investigated to serve as gene carrier. Due to its biocompatibility and 
biodegradability the polymer holds great promise in view of an application on tissue regeneration 
[26, 27]. Our group have been focused on designing new strategies to improve the vector 
efficiency as gene carrier [28, 29]. Here we report a detailed mechanistic study on chitosan-based 
nanoparticles mediated DNA delivery. The results presented in Chapter VI suggest that the 
expression of a delivered gene can be modulated by tuning the degradation rate of chitosan. To 
apply this knowledge into a 3D approach, we tested the incorporation of these nanoparticles into 
P(TMC-CL) fibres. However, the combination of chitosan nanoparticles and P(TMC-CL) solutions 
lead to the formation of large precipitates, impeding the preparation of electrospun fibres 
containing these nanoparticles. As alternative the use of nanoparticles based on trimethylated 
chitosan was investigated, and it is described in Chapter VI. Quaternization is known to increase 
chitosan solubility and nanoparticle stability [30]. Based on this knowledge we hypothesized that a 
more homogeneous electrospun solution may be obtained if the nanoparticle stability is improved. 
The preliminary results show that the formation of fibres can be achieved, suggesting that this 
approach can be applied in the design of a multi-target strategy for SCI regeneration.     
 
In Chapter VII the overall results presented in this thesis are analyzed considering each chapter 
and integrating the whole results. The more striking findings are highlighted and new avenues to 
pursue in this line of research are proposed.  
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1. Spinal cord injury – overview   
Spinal cord injury (SCI) can be caused by compression, contusion, penetration or maceration of 
the spinal cord tissue, being very heterogeneous in cause as well as in the outcome. A lesion 
inflicted to the spinal cord leads to the interruption of motor and sensory neuronal pathways, 
resulting in the loss of motor, sensory and involuntary functions below the point of injury. 
Depending on the severity and location of trauma, SCI can be complete or incomplete, leading to 
different degrees of functional impairment. The primary injury triggers widespread cell death, 
including neurons, oligodendrocytes, astrocytes or precursor cells. In parallel, edema, ischemia 
and haemorrhage take place, resulting in the enlargement of the damaged area and creating, 
ultimately, a fluid-filled cyst (see Figure 1). Subsequently, in the sub-acute phase of SCI, a 
cascade of events that constitute the secondary damage begins with oligodendrocyte apoptosis 
and loss of myelin, glutamate excitotoxicity, increase of free radicals and inflammation. These 
secondary injury results in a protracted period of tissue destruction. In the chronic phase, a glial 
scar is formed and the lesion site turn out to be a particularly hostile scenery for axonal 
regeneration (see [1-4] for a review). 
 
Figure 1. Scheme of spinal cord lesion site. Reproduced with permission from [5]; Macmillan Publishers Ltd., 
copyright 2006. 
 
For a long time, it was considered that neurons from the central nervous system (CNS) could not 
regenerate and the field of research on regeneration on the follow up of a SCI was quiescent.  
About three decades ago the first indications that regeneration can occur in the CNS was obtained 
using peripheral nerve grafts in the CNS [6, 7]. More recently, it was demonstrated that, although 
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for short distances, axonal sprouting occurs after lesion, contributing to compensatory recovery 
and to the formation of new pathways that bypass the lesion [8]. Despite this regenerative 
potential, the fact is that after SCI the interrupted neuronal connections are not rewired and the 
impaired functions cannot be completely restored. This failure is mainly attributed to the 
establishment of an inhibitory environment for regeneration. Several inhibitory pathways are 
activated and the formation of a cavity withdraws the physical support for regrowth. Additionally, 
the formation of a scar tissue constitutes a real physical hurdle for regeneration (see [9-11] for a 
revision on this subject).  
The last thirty years of research brought important findings both at the cellular and molecular level 
on the mechanisms underlying regrowth inhibition after SCI. Although these knowledge still did not 
succeed being translated into the clinical setting, it formed a solid ground for the current view in 
the field that considers that to address such a multi-faced inhibitory environment a combination of 
therapies is required [4]. 
 
2. Inhibitory signals 
After a lesion in the spinal cord, several pathways are activated creating an inhibitory environment 
for regeneration. These include: the inflammatory response, the formation of the glial scar and the 
activation of myelin-associated inhibitory signals, which are described below in more detail. 
 
2.1. Inflammation  
The increase of the blood brain barrier (BBB) permeability is taken as a prelude to the 
inflammatory response elicited by CNS trauma [12]. The breach caused by the mechanical impact 
is maximum in the first day after the lesion and it rapidly declines thereafter [13]. The mechanical 
forces contribute to the initial disruption of the BBB, but the trauma also activates endothelial and 
glial cells, promoting the release of vasoactive molecules – oxygen species, kinins, nitric oxide, 
and histamines – that influence endothelial function and enhance the BBB permeability. Moreover, 
pro-inflammatory cytokines like tumour necrosis factor-α (TNFα) and interleukin-1β (IL-1β) are up-
regulated upon injury, contributing to further increase vascular permeability [13]. These vasoactive 
molecules produced at the site of injury can also lead to toxic effects. Nitric oxide and oxygen 
species are known to produce free radicals that are involved in the oxidation of nucleic acids or 
lipids, as well as in the impairment of the mitochondrial function and consequent energy depletion 
and cell death [14]. These events result in the enlargement of the injured area and exacerbation of 
damage and neurotoxicity. 
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Figure 2. Temporal correlation between functional recovery, secondary neurodegenerative events and 
inflammatory cascades, in SCI rodents. (A) Anatomical and functional outcomes. (B) Activation of resident 
microglia and accumulation of leukocytes. Dashed lines depict data from SCI mice whereas solid curves 
indicate data from SCI rats. Solid curves before these break points are from both species. (C) Expression of 
pro-inflammatory cytokines and reactive oxygen species (ROS). (D) Expression of neurotrophic cytokines. 
(E) Blood–brain barrier permeability to α-aminoisobutyric acid (AIB; 104 Da), horseradish peroxidase (HRP; 
44000 Da) and luciferase (61000 Da). Values on the vertical axis represent relative changes and are not to 
scale. Reproduced from [12], Copyright (2008), with permission from Elsevier. 
 
At the cellular level, when a lesion in the spinal cord occurs, the first cells to arrive to the lesion 
site are the microglia – the resident immune cells of the CNS – followed by infiltrating 
macrophages [15] (see Figure 2). Microglia exist in the CNS in a quiescent state and, upon injury, 
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are activated in a graded fashion. The first stage of this process is characterized by cell 
proliferation, migration as well as morphological, immunophenotypical and functional changes. 
Only in a second stage microglia transform into phagocytic cells, also known as microglia-derived 
brain macrophages [16]. Then, microglia cells start to express specific cell surface molecules and 
releasing cytokines (IL-1β and TNFα) and chemokines (leucotrienes and prostaglandins) [17]. At 
this stage of activation, resident microglia cells and infiltrated blood-born macrophages express 
similar immunohistochemical profile. This fact make difficult to discriminate the role of each cell 
type in the inflammatory response after SCI [17].  
Other immune cells will also populate the site of injury. Neutrophils are rapidly recruited upon 
injury and, as phagocytic cells, produce cytokines, oxygen reactive species and neutrophil 
proteases, augmenting vascular damage [18]. T-lymphocytes are also recruited after injury playing 
a major role recruiting other cells and producing a number of cytokines [19].   
The described inflammatory reaction occurs within days after injury. However, high levels of pro-
inflammatory cytokines, such as IL-2 and IL-6, are detected in patients with chronic SCI, pointing 
to the existence of a continuous and prolonged inflammatory process [20]. 
 
2.2. The glial scar  
The glial scar formed in the site of injury is mainly an astrocytic tissue consisting of 
hyperfilamentous astrocytes, with processes tightly packed, with many gap and tight junctions and 
limited extracellular space [15]. The scar is formed to isolate the injury, reseal the BBB and 
prevent the damage of the spared tissue and the spreading of excitotoxicity and cytotoxic 
molecules [21]. The glial scar constitutes primarily a mechanical barrier for axonal regeneration, 
but it is also a source of chemical inhibitors for axonal re-growth. Reactive astrocytes in the scar 
can produce a variety of inhibitory molecules, like tenascin [22], semaphorin-3 [23], ephrin B2 [24] 
and chondroitin sulfate proteoglycans (CSPGs) [25].  
CSPGs are mainly produced by astrocytes and constitute a large family of sulphated 
glycosaminoglycans including aggrecan, brevican, versican and NG2 [26]. CSPGs are the major 
component of the extracellular matrix in the CNS and play an important role in determining the 
functional responses of cells to their environment during development, cell migration, 
differentiation, maturation and survival, and tissue homeostasis [27]. During maturation of the 
nervous system, the CSPGs are involved in the “lock in” of synaptic connections, avoiding 
disturbances on the functional connectivity [26]. In an injury scenario, the regeneration failure has 
been correlated with axons contacting scar tissue rich in CSPGs [25], being axonal re-growth 
stopped where CSPGs are deposited [15]. Therefore, CSPGs are considered the major inhibitory 
species associated with the glial scar [25]. Nevertheless, the mechanism by which these 
molecules exert their inhibitory action is not completely understood. Some authors proposed that 
the action of CSPGs is mechanical, hindering axonal growth by masking adhesion molecules in 
the matrix, like laminin or fibronectin [28] and inactivating integrins [29]. Alternatively, other studies 
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associated CSPGs with specific intracellular pathways. It is accepted that CSPGs can inhibit axon 
outgrowth by activating Rho signalling and its downstream effector the Rho-associated kinase 
(ROCK) via the epidermal growth factor receptor (EGFR) (see Figure 3) [30, 31]. Significant 
findings have been published in the recent years describing this pathway that is also activated by 
myelin-associated inhibitors, as will be further discussed in the next section. 
 
 
Figure 3. Glial inhibitors and intracellular signalling mechanisms. Dashed arrows show still ambiguous 
pathways. Adapted with permission from [5]; Macmillan Publishers Ltd., copyright 2006. 
 
2.3. Myelin-associated inhibition 
Observations by Ramón y Cajal suggested that white matter can hinder regeneration of the CNS 
(reviewed in [32]). These early findings were confirmed more recently and it is nowadays 
established that myelin and oligodendrocytes are not permissive substrates for axonal growth [33, 
34] and many blockers of regeneration in the CNS are exposed when myelin is damaged [32]. 
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After a lesion, oligodendrocyte cell death results in axon demyelinization and neuron 
degeneration, known as Wallerian degeneration. As in the CNS the myelin debris clearance by 
microglia/macrophages is very slow, it accumulates in the site of injury [15]. Some authors 
suggested that an inefficient ability to remove the myelin debris is one reason for the limited 
regeneration of the CNS [1]. This theory is based on the observation that in the peripheral nervous 
system, where regeneration is successful, the first event occurring upon injury is the rapid 
clearance of the myelin debris by macrophages [35].  
Molecules already identified as inhibitors for axon growth that are present in myelin include Nogo-
A, myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein (OMgp). 
Nogo-A, the first myelin-associated inhibitor described [36], is a membrane protein (~200 kDa) 
particularly predominant in oligodendrocytes. Nogo belongs to the reticulon family of proteins, 
which are mainly associated with the endoplasmic reticulum. Three isoforms were already 
identified – Nogo A, B, and C. The function of Nogo-B and Nogo-C in the CNS is still not fully 
described [37]. Nogo-B was found to be increased in hippocampus of rat receiving amyloid-β 
infusion and to be involved in the activation of microglia [38]. Although further research is needed, 
these first results suggest that Nogo isoforms, other than Nogo-A, can also be involved in the 
nerve regeneration process. Two inhibitory domains were identified in Nogo-A: a 66 amino acid 
sequence (Nogo-66), which is common to the three isoforms, and the unique amino terminal of 
Nogo-A (amino-Nogo). It is considered that upon injury, oligodendrocytes are damaged and both 
inhibitory domains would be exposed to the extracellular environment, contacting with axons that 
are attempting to regenerate [32]. The inhibitory ability of Nogo-A is in line with the observation 
that this isoform appeared late in evolution and it does not exist in fish or salamander, species 
with high regeneration potential [37]. 
Although the mechanism is still not completely understood, it has been shown that Nogo-A 
mediates axonal growth inhibition by activating the Nogo-66 receptor (NgR) (see Figure 3). This 
receptor appears to act as a major convergence point on the surface of growth cones for detecting 
many of the inhibitory influences of myelin. It is also activated by MAG [39] and OMgp [40]. Two 
homologues for NgR (NgR2 and NgR3) were identified in CNS neurons, but their function is still 
not fully described [41]. NgR is a glycosylphosphatidylinositol-linked protein with no 
transmembrane domain. For activation of a cascade of events, it likely works in a complex with 
transmembrane protein(s) capable of transducing inhibitory signals to neurons [42]. It was shown 
that p75 [43], a neurotrophin receptor, and LINGO-1, a nervous system-specific transmembrane 
protein, are needed to form a complex capable to transmit an inhibitory signal to axons [1], as 
represented in Figure 3. The activation of this ternary complex leads to Ras homolog gene family 
member A (RhoA) mediated stimulation of ROCK and actin-myosin contractility, which ultimately 
results in the inhibition of neurite outgrowth and growth cone collapse. RhoA and Rac belong to 
the small GTPases family and their effect on the organization of actin cytoskeleton is well 
characterized [44]. It has been shown that the inhibition of RhoA leads to axon growth in inhibitory 
substrates [40, 45]. Rac was also involved in the myelin-mediated inhibition of axonal growth [40]. 
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Cytosolic calcium transients were proposed as downstream effectors of Nogo-A. Calcium was 
inversely correlated with axonal extension and can play a role in mediating this growth cone 
response [42]. In addition to Nogo-A, MAG and OMgp, other repulsive guidance cues with roles 
on axon pathfinding during development, such as ephrin B3 [46] and Semaphorin 4D [47] can also 
be found in myelin and are likely to be involved in the inhibition of axonal growth after injury. 
 
3. Therapeutic approaches 
For some time, the recommended pharmacological treatment for SCI was the systemic 
administration of high doses of methylprednisolone (MP). MP is a synthetic glucocorticoid with 
anti-inflammatory and antioxidant properties, thought to induce neuroprotection and reduce the 
secondary damage upon injury [48]. A clinical trial in 1990 indicated the bolus injection of MP (30 
mg/kg) during the first 8 hrs after injury as a mean to improve neurological recovery [49]. Based 
on this report, MP has been prescribed worldwide for non-penetrating acute SCI. However, the 
use of MP has been debated and the design of that clinical trial, as well as the data analysis 
performed, were considered of dubious value [50, 51]. Some other studies have reported limited 
beneficial effect of MP and large secondary effects caused by the high dose administrated, like 
gastric bleeding [50, 52]. Additionally, a randomized clinical trial for head injury, demonstrated that 
the mortality rate increases 2% with administration of MP [53]. Still, there is recent experimental 
data supporting the use of MP for SCI [54, 55], and the controversy remains because negative 
reports are also being published [56, 57]. Consequently, the use of MP is no longer “standard of 
care” for acute SCI, although it is still in medical practice.  
The current intervention in SCI is limited to spinal stabilization, rehabilitation, compensation of the 
disturbed or missing sensorimotor functions and complication-prevention [58]. However, there are 
a number of pre-clinical studies and clinical trials ongoing, supported by a highly active research 
on the neurobiology and on the neuropathophysiology of SCI that will result, hopefully, in a 
number of strategies being translated into the clinics in the next few years.  
According to Ramer et al. [2], potential treatments for SCI can be included in one or more of five 
categories according to their target for intervention: 
(1) Protection of spared neural cells;  
(2) Stimulation of axonal growth;  
(3) Bridging the lesion, providing a permissive substrate;  
(4) Enhancing axonal transmission to alleviate conduction blockade;  
(5) Rehabilitation to enhance functional plasticity. 
The boundaries between these categories are subtle and, as previously mentioned, it is expected 
that a combinatorial approach will be needed to circumvent the action of the large variety of 
endogenous cells and molecules that act in concert to prevent functional connectivity after SCI. 
Nonetheless, this classification highlights major keywords on SCI therapeutics: protect, stimulate, 
bridge, enhance and rehabilitate. Some of the strategies currently under investigation are 
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described in the next sections, giving particular emphasis to the ones that are/were tested in 
clinical trials. 
 
3.1. Promoting neuroprotection  
A number of molecules are being studied for administration since the first hours after injury in 
order to promote neuroprotection; some were already tested in clinical trials. An example is a 
phase II clinical trial using erythropoietin [59], an hormone known for its effects in the bone 
marrow. It has been shown that erythropoietin can have a neuroprotective effect by reducing 
apoptotic cell death and decreasing the release of pro-inflammatory cytokines [60]. However, 
some concern arose about its use for a prolonged period, since it can increase erythrocyte volume 
and consequently exacerbate the injury [61]. Current research is focused on the development of 
erythropoietin derivatives, like carbamylated-erythropoietin, that preserves erythropoietin 
neuroprotective effects without increasing erythropoiesis [62]. These derivatives are considered 
very promising and testing in clinical trials is imperative [63]. 
Minocycline, an antibiotic with anti-inflammatory properties, has also been tested recently in a 
phase I/II clinical trial. The drug is known due to its immunomodulatory properties, being able to 
tune the expression of cytokines, attenuate oligodendrocyte and microglia cell death, and improve 
functional recovery in SCI rat models [64, 65]. In the clinical trial for acute SCI, minocycline 
showed to be safe and, although the functional evaluation did not accomplish statistical 
significance, there is a clear tendency towards improvement that encouraged the phase III clinical 
trial [66], currently recruiting participants [59].   
Riluzole has also been tested in phase I clinical trials [59]. Riluzole is a sodium channel blocker 
and the rationale for its use in acute SCI is that removing sodium excess upon injury, neuronal 
depolarization is prevented, reducing the accumulation of glutamate and excitotoxicity. It has been 
shown that the administration of riluzole after SCI in rats reduces edema and improves motor 
recovery [67]. The clinical trial aimed at evaluating the safety of the drug administrated in 36 
patients within 12 hrs after injury. Full results await publication, but a phase II/III trial is currently 
recruiting participants [59].  
Neurotrophic factors are molecules with interest in the context of SCI as they can promote 
neuroprotection. Neurotrophins have been investigated due to their important role in neural 
development, survival and regeneration [68]. Injection of nerve growth factor (NGF) [69], brain-
derived growth factor (BDNF), or neurotrophin-3 (NT-3) [70] was performed in SCI animal models 
with different degrees of success. Bradbury and colleagues found that NT-3 is significantly more 
effective than BDNF promoting the growth of injured axons in a rat dorsal crush model [70]. A 
large-scale animal study indicate that the topical application of BDNF can induce neuroprotection 
if applied at high doses and shortly after trauma [71]. Other neurotrophic factors such as glial-
derived growth factor (GDNF) [70] and insulin-like growth factor (IGF-1) [71] were already 
proposed to treat SCI. Regardless the promising results obtained in vitro and in animal models, a 
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clinical trial using systemic delivery of growth factors for diabetic neuropathy showed limited 
efficacy and significant side effects [72], slowing down the progress of new clinical studies with 
these molecules. Currently, the use of neurotrophic factors appears to be particularly relevant 
when combined with drug/gene delivery strategies and/or cell-based therapies [4], as will be 
detailed afterwards in this chapter. 
 
3.2. Targeting inflammatory cells 
The role of inflammation and inflammatory cells after SCI has been for some time a controversial 
issue. Neuroinflammation is considered a dual-edged sword and both neurotoxic and 
neuroprotective properties are ascribed to inflammatory cells [52].  
Traditionally, inflammatory cell infiltration in the CNS is regarded as pathological [73] and there 
are important experimental data supporting this theory. To impair macrophage function is the 
rationale behind the use of some neuroprotective drugs referred above, like methylprednisolone or 
minocycline [74], or other anti-inflammatory molecules, such as IL-10 [75, 76]. Macrophages were 
proposed to be the secondary damage effectors in SCI and their depletion showed to enhance 
axonal sprouting and improve motor function in a contusion SCI model [77]. On the other hand, 
some authors claim that a well-controlled innate and adaptive immune response is pivotal for 
repair in SCI [78]. The work of M. Schwartz group has been based on the observation that the 
injection of what they called “alternatively ex vivo activated macrophages” in a complete SCI 
promotes functional recovery [79]. Macrophages activated prior injection in the spinal cord by co-
culturing with peripheral nerves showed increased phagocytic and proteolytic activity, and reduced 
pro-inflammatory bias. In the late nineties, this work was very controversial. Nowadays, 
macrophage polarization is well accepted (see [80, 81] for review) and to learn how to control the 
opposing functions that these cells can exert depending on their phenotype is a topic of interest in 
many different research fields. 
The use of macrophages had also been inspired by the observation of the importance of these 
cells in mediating repair in the peripheral nervous system, by means of an effective cleaning of 
myelin debris [35]. The CNS is considered to have a sluggish macrophage/microglia response to 
injury and this has been pointed out as one of the reasons for its limited ability to regenerate [1]. A 
clinical trial for the injection of autologous macrophages (ProCord, Proneuron Biotechnologies, 
USA) was conducted and improvement was detected in 5 out of the 16 acute phase patients [73]. 
The trial evolved to phase II but, the published results, show no improvement on the primary 
outcome comparing treated and non-treated individuals [82].  
A more provocative approach was also proposed by Schwartz and colleagues that championed 
the idea of a “protective autoimmunity”. Their assumption is that T lymphocytes, activated by the 
presence of myelin proteins, can trigger an advantageous response to CNS injury; however it was 
found to be insufficient [19]. Boosting these T-cell response at the appropriate timing, location, 
duration, and dosing is proposed as a mean to augment CNS repair and renewal [78]. They 
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showed that using therapeutic vaccines of T-lymphocytes responding to myelin antigens could 
contribute to CNS recovery after axonal injury [83]. Immunization can induce a local immune 
response that promotes migration of stem/progenitor cells to the injury site [84]. This vaccination 
approach is particularly exciting for application on neurodegenerative disorders like multiple 
sclerosis, Alzheimer and Parkinson’s disease [78]. 
 
3.3. Degrading chondroitin sulfate proteoglicans  
As a major constituent of the glial scar and being an inhibitory signal for axonal growth, CSPGs 
are an evident target for SCI therapeutics. It was demonstrated that digestion of CSPGs by 
chondroitinase ABC promotes axon regeneration and plasticity, leading to functional recovery of 
locomotor and proprioceptive behaviour after SCI [85]. Chondroitinase ABC is a bacterial enzyme 
that cleaves glycosaminoglican side chains from the protein core. Treatment with this enzyme is 
likely to be advantageous even 7 days after injury [86], making this strategy particularly interesting 
for non-acute spinal cord lesions. However, the origin of the enzyme (bacteria), as well as the 
degradation products formed, have been issue of concern due to the possibility of triggering the 
immune response [87]. Moreover, these degradation products can exert some inhibitory influence 
on the growth of spinal axons [88]. The use of lentivirus-based delivery of a modified 
chondroitinase gene (that encodes for a secreted form of the enzyme that can be expressed by 
mammalian cells) is under investigation, as a mean to circumvent some of these caveats [89]. 
Some authors proposed that the mechanism by which chondroitinase ABC improves functional 
recovery after SCI is beyond the degradation of CSPGs. The enzyme can degrade other 
extracellular components interfering on cell adhesion [90] and on the release of growth factors 
bounded to the CSPGs [87].  
 
3.4. Blocking myelin-associated signalling  
Antibodies against Nogo-A had shown to partially neutralize the myelin inhibitory activity [91]. 
Three different blocking antibodies have been used in vivo over the last 15 years [37]. The IN-1 
antibody was the first to be described [36] and has been injected in the cerebrospinal fluid, leading 
to enhanced regenerative sprouting from injured fibres, long-distance regeneration of 
subpopulations of fibres, and impressive recoveries of sensorimotor functions [37, 92]. A Phase I 
clinical trial using an humanized anti-Nogo antibody, ATI355 produced by Novartis, is currently 
being finalized [59]. The anti-Nogo therapy is being tested in acute phase patients, since the time 
window for application of this therapy is limited, showing a progressive loss of responsiveness 
[93]. 
As referred previously, Nogo-A mediates its inhibitory function by activation of NgR receptor. This 
receptor is also activated by other myelin inhibitory components, such as MAG [39] or OMgp [40]. 
Being a convergence point to trigger inhibition, NgR emerged as a very attractive target to SCI 
therapeutics. A competitive antagonist based on the peptide sequence of Nogo-A was already 
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developed (NEP1-40). The subcutaneous application of NEP1-40 immediately or seven days after 
hemisection of the spinal cord of mice leads to improved axonal sprouting and locomotor recovery 
[94]. However, on a re-assessment study only a slight and unpredictable improvement on axonal 
regeneration was observed [95]. 
Inactivation of RhoA has been shown by several groups to overcome axonal growth inhibition by 
individual inhibitors and by myelin in general. Inactivation of Rho by the application at the site of 
injury of the toxin C3 (Clostridium botulinum) promotes an extensive regeneration and functional 
recovery in mice [96]. Hindlimb recovery was also reported after administration of the toxin or 
Y27632 – a specific inhibitor for ROCK [45]. These two molecules had also shown to allow growth 
of primary cortical neurons on inhibitory substrates, like myelin or CSPGs [31, 45]. Additionally, 
blocking RhoA over-activation after SCI has also showed to protect cells from apoptosis mediated 
by the activation of p75 neurotrophin receptor [33]. According to these data, RhoA is a 
convergence molecule for many inhibitors of axonal regeneration and it is, for that reason, a 
promising target for SCI therapeutics. Nonetheless, the use of blockers of second messenger 
pathways (as RhoA) encloses the risk of complex effects on other cell types and functions [73]. 
The first results of a phase I clinical trial using a cell-permeable Rho antagonist, called BA-210 
(Cethrin
®
, a recombinant protein), were recently published by Alseres Pharmaceuticals [59]. 
Cethrin was administered by extradural application with a fibrin sealant to patients with acute 
cervical SCI during spinal decompression surgery conducted within 72 hrs after injury [97]. Twelve 
months after intervention, 5 out of 13 patients (38%) showed marked recovery of motor and 
sensory function after treatment, as measured by a 2-grade improvement or higher in the 
American Spinal Cord Injury Association (ASIA) impairment scale [98]. The results are 
encouraging and a multicenter, randomized, double blind, placebo-controlled, Phase IIb study 
sponsored by Bioaxone Biosciences is expected to start soon. 
 
Ibuprofen is used worldwide as a non-steroidal anti-inflammatory drug. Its action has been 
attributed to the inhibitory effect on cyclooxygenase (COX), the enzyme responsible for the 
conversion of arachidonic acid in prostaglandins. Prostaglandins, like prostaglandin E2 (PGE2), 
are associated with pain, fever and acute inflammatory reaction [99, 100]. In 2007 it was 
described for the first time that ibuprofen can inhibit the activation of RhoA in a SCI scenario [101]. 
The drug prevents myelin inhibition of neurite outgrowth by reducing RhoA activation in vitro, and 
also stimulates corticospinal axonal regeneration after spinal cord transection [101]. Ibuprofen 
effects were observed in two different SCI rat models: when administrated immediately after spinal 
cord transection or seven days after spinal cord contusion [101]. Recovery of locomotion and axon 
growth stimulation activity was also reported by Wang and co-authors, although in this case, 
ibuprofen failed to support corticospinal regeneration [102]. More recently, the administration of 
ibuprofen showed to support peripheral nerve regeneration [103], as well as oligodendrocyte 
survival and axonal myelination following traumatic contusion of the spinal cord [104]. The 
molecular mechanism by which ibuprofen inhibits RhoA is suggested to be related with 
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transcription factor peroxisome proliferator-activated receptor  (PPAR) [105]. Even though in a 
recent re-assessment study the authors were able only to partially replicate the results obtained in 
2007 [106], the number of publications that report positive effects of ibuprofen on nerve 
regeneration is significant and the use of this drug is considered very promising [107]. Due to 
ibuprofen widespread use, its effects are very well documented; the long-term use has a quite 
acceptable risk profile and the clinical application would not be meaningful in economical terms 
[107]. Furthermore, the release of PGE2 was associated with neuropathic pain after SCI [108] and 
targeting COX2 pathway is pointed out as a new avenue to treat this condition [109]. In fact, the 
effect of the chronic administration of ibuprofen after SCI has recently shown to reduce 
neuropathic pain, although in this study significant functional improvement were not achieved 
[110].  
 
3.5. Cell-based therapies 
According to clinicaltrials.gov [59,112], currently there are 14 open clinical trials for SCI using 
cellular therapies, representing more than 5% from all the open trials for this condition. This is a 
consequence of an energetic activity in the stem cell field and emerges, probably, on the outcome 
of the progress attained on stem cell research (see [111-114] for review). Even so, cell-based 
therapies have been facing important caveats when being translated into the clinic. Most of the 
pre-clinical studies are performed with non-human cells and the source and culture conditions of 
these cells vary significantly, compromising result replication. Furthermore, there is still some 
concern about cell survival and integration in the host tissue, what have been slowing down the 
progress of cell-based therapies [114]. 
The implantation in a spinal cord lesion of stem cells holds the promise of repopulating the injury 
site, promote the production of growth factors and cell plasticity. Current literature suggests that 
cell-based therapies will be of particular interest in acute or sub-acute phases of SCI, since 
transplantation in chronic patients showed to yield limited functional benefit [114]. Bone marrow 
stromal cells, umbilical cord blood cells and neural stem cells are stem cells currently under 
investigation in clinical trials. Bone marrow stromal cells present the great advantage of a 
minimally invasive and autologous source. However, some authors claim that the benefit of their 
implantation in SCI is due to immunomodulation and environment modification rather than cell 
differentiation onto neuronal lineage cells [112]. Neural stem cells and also umbilical cord blood 
cells are difficult to obtain from an autologous source; therefore, patients need to be subjected to 
immunosuppressive therapy. Nonetheless, a clinical trial using human-derived stem cells is 
ongoing, supported by Stem Cells, Inc.. The clinical use of embryonic stem/progenitor cells 
showed promising results in early stages [115]. The authors showed that the cells can differentiate 
in oligodendrocytes, astrocytes and neurons. However, its clinical use has been mainly hampered 
by ethical issues. 
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Alternative cell types studied on the context of SCI include macrophages [79] (already mentioned 
in this review), Schwann cells [116], and olfactory ensheathing cells [117, 118]. Schwann cells are 
the responsible for the formation of myelin in the peripheral nerve regeneration, being able to 
physically support nerve regeneration after injury. Implanted cells can be of autologous origin by 
scarifying a peripheral nerve. However, the studies reporting Schwann cell implantation in a SCI 
show limited success, being these cells of particular interest when combined with other SCI 
therapeutic strategies [114]. Olfactory ensheathing cells can be obtained from the olfactory bulb in 
a minimally invasive surgery and can also be of autologous origin. There are publications 
reporting the use of these cells alone [119], combined with other cell types [117] or in pieces of 
olfactory bulb [118]. Although these cells showed an inconsistent regenerative capacity in 
independently replicated experiments [120], the more recent results from the clinics seem to be 
encouraging [118, 119]. 
 
3.6. Other therapeutic strategies 
In addition to the cellular- and molecular-based strategies for the treatment of SCI, other 
approaches are being clinically explored and applied, such as rehabilitation therapy. In fact, this is 
among the few approaches that have shown clear benefits [121]. Rehabilitation can promote 
sensorimotor recovery after SCI by promoting neuronal re-organization and functional plasticity 
[122]. Other procedures, such as early decompression after lesion and electrical stimulation are 
being investigated and are likely to be part of a SCI treatment regimen [123]. 
 
 
4. The biomaterials-based approach for spinal cord injury 
As mentioned in the beginning of section 3, one of the strategies for SCI treatment concerns the 
bridging of the lesion. Here, biomaterials are major players. Nerve regeneration research based 
on the use of biomaterials was primarily focused on the development of scaffolds that can connect 
the lesion site, providing physical support and a path for axonal regrowth. These scaffolds have 
been evolving from the simple hollow conduit to more sophisticated devices with improved 
physical guidance architectures combined with molecules that can contribute for the nerve 
regeneration process (see Figure 4). The application of biomaterials in SCI is nowadays 
considered particularly interesting for the modification of the inhibitory environment at the lesion 
site, either by the release in loco of molecules incorporated in the matrix, or by the delivery of cells 
[123]. Scaffolds can be used as cell vectors, serving as reservoir of molecular or physical cues for 
cell survival and differentiation. Significant amount of research has been conducted on the design 
of the scaffolds and also on its combination with specific molecules or drugs and cells, as 
reviewed in the next sections.  
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Figure 4. Different approaches on the design of nerve guidance channels. Reproduced from [124], Copyright 
(2012), with permission from Royal Society publishing. 
 
4.1. Scaffold materials  
The use of nerve conduits to bridge a nerve lesion was firstly explored for peripheral nervous 
system regeneration, as an alternative to autologous nerve grafting (see [125] for a review). 
Based on the evidence that neurons from the CNS can regenerate into peripheral nerve grafts [6], 
the development of nerve conduits for SCI was also proposed. Nerve conduits should ensure 
permeability to oxygen and nutrients, limited swelling, should be flexible but not kink [125], should 
allow sterilization and processing to the desired dimensions and to be easy to handle and suture 
[35].  
Several materials have been used to prepare bridges for SCI. Those include biodegradable, and 
non-biodegradable polymers, either natural or synthetic. Although it is considered that the 
application in vivo of non-biodegradable materials has limited interest due to chronic nerve 
compression [126], materials like poly(acrylonitrile) /poly(vinylchloride) [127] or poly(2-
hydroxyethyl methacrylate) [128] and copolymers with methyl methacrylate [129] have been 
implanted in the spinal cord. The mechanical properties of these materials closely resemble those 
of the spinal cord, characteristic considered important to avoid necrosis of the tissue in the 
interface tissue-implant [129]. Even so, non-degradable materials are not the focus of most 
current research efforts [130]. Silicone, another non-biodegradable material, has been used in the 
context of SCI research but mainly for testing the effect on axonal elongation of specific molecules 
[131], or extracellular components [126].  
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Biodegradable conduits hold the potential of an ultimate restoration of function without the need of 
removing the device [132] but, to achieve this goal, the polymer degradation rate should match the 
new tissue formation and maturation. The application of degradable materials encloses the 
concern of a potential inflammatory response triggered by the degradation process and products 
[132]. 
The use of synthetic materials to prepare nerve conduits has the advantage of manufacturing 
control and tuning the structure, mechanical properties and degradation rate. Among them, 
aliphatic polyesters, like poly(lactide) (PLA), poly(glycolide) (PGA) and their copolymers are the 
most explored [133-135], probably encouraged by the fact that these are FDA approved (see 
Table 1). Other popular synthetic polymer in the nerve conduits research field is poly(ε-
caprolactone) (PCL) [136, 137], although the number of in vivo studies concerning its application 
in a SCI scenario is still limited. PCL has a very low degradation rate, and to tune its properties it 
has been co-polymerized with 1,3-trimethylene carbonate [138, 139] or ethyl ethylene phosphate 
[140]. Porous scaffolds of poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] showed to 
support peripheral nerve regeneration in vivo [141]. To enhance the bioactivity of conduits 
prepared from synthetic polymers, these have been modified with cell adhesion peptides [142, 
143] or immobilized extracellular matrix proteins like fibronectin [134], or laminin [134, 135, 144]. 
The incorporation of extracellular components on nerve bridges holds the premise of improving 
cell adhesion and promoting axon pathfinding.  
Alternatively, natural polymers are generally considered biocompatible, able to support cell 
migration and avoid the occurrence of toxic effects. These properties make natural polymers 
advantageous materials for the preparation of nerve tissue engineering constructs [126]. Chitosan 
[161, 162] and collagen [165] are popular natural materials used to prepare nerve conduits (for the 
peripheral or central nervous system). Other materials tested in the context of spinal cord injury 
include hyaluronic acid, agarose, fibrin, gelatin, gellan gum or alginate (see Table 1). To combine 
the advantages of both natural and synthetic polymers, blending have been actively investigated, 
as shown by the different combinations of PCL with gelatin [182], collagen [183] or chitosan [184]. 
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Table 1. Materials studied for nerve regeneration and tested in SCI models. 
 POLYMER NATURE TYPE OF BRIDGE COMBINATIONS REF. 
S
Y
N
T
H
E
T
IC
 P
O
L
Y
M
E
R
S
 
PLA               
poly(lactide) 
Synthetic, 
degradable 
Single walled 
conduit, electrospun 
fibres 
Drug release [145-147] 
 
PLGA                         
poly(lactide-co-
glycolide) 
Synthetic, 
degradable 
Multiple channel; 
electrospun fibres 
Plasmid DNA; 
Schwann cells; self-
assembling peptides 
for growth factor 
delivery; drug delivery 
[148-152] 
PCL                           
poly(ε-caprolactone) 
Synthetic, 
degradable 
Porous scaffold Neural stem cells [153, 154] 
Peptide amphiphiles Synthetic; 
degradable 
Hydrogel, fibres Modified with IKVAV 
peptide 
[143, 155] 
P(HEMA)                
poly(2-hydroxyehtyl 
methacrylate) and 
copolymers 
Synthetic;        
non-
degradable 
Hydrogel; scaffold Drug delivery; 
modified with SIKVAV 
[128, 129, 
156, 157] 
P(HPMA)               
poly(N-2-
hydroxypropyl 
methacrylate)  
Synthetic;        
non-
degradable 
Hydrogel Modified with RGD;  
mesenchymal stem 
cells 
[158-160] 
N
A
T
U
R
A
L
 P
O
L
Y
M
E
R
S
 
Chitosan Natural; 
degradable 
Porous scaffold Endothelial cells; 
Collagen hydrogel as 
filler; Bone marrow 
stem cells 
[161-164] 
Collagen Natural, 
degradable 
Electrospun fibres; 
Oriented pore 
channels; hydrogel 
Growth factors; 
chondroitinase ABC  
[163, 165-
167] 
Gelatin Natural; 
degradable 
Scaffold Neuronal + endothelial 
cell lines 
[168] 
Self assembling 
peptides 
Natural; 
degradable 
Hydrogel Neural progenitors;  
Schwann cells 
[169, 170] 
poly-β-
hydroxybutyrate 
Natural; 
degradable 
Hydrogel Schwann cells [171] 
Agarose Natural; 
degradable 
Hydrogel/scaffold Growth factors [55, 172] 
Hyaluronic acid Natural Hydrogel Growth factors [173, 174] 
Fibrin Natural, 
degradable 
Hydrogel Growth factors; 
chondroitinase ABC; 
Neural progenitor cells 
[175-179] 
  
Alginate Natural;        
slowly 
degradable 
Hydrogel  [180] 
Gellan gum Natural; 
degradable 
Hydrogel Modified with GRGDS; 
neural progenitor cells; 
olfactory ensheating 
cells.  
[181] 
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Some of the above mentioned materials can be processed as solid conduits as well as injectable 
materials. The use of injectable materials is of particular interest in SCI lesions where dura matter 
is not compromised. In this case, injectable materials can fill the cavity formed without need for 
further lesion to implant a solid device [123]. Although polymers like chitosan or hyaluronic acid 
can form hydrogels, they need to be crosslinked. Traditionally, chemical agents like 
glutaraldheyde were used, but these were abandoned due to toxicity, being non-toxic crosslinking 
methods currently under investigation. In the SCI research, chitosan has been grafted with 
poly(ethylene glycol) as a mean to allow physical crosslinking driven by the presence of 
thermosensitive moieties [185]. Gupta and colleagues combined hyaluronic acid and 
methylcellulose to obtain a fast-gelling drug delivery system, compatible with the injection in the 
intrathecal space in SCI model [173]. However, this gel does not allow cell adhesion, being 
inappropriate to a direct application into the lesion cavity [173].  
Fibrin is a natural polymer formed by enzymatic cleavage of fibrinogen by thrombin in the 
presence of calcium ions. It is widely used in clinical practice (“fibrin glue”) as surgical haemostatic 
[186]. These gels can support axonal growth and are suitable for an implantation in vivo [175]. 
Fibrin has been actively investigated for the delivery of growth factors in the spinal cord [176, 177, 
179]. The combination of fibrin with fibronectin gels improves axonal infiltration and integration 
with the host tissue after an incomplete lesion in the spinal cord [187]. Furthermore, fibrin 
hydrogels are very promising for cell transplantation, and have been applied in a number of 
recently published reports [178, 188], as will be described in more detail afterwards.  
Self-assembling nanofibrous scaffolds gained in the last few years, considerable importance 
within the research field of injectable materials. Self-assembling peptides (SAP) are based on 
short amino acid sequences that self-assemble in response to mild stimulus, like the increase on 
temperature or ionic strength, allowing gelation in cell culture media or after injection in vivo. 
These synthetic hydrogels have been tested in a wide range of applications, namely for neuronal 
cell growth, being commercially available as PuraMatrix™ [189]. In SCI research, these hydrogels 
are commonly investigated for the delivery of cells, such as Schwann cells [170] and neural 
progenitor cells [169]. Some improvement on axonal growth through the scaffold is reported [169], 
but the most important benefit described for SAPs is on cell survival [169, 170]. To improve the 
ability of these hydrogels to contribute for regeneration after SCI, researchers focused on SAPs 
functionalization [190] or incorporation of molecules that can contribute for axonal regrowth [191]. 
Similarly to SAPs, peptide amphiphiles can self-assemble into nanofibrous hydrogels in vivo due 
to the environmental ionic strength. Peptide amphiphiles present the advantage of containing a 
region that can be modified with no significant interference in the gelation process [192]. It has 
been shown that the implantation of amphiphiles with IKVAV sequence (sequence from laminin 
adhesion protein) can promote a significant improvement on locomotor function in rats with a 
contusive [143, 155] or compressive SCI [155]. These peptides showed to reduce astrogliosis and 
enhance neuronal serotonergic innervation at the lesion site [143, 155]. Peptide amphiphiles are 
claimed to be biodegradable and, although detailed studies are still required, it is believed that the 
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degradation products will most probably not affect nerve regeneration [192]. Furthermore, they 
can also be used as drug delivery devices [193], putting forward these hydrogels as very 
promising materials to use as nerve conduits [192].  
 
An important class of materials that has been proposed for the preparation of nerve conduits is the 
one of conductive polymers. It has been shown that electrical stimulation increases neurite 
outgrowth [194]; therefore, to provide scaffolds with conductive properties can positively contribute 
for the regeneration process. However, synthetic conductive polymers, like poly(pyrrole) and 
poly(aniline), have poor biocompatibility, biodegradability and are difficult to process in different 
scaffold designs. In view of the above, these polymers have been applied as coating or blends 
with other synthetic [195, 196] or natural [197] polymers as a mean to improve their 
biocompatibility while maintaining the electrical conductance and, ultimately allowing the 
stimulation of neurite outgrowth.   
 
4.2. Scaffold design 
It is well accepted that axons need guidance for regeneration and that growth is useless if axons 
wander randomly [198]. However, the use of hollow conduits in the spinal cord showed limited 
success [145, 162, 163]. Oudega and co-workers implanted a PLA single walled conduit in a 
complete transection SCI model and showed that the tube collapsed soon after implantation, 
compromising axonal regeneration [145]. Conduits made of chitosan [163] or chitosan modified 
with laminin by plasma treatment [162] were implanted in the spinal cord after excision of piece of 
tissue, but no improvement on axonal regrowth or function were detected comparing to injured 
rats without implanted device. Furthermore, there is mounting evidence that axons orient their 
processes according to the substrate and are sensible to patterns on the surface [199-202], 
suggesting that to include these features in nerve conduits can improve the guidance performance 
of the device. In view of the above, the development of an internal lumen for the conduits is being 
investigated, namely the incorporation of smaller channels, gels, or nanofibres as illustrated in 
Figure 5. These can favour cell attachment due to a higher surface area and can also serve for 
the incorporation of other molecular cues, like extracellular matrix components and growth factors 
[203].   
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Figure 5. Cross-section illustration of nerve 
conduits. (A) basic hollow nerve conduit with a 
void lumen; (B) nerve conduit comprising different 
luminal structures: a) multichannel, b) inner wall 
surface furnished with nanofibres, c) array of 
nanofibres, d) gel or extracellular matrix or other 
materials. Adapted from [204], Copyright (2012), 
with permission from Elsevier. 
 
Multiple channel bridges of poly(D,L-lactide-co-glycolide) (PLGA) have been prepared by gas 
foaming and particulate leaching [205]. The conduits containing channels between 150-250 μm 
maintained their integrity 13 days after subcutaneous implantation [205]. When implanted in the 
spinal cord, limited macrophage infiltration is found and the conduits are stable at least for 6 
weeks after implantation [148]. Furthermore, the preparation of these conduits is compatible with 
the delivery of bioactive growth factors [205] or DNA [149]. To develop more complex internal 
lumen architectures, the design of moulds by computer aided design and solid freeform fabrication 
has been proposed [206]. Using this approach 7 channel conduits were prepared by injection 
moulding using a number of synthetic polymers. After implantation in a complete transection 
model for SCI combined with Schwann cells [150, 206], conduits of oligo(polyethylene glycol) 
fumarate positively charged hydrogel showed better results in terms of number of axons 
colonizing the scaffold comparing to PLGA scaffolds. Nonetheless, none of the materials tested 
achieved a functional improvement 4 weeks after lesion [150]. 
Although still not tested in vivo, collagen multichannel conduits based on electrospun fibres are 
being investigated and show great potential due to the very high surface area of the structure, 
mimicking the fascicles in nerve [207]. The preparation of scaffolds with oriented microchannels 
has also been explored using freeze-drying technique for polymers like collagen [167] or gelatin 
[168] and blends with chitosan [208]. 
The combination of hydrogels and hollow conduits have been mainly investigated for peripheral 
nerve repair [209, 210]. In the context of SCI, a large-scale study was performed using a chitosan 
conduit filled with a semi-fluid collagen. It was reported a significant improvement on the number 
of axons that can cross the bridge in rats where collagen was used to fill the chitosan tube, 
leading also to a significant increment in the Basso, Beattie and Bresnahan locomotor rating scale 
[163]. Other studies combine nerve conduits with hydrogels and cells, but these combinatorial 
approaches will be reviewed in section 4.3. 
 
4.2.1. Electrospun scaffolds  
In the last few years, the tissue engineering field has directed much attention to the preparation of 
nanofibrous scaffolds, since their structure emulates the extracellular matrix. The nanofibrous 
scaffolds provide large surface area to volume ratio and interconnected porous geometry [211]. 
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Comparing to other techniques available for the preparation of nanofibrous scaffolds, like self-
assembling, electrospinning is the most popular. It is simple and cost-effective; it can be applied to 
a wide range of materials (synthetic and natural polymers, proteins, polymer blends, polymer 
suspensions with nanoparticles, or active agents, metals and ceramics) [212, 213]. The method 
was first described more than a century ago and the first patent dates from 1934, by Formhals 
[214]. However, only more recently the popularity of electrospinning had increased, as can be 
perceived from the recent exponential increase in the number of publications [215]. Fibre 
thickness and morphology can be controlled by adjusting electrospinning parameters, like solution 
properties (viscosity, elasticity, conductivity and surface-tension), electric field strength, distance 
between the spinneret and the collecting plate (see Figure 6), temperature and humidity [216]. 
Electrospun fibres can be used to fill nerve conduits, but also for the preparation of the conduit 
itself. The electrospinning technique also allows some control on the scaffold size, shape, 
thickness and fibre orientation by adjustments on the grounded target [217]. The use of aligned 
nanofibres is particularly promising on the nerve regeneration field [133, 140, 218, 219].  
 
 
Figure 6. Illustration of an electrospinning setup. 
 
Electrospun scaffolds have been broadly investigated for peripheral nerve regeneration [133, 135, 
140, 182, 218, 220-222], and more recently, also explored in the context of SCI [146, 151, 152, 
165, 223-226]. The first report testing electrospun fibres in a SCI scenario was published in 2007. 
Meiners and colleagues implanted a fabric based on randomly-oriented polyamide fibres in a 
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hemisection SCI model. The results were unsatisfactory, since the fabric tends to fold, impairing 
axonal outgrowth [223]. This study highlighted the importance of developing oriented nanofibrillar 
scaffolds for directing axonal growth. Indeed, it has been shown that neurite extension is 
increased when cells are cultured on aligned fibres of PCL or PLA, comparing to anisotropic 
substrates [218, 227]. Furthermore, the alignment of astrocytes [224] or olfactory ensheathing 
cells [228] on aligned electrospun fibres has also been demonstrated. The lack of alignment of 
glial cells after injury is associated to the regeneration failure; therefore, the use of these 
substrates where also glial cells can organize can further contribute for the regeneration process.  
Fibre alignment showed also to play a role on adult stem cell differentiation, potentiating 
differentiation into the neuronal lineage when in differentiation cell culture media [229]. Previous 
reports describe that there is a higher number of cells expressing Tuj1 (marker for neurons) and 
O4 (oligodendrocyte marker) when cells are cultured on aligned PCL nanofibres as compared to 
random fibres. Conversely, the number of cells that differentiate into astrocytes is diminished 
[225].  
 
The topography of the electrospun substrates was also found to influence the behaviour of 
immune cells. This issue has been investigated with particular focus on monocyte and 
macrophages. It has been shown that when cultured on electrospun fibres of PLA [230] or PCL 
[231] macrophages secrete less pro-inflammatory cytokines comparing to cells cultured on 
solvent-cast films, suggesting that the use of these biomimetic approach improves biocompatibility 
of the surfaces [230]. To modulate macrophage response via topographic cues provided by nerve 
conduits is a relevant approach towards spinal cord regeneration taking in consideration their role 
on secondary injury after SCI [77]. Although microglia is the responsible for the early pro-
inflammatory environment after SCI [17], little is known about the response of these cells to 
surface topography. The effect of nanostructured silicone on BV-2 (a microglia cell line) cell 
adhesion was investigated, showing that cells can undergo marked morphogenic changes, 
according to feature size (30 nm - 2 µm) [232]. Additionally, it was demonstrated that microglia 
can interact mechanically with nanostructured 3D features, like 4.7 µm pillars, adapting actin 
cytoskeleton to these structures [233]. These studies clearly demonstrate morphologic plasticity of 
microglia [232-234], however, it is still necessary to understand if this can have an impact on cell 
function. 
 
Despite the fact that the overall reports indicate that the use of electrospun fibres on nerve 
conduits can be beneficial for the regeneration process, the number of studies that tested 
electrospun scaffolds in SCI is still low. To the best of our knowledge the first report using 
electrospun conduits in a SCI in vivo model was published in 2011. Hurtado and co-workers 
tested a rolled conduit of PLA random and aligned micrometer fibres (Figure 7, A) after complete 
transection of the spinal cord. Although the functional recovery was not assessed in the study, the 
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authors showed a robust axonal regeneration in conduits with aligned fibres, 4 weeks after 
implantation. Interestingly, their results suggest that the regeneration is supported by astrocyte 
migration [146]. A preliminary in vivo study using collagen nanofibrous scaffold (Figure 7, C) 
showed limited success after 4 weeks of implantation [165]. The results are believed to be related 
to the degradation of the conduit and the size of the fibres. Fibres with a mean diameter around 
200 μm [165] seem to be less effective guiding axonal growth than micrometer fibres used in other 
studies [146], although the role of fibre diameter on axonal growth after SCI needs to be 
investigated in more detail [165].  
An alternative scaffold design using electrospun fibres was proposed by Gelain and colleagues 
[151]. The authors implanted layers of electrospun tubes with 210 μm diameter filled with self-
assembling peptides and fixed by a PLGA / PCL electrospun sealing lamina (Figure 7, B) 4 weeks 
after contusive lesion. To implant the scaffold, the scar tissue and debris were removed and then 
the resulting cavity was filled. The results showed significant axonal growth inside and between 
the channels, spanning the lesion. Functional motor recovery was also observed, being statistical 
significance achieved only 22 weeks after scaffold implantation [151]. 
Nanofibrous scaffolds have also been applied in SCI research as patches for the delivery of 
rolipram (Figure 7, D) [152, 226], a small molecule that can enhance cAMP activity in neurons and 
suppress inflammatory response, favouring nerve regeneration [235]. It has been shown that 
locomotor function is improved comparing to unloaded patches from the third week on after 
implantation. To better control the release of the drug and increase drug loading, the electrospun 
fibres were combined with an alginate hydrogel. However, the use of high drug doses showed to 
lead to toxic effects and an increased mortality rate [226].  
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Figure 7. Example of electrospinning-based strategies tested in SCI in vivo models. A) Poly(lactide) conduit 
(adapted from [146], Copyright (2011), with permission from Elsevier). B) Multiple channel electrospun 
conduit (adapted from [151], Copyright (2011), with permission from American Chemical Society). C) 
Collagen conduit prepared by [165]. D) Electrospun poly(lactide)/ poly(lactide-co-glycolide) patch for the 
delivery of rolipram  (Adapted from [152], Copyright (2010), with permission from WILEY-VCH Verlag GmbH 
& Co. KGaA, Weinheim). 
 
4.3. Combinatorial strategies 
So far in this review the strategies proposed to treat SCI were presented individually. However, it 
is currently believed that combinatorial strategies are needed to address such a complex condition 
[4], and there is an increasing number of reports combining conduits, gels, growth factors and 
cells, as reviewed in the next paragraphs.  
 
4.3.1. Drug releasing bridges 
In SCI research hydrogels based on hyaluronan and methyl cellulose has been extensively 
explored for the delivery of neurotrophic factors [156, 173] and other bigger proteins (IgG used as 
model) when encapsulated in PLGA microparticles [156]. The release of these proteins is 
dependent on their molecular weight and net charge; therefore, different kinetics are achieved for 
each of the molecules. The release of neurotrophic factors was also explored using a 
poly(ethylene glycol)-based photopolymerizable hydrogel [236] or fibrin [177], showing functional 
improvements after a SCI comparing to unloaded hydrogels.  
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Not only growth factors have been delivered at a spinal cord lesion via release from hydrogels. An 
agarose hydrogel containing PLGA nanoparticles loaded with methylprednisolone implanted in a 
contusion model of SCI showed to reduce lesion volume and macrophage infiltration [55]. The 
localized delivery has been proposed to reduce side effects associated to high amount of the drug 
administered systemically [55]. Chondroitinase ABC has also been delivered through fibrin 
hydrogels in a injured spinal cord [176], and alternatively, from electrospun fibres [166]. Indeed, 
hydrogels are particularly interesting as drug delivery vectors for intrathecal injection after SCI. 
However, when physical support is also required, other materials have to be applied. PLGA 
multiple lumen conduits were investigated for the delivery of NGF [205]; and PLA electrospun 
fibres loaded with 6-aminonicotinamide were studied as mean to limit astrocyte proliferation [147]. 
Collagen fibres were also prepared for the delivery of NT-3 and chondroitinase ABC [166]. 
Although these studies still require in vivo testing, the incorporation of growth factors cocktails in 
nerve conduits have already demonstrated to be a valuable strategy to improve functional 
recovery after SCI [151].  
 
4.3.2. Drug releasing bridges with cells 
The delivery of growth factors can also be used to improve the survival of cells implanted at the 
injury site or to modulate stem cell differentiation/proliferation after injection. Johnson and co-
workers used a sub-acute dorsal hemisection SCI model to test the effect of embryonic neural 
progenitor cell implantation when in a fibrin gel loaded with growth factors (NT-3 and platelet 
derived growth factor). The authors reported an increased cell survival and differentiation into 
neural lineages; however, and particularly in growth factor loaded-hydrogels, overproliferation of a 
subset of the implanted cells occurred and was accompanied with loss of function [178]. More 
exciting results were recently published after implanting neural progenitor cells embedded in a 
fibrin matrix containing a cocktail of growth factors (including: brain-derived growth factor, NT-3, 
platelet-derived growth factor, insulin-like growth factor 1, epidermal growth factor, basic fibroblast 
growth factor, acidic fibroblast growth factor, glial-cell-line-derived neurotrophic factor, hepatocyte 
growth factor, and calpain inhibitor). The authors claimed long-distance axonal regeneration 
without the need of other drugs to ameliorate the inhibitory environment. Additionally, two stem 
cell lines were tested with similar results, being one already under clinical trials for amyotrophic 
lateral sclerosis, putting this study a step ahead for testing in clinical trials [188]. 
 
An alternative to growth factor entrapment in polymeric scaffolds is the genetic modification of the 
cells prior implantation, as a mean to convert the cell into a growth factor supplier. The premise is 
that the implantation of cells expressing growth factors can promote their survival and/or modulate 
the differentiation into neuronal lineages. Different engineered cells were already implanted in vivo 
including Schwann cells expressing NGF [237], bone marrow cells expressing BDNF [238], 
fibroblasts expressing GDNF [239], or olfactory ensheathing cells expressing NT-3 [240]. 
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Recently, Gao and co-workers published promising results after implanting mesechymal stem 
cells expressing BDNF seeded on an agarose injectable gel. The number of axons that can cross 
the bridge is significantly higher when the cells seeded on the polymeric bridge are expressing the 
growth factor, as compared to cells expressing GFP, where the number of axons is similar to the 
implantation of the scaffold without cells [172]. The use of genetically-modified cells still have legal 
and ethical implications that should be solved [241]. 
Scaffolds containing genetic material can serve as depots for the in situ delivery of genes to cells 
at a lesion, potentially inducing the expression of a therapeutic protein for longer periods and 
higher concentrations, as compared to direct protein delivery [242]. In the context of nerve 
regeneration, PLGA disks loaded with poly(ethylenimine)-DNA nanoparticles containing a plasmid 
encoding for NGF showed to promote axonal elongation in dorsal root ganglia neurons co-cultured 
with human embryonic kidney (HEK) 293T cells [243]. Particularly in a SCI scenario, lipid-DNA 
particles were incorporated in a PLGA channel bridge and a high expression of the reporter gene 
was detected in the spinal cord during three weeks [134]. However, to achieve functional 
improvements the implantation of conduits containing more efficient gene delivery vectors 
(lentivirus encoding NT-3 or BDNF) was needed [244]. Alternatively, the use of nanoparticles for 
the delivery of small interference RNA (siRNA) incorporated in fibres was also proposed [245, 
246], but these strategies still need to prove their efficiency in vivo. 
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Abstract  
Microglia play an important role in the central nervous system (CNS) homeostasis and response 
to injury that has been overlooked so far in the field of tissue engineering. Here the response of 
primary microglia cells to topographic cues provided by electrospun fibres and flat films of 
poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] was investigated, envisaging the 
design of instructive surfaces that can contribute to the challenging process of CNS regeneration. 
It was observed that cell morphology is remarkably affected by the substrate topography, mirroring 
the surface main features. Cells cultured on flat substrates presenting a round shape, while cells 
with elongated processes being observed on the electrospun fibres. Unexpectedly, a higher 
concentration of the pro-inflammatory cytokine TNFα was detected in cell culture media from 
microglia cultured on fibres. Still, it was observed that astrogliosis is not exacerbated when 
astrocytes are cultured in the presence of microglia conditioned media obtained from cultures in 
contact with either substrates. Furthermore, a significant percentage of microglia was found to 
participate in the process of myelin phagocytosis, with the formation of multinucleated giant cells 
being only observed on P(TMC-CL) films. Altogether, the results presented suggest that microglia 
in contact with the tested substrates is triggered towards a pro-regenerative phenotype. 
Furthermore, the present findings highlight the role of microglia in the context of CNS tissue 
engineering and the need to consider these cells as active contributors to the regeneration 
process. 
 
Keywords: 
Microglia; surface topography; electrospinning; myelin; multinucleated giant cell; nerve tissue 
engineering.  
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1. Introduction 
Microglia, the resident immune cells of the central nervous system (CNS), play a key role on the 
maintenance of CNS homeostasis and in the management of tissue response to injury, although 
representing only about 10% of the total number of glial cells [1]. Microglia can secrete both pro-
inflammatory cytokines that may lead to cell death, or anti-inflammatory molecules and 
neurotrophic factors that contribute to neuroprotection and regeneration [2]. Furthermore, in the 
context of an insult to the CNS, microglia is involved in the clearance of myelin debris that 
accumulate due to Wallerian degeneration. This process is of paramount importance as the 
accumulation of debris has been associated with the inhibition of axonal regeneration [3]. 
Consequently, the diversity of microglia activities turn these cells into an interesting target for new 
therapies in the context of CNS regeneration [4]. 
It is now well established that topographic cues can have a considerable influence on cellular 
processes such as cell adhesion and differentiation (see [5, 6] for a review). The role of surface 
topography on cells from the CNS has been investigated under the scope of the development of 
tissue engineering scaffolds. Neurons have been under the spotlight of the research in the field, 
so far. It has been shown that fibrous topographies support axonal guidance and growth [7-9], as 
well as stem cell differentiation into the neuronal lineage [10, 11]. Similarly, micropatterned 
surfaces have been successfully applied to promote directional axonal growth and neural stem 
cell differentiation [12]. The number of studies concerning the influence of topographic cues on 
glial cells is, on the other hand, still limited and these have been focused on astrocytes, mainly 
due to their key role on the formation of the glial scar in response to an insult to the CNS [13]. 
Astrocytes have been found to orient their filamentous structure according to the topography of 
the surface [14-17]. Moreover, although some authors did not found significant alterations on 
astrocyte activation when cells were seeded on a fibrous surface in comparison to cells cultured 
on flat solvent cast films (assessed in terms of glial fibrillary acidic protein (GFAP) and vimentin 
protein expression) [15], others claimed that the contact of astrocytes with fibres is able to 
promote a decrease on GFAP expression [16] and an increase on glutamate uptake, what can 
contribute for neuroprotection in vivo [17]. Furthermore, by using micropatterned grooved 
scaffolds, mature astrocytes were found to be reverted into radial glia-like cells, and consequently 
to a more pro-regenerative phenotype [18]. These studies highlight that by providing appropriate 
physical stimuli it is possible to bias the response of glial cells to injury. 
Despite the important role ascribed to microglia, studies on microglia-material interaction are still 
in the infancy and have been focused on materials/structures for the design of implantable 
electrodes. The chemistry of the surface was found to influence the cytokine release profile of 
microglia depending on its hydrophobicity [19]. In what concerns topography, the effect of 
nanostructured silicone or poly(dimethylsiloxane) surfaces on microglia morphology, adhesion [20, 
21] or motility [20] were also investigated. More recently, it was demonstrated that microglia 
interacts mechanically with silicone micropillars on a surface, being affected by surface stiffness 
[22]. 
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Foreseeing the design of a tissue engineering scaffold that can contribute to regeneration in the 
CNS, we explored the use of poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] to 
obtain matrices with different topographic cues. The preparation of fibres of this biodegradable 
polymer by electrospinning was previously reported [23], as well as its remarkable properties in 
the context of tissue engineering for the peripheral [24, 25] and the central nervous system 
regeneration [26]. Noteworthy, P(TMC-CL) showed to stimulate cortical neuron polarization and 
promote axonal elongation. Moreover, even in the presence of myelin, cortical neurons cultured 
on P(TMC-CL) films were found to extend more neurites, showing P(TMC-CL)'s ability to tame 
myelin inhibition in a CNS lesion scenario [26]. Here we investigate microglia response to different 
topographic cues provided by electrospun fibres and solvent-cast films of P(TMC-CL) in order to 
obtain important clues towards the design of instructive surfaces that can contribute to the 
challenging process of CNS regeneration. 
 
2. Materials and Methods 
2.1. Polymer synthesis and characterization 
The statistical P(TMC-CL) copolymer was prepared by ring-opening polymerization and 
subsequently purified as previously described [24]. Chemical composition of the purified 
copolymer was assessed by 1H nuclear magnetic resonance (NMR) and found to contain 11% 
mol of TMC, being in accordance to the monomer ratio charged (10% mol TMC). The average 
number molecular weight and polydispersity index of the purified polymer were determined by size 
exclusion chromatography [23] and were found to be 8.2x10
4
 and 1.61, respectively. 
 
2.2. Substrate preparation 
P(TMC-CL) fibres were prepared by electrospinning as previously described [23]. In brief, 10% 
(w/v) P(TMC-CL) solutions in dichloromethane (DCM, Merck, Germany) were dispensed at a 
controlled flow rate of 1 ml.h
-1
 using a syringe pump (Ugo Basille, Italy). An electric field of 1 
kV.cm
-1
 was applied (Gamma High Voltage source, FL, USA) between the spinneret (inner 
diameter 0.8 mm) and the flat collector (15x15 cm). Fibres were collected during 1-1.5 hrs onto 13 
mm glass coverslips (Menzel-Glaser, Germany) distributed on top of aluminium foil. 
P(TMC-CL) films were prepared by solvent casting as follows. A P(TMC-CL) solution in DCM (6% 
(w/v)) was casted onto a glass petri dish. The solvent was left to evaporate overnight under a 
DCM saturated atmosphere at room temperature (20-25°C).  
After preparation, electrospun fibres and solvent cast films were vacuum dried during 24 hrs 
(vacuum oven, Raypa, Spain). Subsequently, 14 mm discs were punched out, packed under 
vacuum after an Argon purge and sterilized by gamma irradiation (25 kGy, 
60
Co source).  
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2.3. Surface characterization 
P(TMC-CL) samples were sputter-coated with gold-palladium for 90 seconds (SPI Supplies, PA, 
USA). Afterwards, the P(TMC-CL) surfaces were observed by scanning electron microscopy 
(SEM) using a FEI Quanta 400FEG microscope (FEI, the Netherlands). Fibre diameter was 
quantified from SEM micrographs using image analysis software (Image J, version 1.39, NIH, MD, 
USA). Fibre mean diameter and fibre diameter distribution were calculated from at least 100 
measurements from 3 independent samples. 
 
2.4. Primary cell isolation and culture 
Primary cultures of microglia and astrocytes were obtained from postnatal (1-2 days) Wistar rat 
pups based on previously described procedures [27, 28]. All experiments involving animals and 
their care were conducted in compliance with institutional ethical guidelines and with the approval 
of Portuguese Veterinary Authorities – Direcção-Geral de Alimentação e Veterinária (DGAV). 
Briefly, pups were decapitated, the meninges were carefully stripped off and cortices dissected. 
Subsequently, the tissue was enzimatically digested using a papain solution (0.2 units.ml
-1
, 
Sigma-Aldrich Química, Portugal) for 30 min at 37ºC. The tissue was further dissociated using a 
pipette and, subsequently, plated into tissue culture treated flasks (Thermo Scientific, Thermo 
Fisher Scientific, Portugal). The mixed glial cultures were maintained for 8 to 10 days at 37°C in 
high-glucose Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% (v/v) of heat 
inactivated (56°C, 30 min) foetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin (P/S, 
10,000 U.ml
-1
 penicillin, 10,000 μg.ml
-1
 streptomycin), all supplied by Gibco (Life technologies 
S.A., Spain).  
To obtain microglia, after culture confluence, the mixed glial cultures were shaken for 1 hr using 
an orbital shaker (IKA, Germany) at 160 rpm and 37ºC. The supernatant enriched with microglia 
was collected and centrifuged (200 g, 5 minutes). Microglial cell culture purity was quantified after 
immunolabelling using CD11b antibody (1:200, Abcam, Belgium) and found to be above 90% (see 
details in supporting information) in accordance to previous reports that used a similar isolation 
technique [19, 29]. 6x10
4
 viable cells.ml
-1
 were seeded on P(TMC-CL) substrates secured at the 
bottom of a 24-well plate with a silicone o-ring (Epidor, Spain) and cultured in DMEM/F12 medium 
(Gibco) supplemented with 10% FBS and 1% P/S for 1 or 5 days.  
After collecting microglia, mixed glial cultures were shaken for additional 22 hrs to remove 
oligodendrocytes. The remaining cell layer, mainly composed by astrocytes, was maintained in 
culture in supplemented DMEM. 
 
2.5. Cytoskeleton immunolabelling 
To analyze cell morphology, cells were fixed with paraformaldehyde (4% (w/v), in phosphate 
buffered saline – PBS) and immunostained for F-actin as follows. Cell external fluorescence was 
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quenched using 50 mM NH4Cl (Merck) for 10 minutes. After washing with PBS (three times, 5 
minutes) cells were permeabilized with 0.1% (v/v) Triton X-100 (in PBS) for 5 minutes. Afterwards, 
cells were washed with PBS, incubated with 5% (w/v) bovine serum albumin (BSA, Merck) in PBS 
for 30 minutes and, thereafter, incubated with Alexa Fluor® 488 Phalloidin (1:40 Invitrogen, Life 
Technologies). Subsequently, cells were washed with PBS and stained with 4’,6-diamidino-2-
phenylindole (DAPI, 0.1 μg.ml
-1
 in PBS, Sigma-Aldrich). Samples were observed under an 
inverted fluorescence microscope (Axiovert 200, Zeiss, Germany) or confocal microscope (Leica 
Microsystems, Germany).  
 
2.6. Microglia morphology analysis 
Microglia morphology was analysed using the Fraclac plug-in for ImageJ. The box counting fractal 
dimension (DB) [30] as well as morphometrics based on the convex hull were calculated. Images 
of the cytoskeleton (F-actin) of individual cells (n = 50) were applied, after conversion to binary 
images and manually outlining the cell contour. Morphometric parameters calculated include area 
and circularity, and results are presented in pixels. 
 
2.7. Cytokine quantification 
At the defined time point, cell culture supernatants from microglia seeded on different P(TMC-CL) 
substrates were collected and, after centrifugation (16,000g, 4ºC, 10 minutes) to remove cell 
debris, stored at -20ºC for posterior analysis. Cell culture media from cells activated with 
lipopolysaccharide (LPS, 100 ng.ml
-1
, 3 hrs, Sigma-Aldrich) was also analyzed to serve as positive 
control for microglia activation [31].    
Tumour necrosis factor-α (TNFα, RayBiotech, GA, USA) and interleukin-10 (IL-10, Biolegend, CA, 
USA) were quantified from microglia culture supernatants by enzyme-linked immunosorbent assay 
(ELISA) following manufacturer instructions.  
 
2.8. Myelin phagocytosis assay 
Myelin phagocytosis by microglia when seeded on different substrates was evaluated as follows. 
Rat brain myelin was obtained as previously described [32]. Five days after microglia seeding, a 
myelin suspension was added to the cell culture media to a final concentration of 2.5 µg.ml
-1
 [33]. 
After 24 hrs in contact with myelin, cells were washed, stained for CD11b and subsequently fixed 
and permeabilized as described above. Cells were counterstained using myelin binding protein 
(MBP) antibody (1:200, Chemicon, Millipore, MA, USA) at 4ºC, overnight followed by 1 hr of 
incubation with Alexa Fluor® 488 donkey anti-rat IgG (1:1,000, Invitrogen, Life Technologies). 
DAPI was applied to label cell nuclei. Cultures were observed using an inverted fluorescence 
microscope (Axiovert, Zeiss) and the percentage of cells with detectable MBP was used as a 
measure for myelin ingestion. 
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2.9. Effect of microglia conditioned media on astrocyte metabolic activity and gene 
expression 
Astrocytes (4x10
4
 viable cells.ml
-1
) (passage 4-7) were seeded on 24-well plates using 
supplemented DMEM. After adhesion overnight, the cell culture medium was changed by 
microglia conditioned media collected after 5 days in contact with P(TMC-CL) substrates. As a 
control condition (non-treated cells), astrocyte cultures were conducted in supplemented 
DMEM/F12 (microglia culture medium, see section 2.4). 
Cell metabolic activity was assessed after 24 and 72 hrs by two different methods. Cellular ATP 
content was measured using Celltiter-Glo® (Promega, WI, USA), following the manufacturer 
instructions. To assess resazurin metabolization, cells were incubated (4 hrs, 37°C) with a 
resazurin (Sigma-Aldrich) solution (0.1 mg.ml
-1
, in PBS) and the fluorescence (λex=530nm, 
λem=590nm) in the cell culture medium was measured (SynergyMx, Biotek, Portugal). 
Gene expression of genes related to astrogliosis, namely glial fibrillary acidic protein (GFAP), 
collagen IV and vimentin was assessed. Cell lysis and RNA purification were performed using 
Quick-RNA MiniPrep from Zymo Research (CA, USA), according to the manufacturer's 
instructions. Reverse transcription was done with SuperScript III (Invitrogen). Primer sequences 
are provided in supporting information. Hypoxanthine-guanine phosphoribosyltransferase (Hprt) 
was applied as reference gene. PCR was performed using HotStarTaq DNA polymerase (Qiagen, 
USA) for 34 cycles. Quantification of band intensity was done using ImageLab software, version 
3.0 (Bio-Rad, Portugal). 
 
2.10. Statistical analysis  
Statistical analysis was performed using PRISM 5.0 software (GraphPad, CA, USA). A parametric 
t-test was applied to assess differences on cell morphology parameters. Statistical differences 
between groups on cytokine concentration, astrogliosis markers and myelin phagocytosis  were 
calculated applying the nonparametric Mann-Whitney test. A p-value lower than 0.05 was 
considered statistically significant. 
 
3. Results  
3.1. Substrate characterization 
By using different processing techniques (electrospinning and solvent casting), distinctive P(TMC-
CL) surface topographies were obtained, as observed in the representative SEM micrographs 
presented in Figure 1. Solvent cast films show a spherulitic morphology (Figure 1, A, B) 
characteristic of a semicrystalline material [34]. The preparation of P(TMC-CL) fibres by 
electrospinning was previously optimized [23]. Under the conditions selected for the present study, 
the prepared electrospun membranes show a typical fibrous and randomly oriented structure 
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(Figure 1, C, D). Bead defects are not observed. Mean fibre diameter was determined to be  
1.09 ± 0.1 μm, being fibre diameter distribution as depicted in Figure 1, E.  
 
 
Figure 1. Scanning electron microscopy (SEM) photomicrographs of the prepared P(TMC-CL) surfaces. (A 
and B) Films obtained by solvent casting; and (C and D) fibres obtained by electrospinning. (E) Fibre 
diameter distribution as calculated from 100 measurements from 3 independent samples; bars represent 
mean values and error bars show standard deviation. 
 
3.2. Effect of surface topography on microglia 
3.2.1 Microglia morphology 
The morphology of microglia cells when seeded on different P(TMC-CL) surface topographies was 
analyzed after immunolabelling of F-actin. Cell cytoskeleton organization was found to be 
significantly affected by the surface topography, as can be observed in Figure 2. On P(TMC-CL) 
films, microglia presents a round shape and long protrusions (Figure 2, A). Conversely, microglia 
seeded on P(TMC-CL) electrospun fibres show a smaller and more elongated cytoplasm (Figure 
2, B), being actin concentrated at the points of cell adhesion along the fibre (Figure 2, B). Image 
analysis shows that microglia seeded on P(TMC-CL) films has an increased complexity comparing 
to cells cultured on fibres, as indicated by the higher box counting fractal dimension DB [30]. 
Moreover, cell area was also found to be significantly increased on microglia seeded on P(TMC-
CL) films (Figure 2, C). Although no statistical differences were found comparing mean values of 
circularity, it can be observed from the graphs representing the percentage of cells distributed in 
equally weighted grades (Figure 2, D), that on P(TMC-CL) films a higher percentage of cells show 
a circularity close to 1 – the theoretical circularity of a circle.  
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Figure 2. Microglia morphology when cultured (5 days) on P(TMC-CL) substrates. (A and B) Confocal Z-
projection images of F-actin and cell nuclei of microglia seeded on P(TMC-CL) (A) films or (B) fibres. In the 
presented detail of (B) it is also shown the fibrous structure of the electrospun mat (gray). (C and D) 
Characterization of microglia morphology by image analysis using box counting fractal dimension (DB) and 
morphometrics based on convex hull (n=50). (C) Average ± standard deviation values for the morphological 
parameters investigated: DB, cell area and circularity. (D) Graphic representation of the percentage of cells 
with different grade for each parameter. Three equalized grades were defined. * denotes statistical 
significance, p < 0.05. 
 
3.2.2 Cytokine release profile 
Variations on microglia morphology have been traditionally associated with distinct functional 
states [35, 36]. Therefore, to evaluate if the differences found on microglia morphology, as a 
consequence of the different P(TMC-CL) surface topography, can lead to alterations on cytokine 
release profile, IL-10 and TNFα were quantified in the cell culture medium at day 1 and 5 of 
culture (Figure 3). Although the differences did not achieve statistical significance, higher 
concentration of the anti-inflammatory cytokine IL-10 was detected on the cell culture medium 
from microglia cultured on P(TMC-CL) fibres, comparing to medium obtained from cells seeded on 
solvent cast films (Figure 3, A). Additionally, TNFα was found to be increased in cell culture 
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medium of cells adhered to P(TMC-CL) fibrous topography as compared to cells adhered on 
solvent cast films (Figure 3, B), being this difference statistically significant at day 1 of culture. It is 
worthwhile mentioning that a sharp increase on TNFα concentration was observed when microglia 
was stimulated with LPS (Figure 3, C). 
Analyzing the concentration of these cytokines in the cell culture media over time, it can be 
observed that when cells were cultured in contact with P(TMC-CL) fibres IL-10 concentration 
tended to increase, whereas TNFα was maintained. In the case of cells cultured on P(TMC-CL) 
films, no alteration on cytokine concentration was detected between the two time points of 
analysis (Figure 3). 
Figure 3. Box-whiskers plot representing the concentration of (A) IL-10 and (B and C) TNFα released to the 
cell culture medium by primary microglia over time. Cells were cultured in P(TMC-CL) films or electrospun 
fibres during 1 and 5 days (n=5). Non-treated cells (n=5) and cells treated with lipopolysacharide (LPS) (n=3) 
were cultured on regular glass coverslips. DIV - days in vitro. * denotes statistical significance, p < 0.05.  
 
3.2.3. Myelin phagocytosis 
One of the key functions of microglia in the aftermath of a lesion to the CNS is the clearance of 
myelin debris. since myelin accumulation exposes inhibitory molecules converting the lesion 
region in a non-permissive substrate for axonal regrowth [3]. To investigate if the surface 
topography can influence microglia ability to phagocytise myelin, myelin was added in suspension 
to cells cultured on the different substrates and the percentage of cells engulfing myelin was 
quantified after immunolabelling. 
 
Figure 4. Myelin phagocytosis assay. (A) Quantification of the percentage of microglia cells that co-localize 
with myelin. Bars represent mean values and error bars show standard deviation (n=3). (B and C) 
representative fluorescence microscopy images of microglia cultured on P(TMC-CL) (B) films or (C) fibres 
when in contact with myelin. Arrows indicate myelin inside the cells. 
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The overall percentage of microglia found to engulf myelin was above 60% for both cells cultured 
on P(TMC-CL) films and fibres, tending this parameter to be higher for cells seeded on films 
(Figure 4, A). 
As previously mentioned, cell morphology is markedly influenced by the P(TMC-CL) surface 
topography. Figure 4 shows that it is further affected by the presence of myelin. The round cells 
with long protrusions found on P(TMC-CL) films (see Figure 2) were able to form multinucleated 
giant cells (MGC) when in contact with myelin (Figure 4, B). On the other hand, in the microglia 
cultures performed in contact with fibrous substrates, MGC were not observed. Conversely, cells 
tend to increase the number of ramifications (Figure 4, C).  
 
3.3. Effect of microglia conditioned media on primary astrocyte cultures 
3.3.1 Astrocyte metabolic activity  
The increase on astrocyte proliferation is one of the events associated with reactive astrogliosis, 
which is widely used as a pathological hallmark of the injured CNS [37]. Microglia cells are the 
immune regulators of astrogliosis [38], namely by releasing a variety of cytokines [37]. To 
understand if microglia cultured on different (TMC-CL) topographies can release factors with an 
impact on astrocytes, astrocyte metabolic activity was assessed after being cultured with microglia 
conditioned media. Measures of metabolic activity were applied as indicative of cell proliferation. 
 
 
Figure 5. Box-whisker plots (n=4) showing (A) ATP production and (B) resazurin metabolism by astrocytes 
when in contact with microglia conditioned media (µglia CM) during 24 hrs. The medium was recovered from 
microglial cultures after 5 days in contact with P(TMC-CL) films or fibres. Non-treated cells were maintained 
in supplemented DMEM/F12 media. (C) F-actin labelling of astrocytes incubated with microglia conditioned 
media obtained from cultures on fibrous topography. 
 
Cell metabolic activity of astrocytes when in contact with microglia conditioned media showed a 
tendency to increase as compared to non-treated cells (Figure 5, A, B). Conditioned media 
obtained from microglia cultures on P(TMC-CL) fibres or solvent cast films were found to have 
similar effect on astrocyte metabolic activity (Figure 5, A, B). Comparable results were obtained 
when astrocyte metabolic activity was assessed after 72 hrs in contact with microglia conditioned 
media (data not shown). Figure 5, C shows the typical morphology [39] of the astrocytic cell 
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culture. No alterations were identified after incubating astrocytes with the different microglia 
conditioned media under investigation. 
 
3.3.2. Astrocyte gene expression  
Astrogliosis has been associated to the up-regulation of some genes, namely GFAP and vimentin 
[13]. Collagen type IV is the main constituent of the glial scar and its expression is increased in 
astrocytes in response to injury [40]. 
Astrocyte expression of astrogliosis gene markers was found not to be significantly affected by 
microglia conditioned media in comparison to non-treated cells (Figure 6). Additionally, the 
topography of the surface on which microglia was cultured do not shown an effect on GFAP, 
vimentin, or collagen type IV gene expression. 
 
 
Figure 6. mRNA expression of glial fibrillary acidic protein (GFAP), vimentin (VIM) and collagen type IV (Col 
IV) on astrocytes when in contact with microglia conditioned media. Conditioned media was obtained from 
microglia seeded on P(TMC-CL) solvent cast films, or electrospun fibres, after 5 days in culture. Non treated 
cells were maintained in supplemented DMEM/F12. Bars represent mean values and error bars show 
standard deviation (n=4).  
 
4. Discussion  
In the past few years, the understanding of the role of topographic cues has gained substantial 
relevance in the context of the design of tissue engineering scaffolds for nerve regeneration. 
Focus was primarily directed to neuronal cells [7, 9, 11] but more recent studies are contributing to 
shed some light on the effect of this parameter on other CNS cellular key players, as astrocytes 
[15-18]. It is known that microglia, the immune cells of the CNS, play a critical role on CNS 
homeostasis as well as being in the frontline of the tissue response to injury [1]. Particularly, 
microglia cells can release cytokines and other molecules, activating cells at the lesion site, 
recruiting others, and modulating its own function in an autocrine effect [38]. However, taking the 
role of microglia in a lesion scenario into consideration, the impact of the surface properties, in 
particular of surface topography, on the microglia response has been overlooked at large. This 
was the main goal of the present study. 
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As previously reported for other cell types [6], in this work it was shown that microglia organize 
their cytoskeleton according to the topography of the surface to which they adhere. On P(TMC-
CL) solvent cast films, microglia presents a rounder shape and long protrusions, whereas on 
fibres, cell cytoskeleton elongates along the fibre direction and cell area is smaller. Variations on 
microglia cell shape have been commonly taken as indication of distinct functional states. 
Amoeboid features have been traditionally associated with increased phagocytic activity and a 
pro-inflammatory profile, whereas a ramified morphology has been associated with a quiescent 
state [35, 36]. The morphological aspects of the microglia seeded on both tested substrates do not 
show neither the marked amoeboid nor the ramified features. It was demonstrated that cells 
cultured on P(TMC-CL) films are larger (increased area) and tend to present an increased 
circularity what can be considered an indication of a more pro-inflammatory phenotype. However, 
the concentration of TNFα found in the cell culture medium from microglia in contact with these 
films is low, as compared to the one detected on cultures in contact with electrospun fibres, 
particularly at day one of culture. These results indicate that when different topographic cues are 
involved, microglia shape is not a parameter based on which one can directly predict its functional 
state. A similar issue has been previously raised by Bartneck and colleagues when comparing 
macrophages cultured on 2D or 3D substrates [41]. The authors claimed that the effect on cell 
morphology and the expression of surface-markers is strongly affected by the biomaterial where 
cells adhere to and suggest that, for macrophages in contact with biomaterials, cytokine release 
should be taken as main criterion instead of surface-markers for macrophage phenotype 
classification [41]. The analysis of microglia morphology using box counting analysis can, 
however, bring new insights into this topic. The presented results show that cells seeded on 
P(TMC-CL) films have a higher complexity comparing to cells on fibres, as measured by DB 
parameter. It has been suggested that microglia in resting state has an increased complexity [30]. 
Thus, in the present context, DB is a morphological parameter that better correlates with the 
cytokine release profile of microglia cultured on the different surface topographies.  
Interestingly, the effect of the surface topography on the cytokine release by primary microglia 
herein reported shows a different trend comparing to that described for macrophages. Previous 
studies using poly(L-lactide) [42], or poly(ε-caprolactone) [43] demonstrated that the concentration 
of pro-inflammatory molecules is lower in cultures in contact with electrospun fibrous surfaces, as 
compared to cells on solvent cast films. Surface topographies that induce macrophage elongation 
were found to favour macrophage polarization into an anti-inflammatory phenotype, and, although 
the mechanisms are still not fully described, it was suggested that polarization via topographic 
signalling is mediated by actin cytoskeleton contractility [44]. The differences found in the present 
study on microglia behaviour highlight the need for studying microglia in detail. Even though 
sharing relevant lineage features with macrophages, these cells can react differently to stimuli, as 
previously reported when testing different chemical factors [33, 45].  
In the context of an insult to the CNS, the contribution of microglia to the clearance of debris is of 
primary importance, as an inefficient removal of myelin debris is associated with the inhibition of 
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nerve regeneration [3]. It has been demonstrated that myelin phagocytosis is affected by the 
stimulation of microglia with different cytokines [33]. Thus, in the present work it was investigated 
whether culturing cells on substrates with a different topography can have an impact on microglia-
mediated phagocytosis. A previous report showed that microglia in basal conditions or stimulated 
with anti-inflammatory cytokines (IL-4 and IL-13) were more efficient on myelin phagocytosis, 
being found that 70-75% of these cells were able to incorporate myelin in a phagocytosis assay. 
Conversely, less than 50% of the cells engulfed myelin if stimulated with LPS and interferon-γ 
[33]. In the context of Alzheimer’s disease, it has been demonstrated that the accumulation of pro-
inflammatory molecules such as LPS, IL-1β or β-amyloid fibrils induces microglia dysfunction, 
limiting their phagocytosis activity [46]. In the present study, the percentage of cells that engulfed 
myelin was found to be above 60% for cultures conducted either on P(TMC-CL) solvent cast films 
or on fibrous topography. This result suggests that the P(TMC-CL) surfaces provide physical 
and/or chemical cues that promote phagocytosis without the need of additional chemical stimuli, 
and may actively contribute for the establishment of a pro-regenerative environment. 
Despite the fact that the percentage of cells that engulfed myelin was found not to be influenced 
by the topographic cues provided by the surface, a remarkable difference was observed on the 
morphology of microglia when in the presence of myelin. Microglia seeded on P(TMC-CL) films 
were found to form multinucleated giant cells (MGCs), a phenomenon that was not observed 
when cells were adhered to fibres. Though the morphology of microglia cells was affected by the 
surface topography as described above, the formation of MGC was clearly a consequence of the 
presence of myelin, as this event was not detected in its absence. The role of MGCs derived from 
microglia has been poorly discussed in the open literature. These cells have been found to 
accumulate with age [47], being also associated with some neuropathologies, namely HIV-related 
dementia [48]. Microglia activation to form MGCs can be triggered by inflammatory cytokines [49-
51] as well as in response to phagocytosis of cell debris [50, 52]. MGCs have an increased 
phagocytic activity [52] what could represent an advantage when large amounts of debris 
accumulate due to Wallerian degeneration. The results obtained in this work do not directly point 
to an increased percentage of cells engaged in phagocytosis when microglia was cultured in the 
presence of the P(TMC-CL) films in which MGCs were detected. However, it is important to note 
that in the calculation of the percentage of cells with engulfed myelin, multinuclear cells were 
considered as one cellular entity. To the best of our knowledge this is the first study that analyzes 
the effect of biomaterials on microglia in light of MGC formation. A recent publication using 
monocyte-derived macrophages demonstrates that orthogonal features on chitosan scaffolds 
favoured macrophage fusion and MGC formation, comparing to a diagonal architecture [53]. 
Nonetheless, the authors were able to correlate this effect with the increase of TNFα in the cell 
culture media. In the present study, the concentration of TNFα when cells were seeded on 
P(TMC-CL) films was found to be low, suggesting that this cytokine was not involved on the 
stimulation of MGC formation. It cannot be excluded that concentration of TNFα was altered in the 
presence of myelin, but if it was the case, it remains to be clarified why only in cells seeded on 
P(TMC-CL) films. In this context, the topography of the substrate may be influencing directly the 
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formation of MGCs. In our interpretation of the obtained results, the surface provided by 
electrospun fibres may be hampering cytoskeleton re-arrangement, cytoplasm enlargement and 
cell fusion compromising, therefore, the formation of MGC in comparison to what occurs on 
solvent cast films. 
There is increasing evidence that a reciprocal modulation between microglia and astrocytes takes 
place after CNS injury [54]. Microglia are the first cells arriving to the lesion site and the cytokines 
released by these cells, namely TNFα and IL-1β, can induce astrocyte proliferation, influencing the 
glial scar formation [55]. On the other hand, molecules produced by astrocytes are believed to 
modulate microglia activation in the chronic phase of injury [54]. Taking these aspects into 
consideration, in this study it was investigated how the response of microglia to different surface 
topographies can influence astrocyte activation markers. Microglia conditioned media was applied 
to astrocyte primary cultures and it was found that none of the markers investigated was 
significantly up-regulated. It is worthwhile mentioning that in these experiments microglia 
activation with LPS led to a dramatic increase on TNFα concentration in the cell culture medium in 
comparison to that detected for microglia seeded on P(TMC-CL) fibres or films. This result points 
to the fact that the amount of TNFα produced by cells when seeded on P(TMC-CL) substrates 
may not be sufficient to trigger a significant activation of microglia that could, consequently, have 
an impact on astrocytes. The obtained results are in accordance with a previous study reporting 
no alteration on astrogliosis markers when astrocytes were treated with conditioned media from 
resting microglia [56]. 
 
5. Conclusion  
This work describes for the first time the effect of scaffold surface topography – fibres and flat 
films – on primary microglia cells. Overall the results presented show that both structures provide 
topographic cues that can modulate microglia towards a pro-regenerative phenotype, while 
remarkable differences were found on cell morphology, in line with the topography of the surface. 
Accordingly, it was pointed out that, when different surface topographies are under investigation, 
cell behaviour cannot be anticipated from cellular shape. Although TNFα concentration was found 
to be increased in response to fibrous substrates, overall, the factors released by the cells were 
not able to trigger astrogliosis, independently of the surface’s topography. Noteworthy, a 
significant percentage of microglia seeded on P(TMC-CL) substrates was found to participate on 
the phagocytosis of myelin, putting forward these materials as supportive of tissue regeneration in 
the context of an insult to the CNS. 
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Supporting information 
 
1. Microglial culture purity 
The purity of microglial cultures was assessed by immunocytochemistry after labelling the 
conducted cultures with an antibody against CD11b (Abcam), following the manufacturer 
instructions. In brief, 24 hrs after seeding, cell culture medium was removed and the cells washed 
with phosphate buffered saline (PBS). The cells were incubated 20 minutes with CD11b antibody 
(diluted in DMEM, 1:200) at 37ºC and, subsequently, with the secondary antibody (20 minutes, 
1:500, anti-mouse AlexaFluor® 488, Invitrogen). Cells were then fixed using 4% (w/v) 
paraformaldehyde, permeabilized with Triton X-100 (0.2% (v/v) in PBS) and counterstained with 
4’,6-diamidino-2-phenylindole (DAPI, 0.1 μg.ml
-1
 in PBS, Sigma). Cells were observed using an 
inverted fluorescence microscope (Axiovert, Zeiss) and the percentage of CD11b+ cells was 
calculated relative to the total number of cells (number of nuclei labelled with DAPI) and found to 
be above 90% (Figure 1, A). 
Microglia cultures were also labelled for glial fibrilary acidic protein (GFAP) antibody in order to 
assess possible culture contamination with astrocytes. In brief, after fixation, cells were 
permeabilized 0.2% (v/v) Triton X-100 solution containing 5% (v/v) of normal goat serum (NGS, 
Sigma-Aldrich) during 30 minutes. Afterwards an anti-GFAP (Dako, 1:500) solution containing 1% 
(v/v) NGS and 0.15% (v/v) Triton X-100 was added and incubated overnight at 4°C. After washing 
with PBS (three times, 5 minutes), the cells were incubated with anti-rabbit AlexaFluor® 568 
(Invitrogen) for 1 hr at room temperature. Cells were thereafter counterstained with DAPI as 
described above. The occurrence of GFAP positive cells was rare, consisting in less than 5% of 
the total number of cells (Figure 1, B). 
 
Figure 1. Microglia cultures immunolabelling. (A) CD11b
+
 cell detection or (B) combined with GFAP, an 
astrocytic marker. 
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2. Primer sequences applied in RT-PCR 
 
Primer sequences used for RT-PCR were as follows:  
GFAP sense 5'AGGCTGGAGGCGGAGAAC3' 
GFAP anti-sense 5'GCTGTGAGGTCTGGCTTGG3' 
Vimentin sense 5'CGTGATGTCCGCCAGCAGTATG3' 
Vimentin anti-sense 5'GGCATCCACTTCGCAGGTGAG3' 
Collagen IV sense 5'AAGGCGAGGAAGGCATCATG3' 
Collagen IV anti-sense 5'GGGTGAGTAGGCTGGAGGTC3' 
Hprt sense 5'ATGGACTGATTATGGACAGGACTG3' 
Hprt anti-sense 5'GCAGGTCAGCAAAGAACTTATAGC3' 
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Abstract 
The development of scaffolds that combine the delivery of drugs with the physical support 
provided by electrospun fibres holds great potential in the field of nerve regeneration. Here it is 
proposed the incorporation of ibuprofen, a well-known non-steroidal anti-inflammatory drug, in 
electrospun fibres of the statistical copolymer poly(trimethylene carbonate-co-ε-caprolactone) 
[P(TMC-CL)] to serve as a drug delivery system to enhance axonal regeneration in the context of 
a spinal cord lesion, by limiting the inflammatory response. P(TMC-CL) fibres were electrospun 
from mixtures of dichloromethane (DCM) and dimethylformamide (DMF). The solvent mixture 
applied influenced fibre morphology, as well as mean fibre diameter, which decreased as the DMF 
content in solution increased. Ibuprofen-loaded fibres were prepared from P(TMC-CL) solutions 
containing 5% ibuprofen (w/w of polymer). Increasing drug content to 10% led to jet instability, 
resulting in the formation of a less homogeneous fibrous mesh. Under the optimized conditions, 
drug-loading efficiency was above 80%. Confocal Raman mapping showed no preferential 
distribution of ibuprofen in P(TMC-CL) fibres. Under physiological conditions ibuprofen was 
released in 24 h. The release process being diffusion-dependent for fibres prepared from DCM 
solutions, in contrast to fibres prepared from DCM–DMF mixtures where burst release occurred. 
The biological activity of the drug released was demonstrated using human-derived macrophages. 
The release of prostaglandin E2 to the cell culture medium was reduced when cells were 
incubated with ibuprofen-loaded P(TMC-CL) fibres, confirming the biological significance of the 
drug delivery strategy presented. Overall, this study constitutes an important contribution to the 
design of a P(TMC-CL)-based nerve conduit with anti-inflammatory properties.  
 
Keywords 
Confocal Raman microscopy; drug delivery; electrospinning; ibuprofen; inflammation; nerve guide 
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1. Introduction 
The first patent on electrospinning dates from 1934 by Formhals (1934). More recently, the 
technique was ‘reinvented’, becoming very popular for the preparation of tissue engineering 
scaffolds (Martins et al., 2007; Agarwal et al., 2009). Electrospinning allows the fabrication of 
nanofibrous scaffolds that can emulate the extracellular matrix, providing a biomimetic 
environment for cell growth, polarization and differentiation. In addition, a number of parameters in 
the electrospinning setup can be adjusted in order to modulate fibre diameter and orientation, as 
well as scaffold size and shape. The possibility of preparing aligned fibres has been especially 
explored in the context of nerve repair (Xie et al., 2010; Lee and Arinzeh, 2011). Previous reports 
show that neurons align their cellular processes in the direction of electrospun fibres in vitro 
(Corey et al., 2007; Yao et al., 2009). A similar outcome was observed in vivo, both in the 
peripheral (Yu et al., 2011; Jiang et al., 2012) and in the central nervous system (Hurtado et al., 
2011). Electrospun scaffolds can also serve as drug delivery devices. Owing to the versatility of 
the electrospinning technique, different types of molecules can be incorporated in fibres. For nerve 
regeneration applications, fibres have been loaded with neurotrophins (Chew et al., 2005; Liu et 
al., 2012) or drugs, like 6-aminonicotinamide, known to limit astrocyte proliferation (Schaub and 
Gilbert, 2011). To promote central nervous system regeneration, the combination of nanofibrous 
scaffolds with molecules that can locally hinder the inhibitory environment after a lesion is of 
particular interest (Liu et al., 2012). 
Inflammation is one of the secondary events activated after a central nervous system lesion and 
one of the most relevant targets in nerve regeneration strategies (Thuret et al., 2006; Fitch and 
Silver, 2008). Although the role of inflammation in central nervous system regeneration is currently 
an issue of active debate (Chan, 2008; Schwartz et al., 2009), the results of clinical trials that 
involved assessment of drugs with described anti-inflammatory properties, namely the antibiotic 
minocycline (Casha et al., 2012), support strategies targeting the modulation of the inflammatory 
response. 
This report proposes the incorporation of ibuprofen in electrospun fibres as a drug delivery system 
to enhance axonal regeneration in the context of a spinal cord lesion by limiting the inflammatory 
response. Ibuprofen is a non-steroidal anti-inflammatory drug and its action is attributed to the 
inhibitory effect on cyclooxygenase (COX). This enzyme is responsible for the conversion of 
arachidonic acid in prostaglandins, the latter being associated with pain, fever and acute 
inflammatory reaction (Mitchell et al., 1993; Rainsford, 2009). In addition to the classical view of 
the action of ibuprofen, the release of prostaglandin E2 (PGE2) has been more recently associated 
with neuropathic pain after spinal cord injury (Zhao et al., 2007). Consequently, targeting the COX 
pathway is currently indicated as a new avenue to treat this condition (Ma et al., 2012), providing 
added value to the strategy proposed in this manuscript.  
Poly(trimethylene carbonate-co-ϵ-caprolactone) [P(TMC-CL)] is a biodegradable elastomer 
previously studied in the field of nerve regeneration research. The polymer possesses mechanical 
properties and a degradation profile appropriate to serve as nerve conduit (Pêgo et al., 2001, 
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2003) and it has shown to be able to support peripheral nerve regeneration in vivo (Vleggeert-
Lankamp et al., 2008). In the present work, it is proposed that P(TMC-CL) serve as polymeric 
matrix for the delivery of ibuprofen. The optimization of electrospun P(TMC-CL) fibre preparation, 
the incorporation of the drug and its release profile and bioactivity are investigated. 
 
2. Materials and methods  
2.1. Polymer synthesis 
Poly(trimethylene carbonate-co-ε-caprolactone) was prepared by ring-opening polymerization as 
previously described (Pêgo et al., 2001). In brief, ε-caprolactone (CL) (Merck, Darmstadt, 
Germany) was dried overnight (calcium hydride; Sigma-Aldrich Química, Sintra, Portugal) and 
distilled before the polymerization with trimethylene carbonate (TMC, used as received from 
Boehringer Ingelheim, Ingelheim am Rhein, Germany). Polymerization was carried out in 
evacuated and sealed glass ampoules using stannous octoate (Sigma-Aldrich) as catalyst (2×10
–4
 
mol per mol of monomer). After 3 days of reaction at 130 °C the polymer obtained was purified by 
dissolution in chloroform (BDH-Prolabo, Carnaxide, Portugal) and subsequent precipitation into a 
tenfold volume of ethanol (96%, v/v; AGA, Prior Velho, Portugal). The chemical composition of the 
copolymer was assessed by 
1
H nuclear magnetic resonance (NMR) and found to contain 11% mol 
of TMC, which is in accord with the monomer ratio charged (10% mol TMC). The molecular weight 
of the obtained polymer was determined by size exclusion chromatography using chloroform as 
the mobile phase. The average weight molecular weight was found to be 8.2×10
4
 g/mol and the 
polydispersity index was 1.61. 
 
2.2. P(TMC-CL) and ibuprofen-loaded P(TMC-CL) fibre preparation by electrospinning 
Initially, a range of electrospinning parameters was assessed. The parameters tested included 
polymer concentration in the electrospun solution (6–10%, w/v), polymer solvent [dichloromethane 
(DCM; Merck), chloroform (Sigma-Aldrich) and N,N-dimethylformamide (DMF), Merck)], flow rate 
(0.1–1.5ml/h), and electric field applied (0.5–1 kV /cm). Based on the morphology of the fibres 
obtained (data not shown) the selected conditions for the subsequent experiments were: P(TMC-
CL) solutions (10%, w/v) dispensed at a flow rate of 1ml/h using a syringe pump (Ugo Basile, 
Italy); an electric field (Gamma High Voltage source; Ormond Beach, FL, USA) of 1 kV/cm applied 
between the spinneret (inner diameter 0.8mm) and a flat copper plate (15×15 cm) separated by 14 
cm; DCM and DMF mixtures used as solvent at the volume ratios of 1:0, 6:1, 3:1 and 1:1. Fibres 
were collected into an aluminium foil for 1–1.5 h. After vacuum drying (vacuum oven, Raypa, 
Barcelona, Spain) for 24 h, 14mm discs were punched out from the electrospun membranes and 
stored at room temperature (20-25 °C) until further use. 
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Ibuprofen-loaded fibres were obtained by adding 5% and 10% of ibuprofen powder (w/w of 
polymer) to the polymer solution 5 h before electrospinning. Pharmaceutical grade ibuprofen 
(purity>99%) was kindly supplied by Sérgio Simões (Bluepharma, Coimbra, Portugal).  
 
2.3. Fibre characterization 
2.3.1. Fibre morphology 
Fibre morphology was analysed by scanning electron microscopy (SEM). A low vacuum (5 kV) 
Phenom™ G2 (Phenom-World, Eindhoven, the Netherlands) and a Quanta 400FEG ESEM (FEI, 
Eindhoven, the Netherlands) microscopes were used. Fibre diameter was quantified from SEM 
micrographs using image analysis software (Image J, version 1.39; NIH, Bethesda, MD, USA). 
Fibre mean diameter and fibre diameter distribution were calculated from at least 100 
measurements from three independent samples. 
 
2.3.2. Drug loading efficiency 
1
H NMR spectroscopy was used in order to quantify ibuprofen in the P(TMC-CL) electrospun 
meshes. The analyses were performed in an AVANCE III 400 spectrometer (Bruker Corporation, 
Barcelona, Spain), operating at 400MHz. The 
1
H chemical shifts were internally referenced to the 
tetramethylsilane (TMS; Eurisotop, Saint-Aubin, France) signal (0.00 ppm) for spectra recorded in 
CDCl3 (Sigma-Aldrich). Ibuprofen-loaded P(TMC-CL) fibres were dissolved in CDCl3 before 
analysis. Characteristic peaks from ibuprofen and P(TMC-CL) were used to identify both species. 
The drug loading efficiency was calculated from the ratio between the area of the signal at δ=2.45 
ppm corresponding to the CH2 group of ibuprofen (2H), and the area of the peak corresponding to 
the resonance of the α-methylene (δ=2.30, 2H, CH2) of polymeric caprolactone. 
 
2.3.3. Ibuprofen distribution in P(TMC-CL) fibres 
Ibuprofen powder and P(TMC-CL) fibres prepared from 1:0 and 3:1 DCM–DMF mixtures with and 
without ibuprofen incorporated (5%, w/w, of polymer) were analysed using Fourier transform 
infrared spectroscopy (FTIR) and confocal Raman microscopy.  
The FTIR characterization was performed using a Perkin Elmer 2000 spectrometer (Perkin Elmer, 
Waltham, MA, USA) and an attenuated total reflectance (ATR) accessory (SplitPea™; Harrick 
Scientific, Pleasantville, NY USA), provided with a silicon internal reflection element and 
configured for external reflectance mode, where the spectra were acquired from a 200 μm 
diameter sampling area. A nitrogen purge was performed before each experiment. All samples 
were run at a spectral resolution of 4/cm and 200 scans were accumulated in order to obtain a 
high signal-to-noise level. The band at 1675–1775/cm was deconvoluted by applying the 
derivative and curve fitting algorithms using PEAKFIT from AISN Software (Florence, Oregon, 
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USA). Initial peak positions were obtained from second derivative spectra of the raw data. A 
Lorentzian band-shape was used to fit the contours. 
Confocal Raman microscopy analyses were performed using a LabRAM HR 800 confocal Raman 
microscope system (Horiba Jobin Yvon, Lille, France) comprising a spectrometer and a fully 
integrated Olympus BX41 confocal microscope (Olympus Iberia, S.A.U., Lisboa, Portugal). Raman 
spectra were generated using a 514 nm laser diode as excitation source, focused on the sample 
with a x100 objective, a confocal hole of 100 μm and an exposure time of 100 s. For the 
experimental setup used, the spatial resolution is between 0.5 μm and 1 μm. The scattered light 
was dispersed by a grating with 1800 lines/mm (Jobin-Yvon) at 4/cm spectral resolution. Spectral 
analysis was carried out using LABSPEC5 software (Horiba Jobin Yvon). Imaging experiments on 
fibres were performed by scanning the laser beam over the region of interest and accumulating a 
full Raman spectrum at each pixel. Raman images were constructed by plotting the integrated 
intensity of the vibrational bands of interest as a function of position. For these experiments, fibres 
with a diameter > 2 μm were selected and step size for data acquisition was approximately 0.6 
μm. The spectral range measured was 1400–1800/cm and the mapping area varied according to 
the fibre dimension. 
 
2.4. Drug-release studies 
The amount of ibuprofen released from the electrospun P(TMC-CL) fibres was evaluated as 
follows. Samples loaded with 5% of ibuprofen (w/w of polymer) were incubated at 37 °C and 120 
rpm (Orbital Shaker Oven; IKA, Staufen, Germany) in phosphate buffered saline (PBS) at the final 
concentration of 5 mg/ml (mass of fibres/volume of PBS). At defined time-points (0.5, 1, 2, 4, 6, 8, 
and 24 h) the releasing medium was refreshed. Ultraviolet/ visible spectroscopy (UV/Vis) at 
230nm (SynergyMx; Biotek, Carnaxide, Portugal) was used to monitor the amount of ibuprofen 
released. Values were interpolated from an ibuprofen calibration curve (see the Supporting 
Information, Figure S4). Cumulative release was calculated relative to the maximum loading of 5% 
(w/w of polymer). The drug release kinetics was analysed using the Higuchi simplified model:  
Mt=M∞ ¼ k√t (1) 
where Mt/M∞ represents cumulative ibuprofen release, t is time of incubation and k is a constant 
reflecting the design variables of the system (Siepmann and Peppas, 2001). 
 
2.5. Biological effect of ibuprofen on human macrophages 
2.5.1. Peripheral blood-derived monocyte isolation 
Human peripheral blood-derived monocytes were isolated from Buffy coats (kindly donated by 
Instituto Português do Sangue, Porto, Portugal) by negative selection using Rosettesep™ 
(StemCell Technologies, Grenoble, France) as previously described (Oliveira et al., 2012). A day 
after isolation, adherent cells were collected applying a 5mM solution of ethylenediamine 
Chapter IV 
83 
tetraacetic acid (EDTA; BDH-Prolabo) and reseeded on glass coverslips at a cell density of 
1.25×10
5
 cells/cm
2
. The cell population contained >70% of CD14 positive cells and no 
contamination by CD3-positive T lymphocytes, as determined by flow cytometry (Oliveira et al., 
2012). Cells were allowed to differentiate in RPMI medium (Gibco, Life technologies S.A., Madrid, 
Spain) supplemented with 10% of heat-inactivated (56 °C, 30 min) fetal bovine serum (Lonza, 
Barcelona, Spain) for additional 8 days. Ten days after isolation, monocyte-derived macrophages 
were stimulated with 10 ng/ml lipopolysaccharide (LPS; Sigma) for 72 h. Specific cell treatments 
were performed after LPS activation. 
 
2.5.2. Cell culture 
The effect of ibuprofen on macrophage metabolic activity was assessed by means of a resazurin-
based assay. In brief, different ibuprofen solutions in ethanol–water mixtures (7:3) were prepared 
and added (5 μl) to the cell culture media (500 μl) in order to obtain a final drug concentration 
ranging from 0.001 mg/ml to 1 mg/ml. Cell metabolic activity was evaluated at 24 h and 72 h after 
treatment. At the defined time-point cells were incubated (4 h, 37 °C) with a resazurin (Sigma-
Aldrich) solution (0.1mg/ml, in PBS) and the fluorescence (λex=530nm, λem=590nm) in the cell 
culture medium was measured (SynergyMx; Biotek). Results are represented as percentage of 
cell viability relative to cells treated with equal volume of the ibuprofen solvent (5 μl).  
In order to evaluate the bioactivity of ibuprofen released from P(TMC-CL) electrospun fibres, fibre 
discs (14mm) were incubated with macrophages for 72 h. The fibres tested were prepared from 
1:0 DCM–DMF solutions loaded with 5% ibuprofen (w/w of polymer). The punched discs weighed 
between 0.9 mg and 3 mg. Fibre sterilization was performed by irradiating (gamma rays, 25 kGy, 
60
Co source) samples previously packed under vacuum. Fibre discs were suspended in the well 
without direct contact with the cells. Macrophages treated with ibuprofen in the medium (final 
concentration 0.1mg/ml), as well as cells cultured in presence of unloaded P(TMC-CL) fibres, 
were used as control. 
 
2.5.3. Immunofluorescence 
To analyse cell morphology, macrophages were fixed with 4% (w/v) paraformaldehyde (Merck) 
and immunostained for α-tubulin and F-actin as follows. Cell external fluorescence was quenched 
by treating the cells with 50mM NH4Cl for 10 min. Subsequently, cells were permeabilized with 
0.1% (v/v) Triton X-100 (in PBS) for 5 min. After washing with PBS, cells were incubated with 5% 
(w/v) bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 30 min and, thereafter, incubated 
with the primary antibody mouse anti-α-tubulin (1:4000; Sigma-Aldrich) for 1 h. Subsequently, 
cells were thoroughly washed and incubated with Alexa Fluor 594 goat anti-mouse IgG (1:1000; 
Invitrogen, Life technologies Madrid, Spain) for 45 min. F-actin was stained for 15 min using 5 μM 
Phalloidin-FITC (Sigma-Aldrich). Cells were washed with PBS and mounted on Vectashield with 
4′,6- diamidino-2-phenylindole (DAPI; Vector Laboratories, Peterborough, UK). Samples were 
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observed under an inverted fluorescence microscope (Axiovert 200; Zeiss, Oberkochen, 
Germany). 
 
2.5.4. PGE2 and quantification of cytokines 
At the defined time-point (72 h after treatment), cell culture supernatants were collected and, after 
centrifugation (16000 g, 4 °C, 10min) to remove cell debris, stored at –20 °C for posterior analysis. 
The concentration in the cell culture supernatant of PGE2 (Cayman Chemical, Ann Arbor, MI, 
USA), interleukin 6 (IL-6), IL-10 and tumour necrosis factor-α (TNFα) were quantified by enzyme-
linked immunosorbent assay (ELISA; Biolegend, San Diego, CA, USA) following the 
manufacturer's instructions. Results are presented normalized for the total protein content in the 
cell culture medium, as determined by the DC protein assay (Bio-Rad, Amadora, Portugal). 
 
2.6. Statistical analysis 
Statistical analysis was performed using PRISM 5.0 software (GraphPad, La Jolla, CA, USA). 
Statistical differences between two groups were calculated applying a t-test when analysing 
results from PGE2 and release of cytokines. Mean fibre diameters obtained when using different 
solvent combinations loaded or unloaded with ibuprofen were analysed using non-parametric 
Kruskal–Wallis test and Bonferroni correction for multiple comparisons. A p-value lower than 0.05 
was considered statistically significant. 
 
3. Results 
3.1. Characterization of P(TMC-CL) and ibuprofen-loaded P(TMC-CL) fibres 
3.1.1. Fibre morphology 
The influence of solvent composition on P(TMC-CL) fibre morphology was evaluated by testing 
different DCM–DMF mixtures (Figure 1, Table 1). Fibres prepared from 1:0 DCM–DMF solutions 
showed a broad diameter distribution. Improved homogeneity of the fibres was observed when 
increasing the DMF fraction in solution, as shown by the narrowing of the fibre diameter 
distribution (Figure 1). The fibre mean diameter was found to be 1.09±0.10 μm for fibres prepared 
from 1:0 DCM–DMF solutions, decreasing to 0.48±0.03 μm for fibres prepared from 1:1 DCM–
DMF solutions (Table 1). 
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Figure 1. Representative scanning electron microscopy photomicrographs of poly(trimethylene carbonate-
co-ϵ-caprolactone) [P(TMC-CL)] fibres and fibre diameter distribution (n=3). Samples were prepared using 
P(TMC-CL) solutions in a dichloromethane (DCM)–N,N-dimethylformamide (DMF) mixture with increasing 
amounts of DMF: (A) 1:0 DCM–DMF; (B) 6:1 DCM–DMF; (C) 3:1 DCM–DMF; (D) 1:1 DCM–DMF. Higher 
magnification images scale bar=20 μm. 
 
Table 1: Poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] electrospun fibres diameter. 
Fibre diameter (μm) 
 1:0 DCM-DMF 6:1 DCM-DMF 3:1 DCM-DMF 1:1 DCM-DMF 
Non-loaded 1.09 ± 0.10 1.02 ± 0.19 0.67 ± 0.12 0.48 ± 0.03 
Ibuprofen 5% 0.84 ± 0.08 0.91 ± 0.09 0.76 ± 0.06 – 
Ibuprofen 10% 1.2 ± 0.05 0.91 ± 0.2 0.84 ± 0.12 – 
Mean diameter ± standard deviation (n=3) of P(TMC-CL) fibres prepared from dichloromethane (DCM)–N,N-
dimethylformamide (DMF) solutions at ratios of 1:0, 6:1, 3:1 and 1:1 in the absence or presence of 5% and 
10% of ibuprofen (w/w of polymer), respectively. Standard deviation represents variability between different 
samples.  
 
Ibuprofen-loaded P(TMC-CL) fibres were prepared by adding 5 % and 10 % of the drug (w/w of 
polymer) to the polymer solution before electrospinning. Electrospinning parameters applied were 
the same as those optimized for the preparation of the non-loaded fibres. When 5% of ibuprofen 
(w/w of polymer) was added to the P(TMC-CL) solution, smaller fibres were formed, as indicated 
by the decrease in mean fibre diameter in comparison with unloaded fibres (Table 1). When 
analysing the effect of the solvent composition on the morphology of 5% ibuprofen-loaded fibres, 
under the conditions tested, fibres prepared from 1:1 DCM–DMF solutions fused (Figure 2). For 
this reason, a 1:1 DCM–DMF solutions was not tested for 10% ibuprofen loaded fibres. No 
significant differences in terms of mean fibre diameter were detected when comparing loaded 
fibres prepared from 1:0, 6:1 and 3:1 DCM–DMF solutions. However, in terms of fibre diameter 
distribution a higher percentage of bigger fibres (> 3 μm) were formed from 1:0 DCM–DMF 
Ibuprofen-loaded P(TMC-CL) fibres 
86 
solutions (Figure 2). When fibres were prepared from solutions with 10% ibuprofen (w/w of 
polymer), the high drug content led to jet instability, resulting in a less homogeneous fibre mesh. 
Under these conditions a tendency towards the formation of defects and large-diameter fibres was 
observed, as indicated by the fibre diameter distribution graphs (Figure 2), albeit the mean fibre 
diameter was not remarkably affected (Table 1). For fibres prepared from 3:1 DCM–DMF 
solutions, in particular, fusion of the deposited fibres was also observed. 
 
Figure 2. Scanning electron microscopy photomicrographs of ibuprofen-loaded poly(trimethylene carbonate-
co-ϵ-caprolactone) [P(TMC-CL)] fibres and respective fibre diameter distribution (n=3). Fibres were obtained 
from solutions containing 5% (A–D) and 10% (E–G) of ibuprofen (w/w of polymer) and applying different 
dichloromethane (DCM)–N,N-dimethylformamide (DMF) mixtures as solvent: (A,E) 1:0 DCM–DMF; (B,F) 6:1 
DCM–DMF; (C,G) 3:1 DCM–DMF; (D) 1:1 DCM–DMF. Higher magnification images scale bar=20 μm. 
 
3.1.2. Drug loading and distribution 
The chemical composition of ibuprofen-loaded P(TMC-CL) fibres was analysed by means of three 
spectroscopic techniques: 
1
H NMR, ATR-FTIR and Raman.  
By 
1
H NMR spectroscopy, ibuprofen was clearly distinguished from P(TMC-CL) signals (see the 
Supporting information, Figure S1). The amount of drug relative to the polymer was quantified 
using this technique. It was found that in the 5% ibuprofen (w/w of polymer) loaded P(TMC-CL) 
fibres the actual loading was 4.21±0.02 % (w/w of polymer; n=3), corresponding to a loading 
efficiency of over 80%.  
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As NMR provides information about the bulk chemical composition of the prepared samples, to 
obtain complementary chemical characterization of the fibres, these were also analysed by ATR-
FTIR. Figure 3A shows the spectra of ibuprofen-loaded P(TMC-CL) fibres prepared from 1:0 
DMC-DMF solution, unloaded fibres and ibuprofen powder. The most intense bands of ibuprofen 
are located at 2955, 1721 and 1231/cm, being assigned to CH3 asymmetric stretching, C=O 
stretching and C–C stretching, respectively (see full FTIR spectra in Figure S2). These bands 
cannot be distinguished in the ibuprofen-loaded fibres because of overlapping with the polymer 
signals. Although weak, the band corresponding to the aromatic C=C stretching vibration of 
ibuprofen (1509/cm) can be identified in the ibuprofen-loaded P(TMC-CL) fibre spectrum, 
confirming the presence of the drug in the fibres (Figure 3A). In order to identify the presence of 
subtle spectral changes in the region of the most intense bands of ibuprofen and P(TMC-CL) 
(1670–1800/cm) a second derivatization and curve fitting of the raw data was performed. Figure 
3AI, AII shows that the number of bands in that particular zone of the spectrum increases in the 
loaded polymer samples further supporting the presence of ibuprofen in the fibres. Analysis of the 
ibuprofen-loaded P(TMC-CL) spectrum compared with those of P(TMC-CL) and ibuprofen showed 
no differences other than the characteristic bands of the starting materials, suggesting that no 
chemical interaction between ibuprofen and the polymer occurred. ATR-FTIR analysis of P(TMC-
CL) fibres prepared from 3:1 DCM–DMF solutions was also performed and similar spectra were 
obtained. 
 
As a complementary technique to FTIR P(TMC-CL), individual fibres were analysed by confocal 
Raman spectroscopy. By using this technique it was possible to identify the C–C stretching 
(1610/cm) on the fingerprint region of ibuprofen (Figure 3B). The presence of this clear marker 
band allowed the use of Raman mapping to determine and compare the spatial distribution of 
ibuprofen in P(TMC-CL) fibres prepared with 1:0 and 3:1 DCM–DMF solutions. Data was acquired 
on an area of the fibre as shown in Figure 3CI, DI. Mapping was performed by rationing the 
ibuprofen fingerprint region to the background signal in two different spectral regions: 1510–
1525/cm and 1645–1665/cm. Regions with high concentration of ibuprofen are depicted in bright 
green, while regions with low ibuprofen concentration are shown in black (see Figure 3E). 
Although drug distribution is not completely homogeneous, results show no preferential 
distribution of the drug at fibre edges or in the centre for both ibuprofen containing fibres prepared 
from 1:0 and 3:1 DCM–DMF P(TMC-CL) solutions (Figure 3 (CII, DII)). 
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Figure 3. (A) Attenuated total reflectance–Fourier transform infrared spectroscopy spectrum of ibuprofen-
loaded poly(trimethylene carbonate-co-ϵ-caprolactone) [P(TMC-CL)] fibres prepared from 1:0 
dichloromethane (DCM)–N,N-dimethylformamide (DMF) solutions (pink). The spectra of ibuprofen (in green) 
and non-loaded fibres (blue) is shown for comparison. Curve fitting in the spectral region between 1670/cm 
and 1800/cm of (I) P(TMC-CL) fibres and (II) ibuprofen-loaded P(TMC-CL) fibres. (B) Raman spectra of 
ibuprofen (dark blue), P(TMC-CL) fibres (green), and ibuprofen-loaded P(TMC-CL) fibres (light blue) obtained 
from 1:0 DCM–DMF solutions. (C, D) Confocal Raman microscopy analysis of ibuprofen-loaded P(TMC-CL) 
fibres. (I) In images blue indicates the region analysed from ibuprofen-loaded P(TMC-CL) fibres prepared 
from (C) 1:0 DCM–DMF and (D) 3:1 DCM–DMF solutions, respectively (axis indicates distance in μm). (II) 
For each sample the mapping of the 1610/cm ibuprofen Raman band relative to background bands (1510–
1525/cm and 1645–1665/cm; axis indicates distance in μm) is presented. These are representative images 
from three different areas analysed. The overlay of the spectra obtained for each point is presented in Figure 
S3 (see Supporting Information). Regions with high concentration of ibuprofen are depicted in bright green (*) 
and regions with lower concentration are depicted in dark green (+). (E) Representative spectra of these 
regions are shown. 
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3.2. Drug-release studies  
The release of ibuprofen from P(TMC-CL) fibres was evaluated in PBS at 37°C, to mimic 
physiological conditions. The amount of ibuprofen released was interpolated from a calibration 
curve and the percentage of cumulative release was calculated relative to the maximum loading of 
5% (w/w of polymer).  
 
 
Figure 4. Cumulative release of ibuprofen from poly(trimethylene carbonate-co-ϵ-caprolactone) [P(TMC-CL)] 
fibres in phosphate buffered saline (PBS) (37 °C). Samples were prepared from (A) 1:0 dichloromethane 
(DCM)–N,N-dimethylformamide (DMF), (B) 6:1 DCM–DMF and (C) 3:1 DCM–DMF solutions containing 5% 
ibuprofen (w/w of polymer). Fibre concentration in PBS was 5 mg/ml (n=9). 
 
Under the experimental conditions tested, ibuprofen was released from the P(TMC-CL) fibres 
within the first 24 h of incubation in PBS (37°C), independently of the solvent mixture used for fibre 
preparation. None, or residual amounts of ibuprofen were detected in the releasing medium when 
loaded fibres were incubated for longer periods (data not shown). In the case of fibres prepared 
from 6:1 and 3:1 DCM–DMF solutions, a burst release appeared to occur (Figure 4B, C). In 
contrast, the release kinetics of ibuprofen from fibres prepared in 1:0 DCM– DMF was slower, 
suggesting time-dependency (Figure 4A).  
Analysing ibuprofen release using the Higuchi model it was found that the release profile of 
ibuprofen from P(TMC-CL) fibres prepared from 1:0 DCM–DMF solutions fitted better in the 
model, indicating that the release is diffusion dependent for the first 8 h of incubation in PBS (see 
fitting curve in Figure S5). Observation of the fibres after the drug release experiments showed 
that fibre morphology was maintained upon drug release (Figure S6). 
 
3.3. Biological evaluation 
Ibuprofen anti-inflammatory properties have been associated to its inhibitory action on COX 
(Mitchell et al., 1993). This enzyme is responsible for the formation of prostaglandins (such as 
PGE2) from arachidonic acid, and is related with the inflammatory response (for a review see 
Rainsford, 2009). To ensure that the ibuprofen incorporated into the P(TMC-CL) fibres exerted its 
biological activity, the release of cytokines and PGE2 by monocyte-derived human macrophages 
was quantified after incubating the cells with the fibres or soluble ibuprofen (positive control). 
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Taking advantage of the fact that P(TMC-CL) density is similar to water density and consequently 
the discs hang in cell culture medium, the fibres were incubated without direct contact with the 
adhered cells. This set up made it possible to distinguish the effect of the drug from any effect 
triggered by the polymer surface, as macrophage response and differentiation is affected by 
surface chemistry (Brodbeck et al., 2002), and by its topography (Cao et al., 2010). In this study 
the aim was to discern the effect of the released drug regardless of cell–material interaction. 
 
3.3.1. Effect of ibuprofen on macrophage cell viability and morphology 
To assess ibuprofen cytotoxic profile on monocyte-derived human macrophages, the drug was 
added in its soluble form to the cell culture medium to a final concentration ranging from 0.001–
1mg/ml. Ibuprofen solvent (ethanol 70% v/v) was also applied as a negative control. The graph 
presented in Figure 5A indicates that, at the highest concentration tested (1mg/ml), ibuprofen was 
toxic for macrophages, significantly reducing cell viability (< 10%). Similar results were obtained 
when cell metabolic activity was assessed 24 h post-treatment (data not shown). Taking into 
consideration these results, 0.1mg/ml soluble of ibuprofen was applied in the following 
experiments as control.  
 
 
Figure 5. (A) Macrophage viability when incubated for 72 h with ibuprofen at different concentrations. The 
percentage of viable cells was calculated relative to cells treated with ibuprofen solvent (ethanol 70% v/v). 
Bars represent mean values and error bars show standard deviation. Results are representative of three 
independent experiments. (B–E) Actin–tubulin cytoskeleton immunolabelling of macrophages. Macrophages 
were incubated for 72 h in the presence of (B) ethanol 70% (v/v), (C) ibuprofen 0.1mg/ml, (D) 
poly(trimethylene carbonate-co-ϵ-caprolactone) [P(TMC-CL)] fibres, and (E) ibuprofen-loaded P(TMC-CL) 
fibres. Scale bar=100 μm. α-Tubulin is shown in red, F-actin in green and the cell nucleus in blue. Magnified 
images of each condition are also presented (scale bar=20 μm). 
 
The effect of ibuprofen-loaded P(TMC-CL) fibres on macrophage morphology was investigated by 
observing the distribution pattern of cytoskeleton proteins (α-tubulin and F-actin). Therefore, 
human primary macrophages were incubated for 72 h with soluble ibuprofen at a final 
concentration of 0.1 mg/ml, with ethanol (70% v/v, ibuprofen solvent), with P(TMC-CL) fibres or 
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with ibuprofen-loaded P(TMC-CL) fibres. In all the experimental conditions tested macrophages 
showed evidence of heterogeneous cell morphology, with round-shaped cells and F-actin staining 
concentrated at the cell periphery in podosome-like structures, and elongated cells with less 
intense and peripheral F-actin staining. In contrast, α- tubulin staining was always homogeneously 
distributed along the cell body and according the cell axis (Figure 5). No significant differences in 
terms of macrophage morphology were observed between the different experimental conditions. 
 
3.3.2. Anti-inflammatory properties of ibuprofen loaded P(TMC-CL) fibres 
To assess if the ibuprofen released from ibuprofen-loaded P(TMC-CL) electrospun fibres is 
bioactive, the concentration of soluble PGE2 produced by exposed macrophages was quantified in 
the cell culture supernatants after 72 h of incubation. 
 
 
Figure 6. Effect of ibuprofen on (A) prostaglandin E2 (PGE2) and (B) cytokine [interleukin (IL)-6 and IL-10] 
release by human macrophages. Results are expressed as box-whisker plots showing the quantification of 
(A) PGE2 or (B) IL-6 and IL-10 released into the cell culture medium after 72 h in contact with soluble 
ibuprofen added in solution to the cell culture medium or released from P(TMC-CL) electrospun fibres. The 
P(TMC-CL) fibres were prepared from 1:0 dichloromethane (DCM)–N,N-dimethylformamide (DMF) solutions. 
Cells incubated with non-loaded fibres (Fibre) or with ibuprofen (IBU) solvent (ethanol 70% v/v, Control) were 
used as controls. Results were obtained from cells from five independent donors and seven samples and are 
normalized by the total amount of protein in the supernatant. The p-value calculated by t-test. 
 
The results (Figure 6) indicate that when ibuprofen is added to the medium the release of PGE2 
decreases, suggesting that COX is being inhibited. The same tendency is observed when 
comparing the effect of ibuprofen-loaded fibres and non-loaded fibres (Figure 6), although none of 
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the differences achieved statistical significance. In terms of inhibition, considering the mean 
values, when ibuprofen is added in solution there is a 56% decrease in PGE2 release, while 
ibuprofen released from P(TMC-CL) electrospun fibres can reduce the release of PGE2 by 47%. 
However, when comparing the effect of ibuprofen released from P(TMC-CL) fibres directly with 
control conditions one should take into account that the amount of drug that can be released from 
P(TMC-CL) fibres is in a concentration range and can slightly differ from the control concentration 
used in this assay.  
The effect of ibuprofen on the release of IL-6, IL-10 and TNFα was also evaluated. Under the 
experimental conditions of this study, ibuprofen was found to induce no significant effect on the 
release of IL-6 or IL-10 when added in solution or when released from electrospun P(TMC-CL) 
fibres (Figure 6). The concentration of TNFα secreted into the cell culture medium was found to be 
below the detection limit (3.5 pg/ml) of the ELISA assay (data not shown). 
 
4. Discussion 
The preparation of nerve conduits by electrospinning holds the promise of allowing easy 
preparation of fibres, at the nanometre scale, that can guide axonal growth and be loaded with 
biologically active molecules able to enhance nerve regeneration processes (Lee and Arinzeh, 
2011). In the present work, the aim was to prepare fibres of a statistical copolymer of TMC and CL 
with low TMC content (11 mol%) by electrospinning and to load these with an anti-inflammatory 
drug. The idea beyond this strategy is to design scaffolds that can provide physical support for 
nerve cell growth, and that simultaneously minimize, at the lesion site, the inflammatory reaction 
that could counteract nerve regeneration. The preparation of electrospun structures based on a 
block copolymer of TMC and CL (Jia et al., 2006) or blends of P(TMC) and P(CL) (Han et al., 
2010) have been reported in the literature. Nevertheless, a statistical copolymer holds the 
advantage of reducing the formation of crystalline domains and reducing phase separation within 
the polymer structure, which is desirable when envisaging the use of these materials in 
implantable devices (Pêgo et al., 2001). The authors have previously reported on the use of 
selected statistical P(TMC-CL) for the preparation of microporous and macroporous conduits for 
nerve reconstruction in the peripheral nervous system. P(TMC-CL) with a high CL content has 
been shown to possess adequate mechanical properties and degradation rate to be used in a 
nerve regeneration strategy (Pêgo et al., 2001, 2003), as it is able to support nerve regeneration 
in vivo (Vleggeert-Lankamp et al., 2008). This paper describes for the first time the preparation of 
electrospun fibres from this copolymer. 
By using different DCM–DMF mixtures in the electrospinning solution it was possible to prepare 
fibrous meshes with variable mean fibre diameter. Increasing the DMF content in solution, mean 
fibre diameter was decreased from 1.09 μm to 0.48μm. DMF is a high conductivity solvent, and its 
use in the preparation of solutions for electrospinning leads to an increase in jet splaying and a 
reduction of fibre diameter (Hsu and Shivkumar, 2004). Typically, DMF is used below 30% in 
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solution, as described for the preparation of fibres of P(CL) (Bölgen et al., 2005) and 
P(CL)/P(TMC) blends (Han et al., 2010). Herein, the preparation of fibres from solutions 
containing up to 50% of DMF was explored. Results show that by increasing the DMF content one 
can obtain very homogeneous fibre meshes, with narrower fibre diameter distribution and smaller 
mean fibre diameter. However, the use of 1:1 DCM–DMF solutions was revealed to be unsuitable 
for the preparation of ibuprofen-loaded P(TMC-CL) fibres at the drug concentrations tested. It was 
previously described that the incorporation of drugs in electrospinning solutions can lead to an 
increase in solution conductivity (Kim et al., 2004). This increase, combined with the high DMF 
content, may cause fibres to bind together because of the high conductivity (Heikkilä and Harlin, 
2008) and high boiling point of DMF, which prevent solvent evaporation during fibre deposition 
(Hsu and Shivkumar, 2004). 
Ibuprofen-loaded fibres were obtained from 1:0, 6:1 and 3:1 DCM–DMF mixtures. In terms of 
morphology, when applying a 5% of ibuprofen (w/w of polymer) load, a tendency towards a 
decrease in mean fibre diameter is observed compared with unloaded fibres. This effect is 
particularly noticeable for 1:0 DCM–DMF solutions, probably because the presence of the drug led 
to a more marked increase in solution conductivity compared with solutions containing DMF (Kim 
et al., 2004). Although the differences in terms of mean fibre diameter are not significant, when 
loading 10% ibuprofen in solution, jet stability and solvent evaporation are reduced, the latter 
being particularly evident in the case of the 3:1 DCM–DMF solution. The increase in jet instability 
with higher drug loading has also been reported previously (Natu et al., 2010). 
The presence of ibuprofen in P(TMC-CL) fibres was clearly demonstrated by ATR-FTIR and 
Raman spectroscopy. Both techniques showed that the chemical stability of ibuprofen is 
maintained after electrospinning. In addition, no alterations in the characteristic peaks of P(TMC-
CL) and ibuprofen are seen in ibuprofen-loaded P(TMC-CL) spectrum, indicating that there is no 
significant chemical interaction between the polymer and the drug, as previously observed in 
ibuprofen-loaded cellulose acetate fibres (Tungprapa et al., 2007).  
The ibuprofen release kinetics from P(TMC-CL) fibres were assessed in physiological medium 
(PBS, 37 °C). Results demonstrate that ibuprofen is released within the first 24 h after incubation 
in PBS, independently of the solvent mixture used for the preparation of the fibres. It was 
previously reported that the expression of cycloxygenase-2 peaks 3 h after spinal cord injury 
(SCI), and is maintained for 3 days (Adachi et al., 2005). In this context, the release of ibuprofen in 
the early hours after the lesion can provide the expected therapeutic benefit. A complete ibuprofen 
release in the first 24 h of incubation under physiological conditions has also been reported using 
cellulose acetate fibres (Tungprapa et al., 2007). In terms of kinetics, we found an initial burst 
release for fibres prepared from 6:1 and 3:1 DCM–DMF mixtures. However, in the case of fibres 
prepared from 1:0 DCM–DMF the release was found to be diffusion dependent, as it fits the 
Higuchi model for drug release (Siepmann and Peppas, 2001). Indeed, the cumulative amount of 
ibuprofen correlates with the square root of the time (R
2
>0.94) for the first 8 h of incubation for 
fibres prepared from 1:0 DCM–DMF solutions. Conversely, no linearity was observed for ibuprofen 
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release from P(TMC-CL) fibres prepared from the 3:1 and 6:1 DCM–DMF solutions. It was 
hypothesized that the presence of DMF in solution could affect the drug distribution within the 
fibre, leading to a burst release compared with fibres prepared from solutions without DMF. To 
address this point samples were analysed using confocal Raman microscopy. To the best of the 
authors' knowledge this is the first report using confocal Raman microscopy to assess drug 
distribution in an electrospun fibre. Mapping experiments by confocal Raman allowed screening of 
specific areas within an electrospun fibre. By using a step slightly smaller than the theoretical size 
of the spot of the laser beam (0.7 μm), mapping experiments provided the profiling of all the 
sample area and discrimination of subtle differences in composition (Adar, 2008). The mapping of 
the drug in P(TMC-CL) fibres showed that ibuprofen distribution was not completely homogenous. 
Nevertheless, at the spatial resolution offered by the experimental setup used, no preferential 
localization of the drug was identified that could be correlated with the burst release (for example, 
at the fibre edge). In addition, no significant differences were detected when comparing fibres 
prepared from 1:0 and 3:1 DCM–DMF solutions, suggesting that, at the submicrometer scale, the 
drug distribution is independent of the solvent mixture applied during electrospinning. The results 
indicate that other parameters are probably playing a role in ibuprofen release, for example the 
fibre diameter (Cui et al., 2006). Although no significant differences were detected in terms of 
mean fibre diameter, the fibre diameter distribution was different between these two types of 
samples. In fibres prepared from 1:0 DCM–DMF mixtures the presence of a small percentage of 
fibres with a large diameter (> 3 μm) was observed and could have contributed to delaying the 
release of the drug by increasing the drug diffusion pathway within the polymeric fibre structure. 
Owing to the important role of macrophages as effectors of an inflammatory response and as 
these cells are targets of ibuprofen, primary human monocyte-derived macrophages were 
selected to evaluate ibuprofen bioactivity after the release from electrospun fibres. Macrophages 
are highly dynamic and versatile cells, and their response to exogenous stimuli is generally 
accompanied by alterations in actin assembly/disassembly and cell morphology. These alterations 
may occur as a consequence of a number of effects such as surface topography (Cao et al., 
2010), drugs (Chiou et al., 2003) or soluble factors (Shinji et al., 1991; Porcheray et al., 2005). 
Thus, the effect of ibuprofen-loaded P(TMC-CL) fibres on macrophage morphology was 
investigated by observing the distribution patterns of cytoskeleton proteins (α-tubulin and F-actin). 
The results show no major alterations of actin/tubulin cytoskeleton organization in macrophages 
incubated with ibuprofen or ibuprofen-loaded P(TMC-CL) fibres. However, it cannot be excluded 
that, to be perceived, considerable alterations would need to have occurred in the heterogeneous 
macrophage cell population under study. Cells incubated with ibuprofen-loaded P(TMC-CL) fibres 
secreted less PGE2 into the cell culture medium than did non-loaded fibres. Although the result did 
not accomplish the statistical significance (p=0.06) because of the high variability between cell 
donors, this result strongly suggests that the drug incorporated in the electrospun fibres retains its 
bioactivity. This result is reinforced by the fact that the percentage of inhibition obtained (47%) is 
similar to that found with treatment with ibuprofen in solution (56%).  
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In addition to the classical view of ibuprofen activity, acting on the prostaglandin pathway, there is 
mounting evidence that lowering levels of eicosanoids is not the only mechanism by which 
ibuprofen exerts its effects (Stuhlmeier et al., 1999; Zhou et al., 2003). Stuhlmeier and co-workers 
(1999) showed that ibuprofen can inhibit the nuclear translocation of the nuclear factor kappa B 
(NF-kB), a transcription factor critical for the up-regulation of expression of pro-inflammatory 
genes. These reports prompted evaluation of the concentration of pro-inflammatory cytokines 
(TNFα and IL-6) and an anti-inflammatory cytokine (IL–10) in the cell culture medium in this study. 
Under the experimental conditions applied in this study, no significant levels of TNFα were found 
in the cell culture medium. For IL-6 and IL-10, no major differences were found when comparing 
cytokine levels secreted by cells incubated with ibuprofen-loaded P(TMC-CL) fibres or non-loaded 
fibres. Similar results were obtained when cells were treated with ibuprofen in the medium 
(0.1mg/ml), suggesting that under the set conditions the drug exerts no effect on the cytokine 
release profile. In the literature divergent effects on cytokine release are ascribed to ibuprofen. 
Some authors have shown that ibuprofen induces a decrease in the secretion of TNFα and IL-1β 
by mononuclear cells (Stuhlmeier et al., 1999; Lamanna et al., 2012), whereas a concentration-
dependent increase of TNFα and IL-6 has been observed by others (Sirota et al., 2001; Lee and 
Chuang, 2010). Recently, Lamanna and colleagues (2012) reported the inhibition of TNFα 
secretion by a macrophage cell line when cells were incubated with a high concentration of 
ibuprofen (1mg/ml). However, when applying this concentration, the authors (Lamanna et al., 
2012) also found ibuprofen-mediated cytotoxicity and, in agreement with the results of the present 
study, incubating cells with 0.1mg/ml of ibuprofen was found to have no effect on IL-6 and TNFα 
release into the culture medium. 
 
5. Conclusions 
Fibres from P(TMC-CL) were successfully prepared by electrospinning. It is shown here that by 
adjusting the solvent composition, one can change the mean fibre diameter in a controlled 
manner. An anti-inflammatory drug can be loaded in P(TMC-CL) fibres, the release kinetics being 
dependent on fibre morphology, which is tuned by the solvent mixture applied for preparation of 
the electrospinning solution. Ibuprofen was found to maintain its chemical stability and bioactivity 
after electrospinning, as demonstrated by the fact that the drug was able to reduce the amount of 
PGE2 secreted into the cell culture medium by human macrophages. The use of confocal Raman 
microscopy as a mean to assess the drug distribution within electrospun fibres is also proposed 
for the first time, being a promising technique to provide new cues on the drug-release process.  
The results provide an important insight into the design of a P(TMC-CL)-based nerve conduit 
combining physical cues provided by the fibres with an anti-inflammatory signalling molecule, 
which, together, can assist nerve regeneration. 
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Supporting information 
 
 
Figure S1. 
1
H Nuclear magnetic resonance spectrum of ibuprofen-loaded poly(trimethylene carbonate-co-ε-
caprolactone) [P(TMC-CL)] fibres, showing the identification of ibuprofen characteristic peaks. 
 
 
Figure S2. Full attenuated total reflectance Fourier transform infrared spectrum of ibuprofen (grey), 
ibuprofen-loaded poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] fibres (black) and P(TMC-CL) 
(red). 
 
Ibuprofen-loaded P(TMC-CL) fibres 
 
102 
 
Figure S3. Overlay Overlay of spectra obtained from mapping experiments of ibuprofen-loaded 
poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] fibres prepared from (A) 1:0 dichloromethane 
(DCM)–N,N-dimethylformamide (DMF) and (B) 3:1 DCM–DMF solutions. 
 
 
Figure S4. Standard calibration curve obtained for ibuprofen. 
  
 
 
Figure S5. Fittings according to Higuchi model for drug release for fibres prepared from (A) 1:0 
dichloromethane (DCM)–N,N-dimethylformamide (DMF), (B) 6:1 DCM:DMF and (C) 3:1 DCM–DMF.  
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Figure S6. Scanning electron microscopy photomicrographs of ibuprofen-loaded poly(trimethylene 
carbonate-co-ε-caprolactone) [P(TMC-CL)] fibres prepared from 1:0 dichloromethane (DCM)–N,N-
dimethylformamide (DMF) solution (A) before and (B) after ibuprofen release. 
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Abstract  
It is now well accepted that a therapeutic strategy for spinal cord injury demands a multi-target 
approach. Here we propose the use of a poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-
CL)]-based scaffold that gathers physical guidance cues provided by electrospun aligned fibres 
and the delivery of ibuprofen as a mean to reduce the inhibitory environment at the lesion site by 
targeting RhoA activation. Bilayer scaffolds were prepared being composed by a solvent cast film 
onto which electrospun aligned fibres have been deposited. Both layers were loaded with the 
ibupofen. The release of the drug was found to occur in the first 24 hrs of incubation when this 
was assessed in vitro under physiological conditions. The bioactivity of the released drug was 
demonstrated by the inhibition of RhoA activation when the neuronal ND7/23 cells were 
challenged with lysophosphatidic acid. The ibuprofen-loaded bilayer scaffolds were successfully 
implanted in vivo in a dorsal hemisection SCI model. The implantation of the scaffold did not 
compromise animal survival. The effect of scaffold implantation and ibuprofen release on RhoA 
activity, and the histological characterization of the tissues are under investigation. 
 
 
 
Keywords 
Spinal cord injury; Ibuprofen; electrospinning, RhoA. 
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1. Introduction 
Injury to the spinal cord is marked by the disruption of ascending and descending axonal 
pathways, interrupting the communication between the brain and other parts of the body. In the 
adult central nervous system (CNS) axonal regrowth after injury, necessary to restore 
connectivity, is prevented by the lack of physical support and by the presence of inhibitory 
molecules in the extracellular milieu (see [1, 2] for a review). The Ras homolog gene family, 
member A (RhoA) is considered a key convergence effector for several of these molecules 
involved in inhibitory processes. It has been demonstrated that the use of RhoA antagonists can 
promote axonal regeneration and functional recovery [3-5]. Consequently, limiting RhoA activation 
has been pointed out as a promising therapeutic approach for spinal cord injury (SCI).  
In 2003, it was reported for the first time that some non-steroidal anti-inflammatory drugs, namely 
ibuprofen, can inhibit RhoA signalling [6]. Some years later, it was demonstrated that ibuprofen 
can prevent myelin mediated inhibition of neurite outgrowth in vitro [7] and, in different in vivo 
models of SCI, the administration of ibuprofen showed to promote corticospinal axonal 
regeneration [7] and functional recovery [7, 8]. A re-assessment study [9] aiming at replicating the 
first results obtained with ibuprofen on SCI [7] has recently confirmed that ibuprofen inhibits RhoA 
activation, although the significant improvement on corticospinal axonal regeneration was not 
achieved [9]. The administration of ibuprofen has also been associated with the reduction of 
neuropathic pain [10] and the increase of oligodendrocyte survival and axonal myelination [11], 
further supporting the use of the drug in the context of SCI.  
Ibuprofen has been used worldwide for pain relief, lowering fever and acute inflammatory reaction 
based on its action as an inhibitor of cyclooxygenases [12, 13]. Due to its widespread use, 
ibuprofen long-term administration presents an acceptable risk profile and reduced economical 
costs [14], holding a great potential to become a new therapeutic tool for SCI [14]. 
Considering the increasing evidence that the multi-faced inhibitory nature of SCI will imply a 
combinatorial therapeutic approach [15], the present work aimed at designing a scaffold that can 
be implanted at the lesion site after SCI, providing guidance for axonal growth and also the 
delivery of ibuprofen as a mean to convert the lesion site in a more permissive substrate for 
regeneration. Here we explore the application of poly(trimethylene carbonate-co-ε-caprolatone) 
[P(TMC-CL)], a synthetic copolymer previously applied for the preparation of nerve conduits [16], 
as starting material for the development of a scaffold based on longitudinally aligned nanofibres. 
In a SCI scenario, the use of aligned fibrous scaffolds is of particular interest as these structures 
can provide physical guidance cues for neurons, allowing cellular processes to orient in the 
direction of the fibres in vitro [17, 18] and ultimately leading to improved regeneration in vivo [19]. 
It has been demonstrated that P(TMC-CL) can support peripheral nerve regeneration in vivo [20] 
and, in the context of the CNS, P(TMC-CL) showed to stimulate neuronal polarization and axonal 
elongation, favouring neurite outgrowth when in an inhibitory environment [21]. Our group has 
previously described the preparation of P(TMC-CL) fibres by electrospinning and demonstrated 
that these structures can combine the delivery of ibuprofen, yielding fibres with anti-inflammatory 
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properties [22]. Here the inhibition of RhoA pathway by ibuprofen-loaded P(TMC-CL) scaffolds 
was investigated both in vitro and in vivo. 
 
2. Materials and Methods 
2.1. Scaffolds preparation and design 
Bilayer scaffolds were prepared using a statistical P(TMC-CL) copolymer. The copolymer was 
prepared by ring-opening polymerization and subsequently purified as previously described [23]. 
In brief, ε-caprolactone (CL) (Merck, Germany) was dried overnight (calcium hydride; Sigma-
Aldrich Química, Portugal) and distilled before the polymerization with trimethylene carbonate 
(TMC, used as received from Boehringer Ingelheim, Germany). Polymerization was carried out in 
evacuated and sealed glass ampoules using stannous octoate (Sigma-Aldrich Química, Portugal) 
as catalyst (2×10
–4
 mol per mol of monomer). After 3 days of reaction at 130°C the polymer 
obtained was purified by dissolution in chloroform (BDH-Prolabo, Portugal) and subsequent 
precipitation into a tenfold volume of ethanol (96%, v/v; AGA, Portugal). The chemical composition 
of the purified copolymer was assessed by 
1
H nuclear magnetic resonance (NMR) and found to 
contain 11% mol of TMC, being in accordance to the monomer ratio charged (10% mol TMC). The 
average number molecular weight and polydispersity index of the purified polymer were 
determined by size exclusion chromatography [22] and were found to be 8.2x10
4
 and 1.61, 
respectively.  
Bilayer scaffolds were composed by an outer layer comprising a P(TMC-CL) film prepared by 
solvent casting, and an inner layer, made of preferentially aligned electrospun P(TMC-CL) fibres 
(Figure 5, A). To prepare solvent cast films, a 6% (w/v) P(TMC-CL) solution in dichloromethane 
(DCM; Merck, Germany) was casted onto a glass mould. The solvent was left to evaporate 
overnight under a DCM saturated atmosphere at room temperature (20-25 ºC) and subsequently, 
the films were vacuum dried for 24 hrs (vacuum oven, Raypa, Spain). For the preparation of 
ibuprofen-loaded scaffolds, 5% of ibuprofen (w/w of polymer) was added to the polymer solution 
and slowly stirred for 5 hrs, before casting. Pharmaceutical grade ibuprofen (purity>99%) was 
kindly supplied by Sérgio Simões (Bluepharma, Portugal). 
Based on previous findings from our group [22], P(TMC-CL) electrospun fibres were prepared as 
follows. P(TMC-CL) was dissolved overnight in a mixture of DCM and N,N-dimethylformamide 
(DMF, Merck) at a volume ratio of 3:1. When preparing ibuprofen-loaded fibres, the drug (5% (w/w 
of polymer)) was added to the polymer solution and stirred for 5 hrs before electrospinning. The 
prepared solutions were dispensed at a controlled flow rate of 1 ml.h
-1
 using a syringe pump (Ugo 
Basille, Italy). The blunt needle serving as spinneret (inner diameter 0.8 mm) was placed at 13 cm 
from the collector and an 18 kV electric field was applied (Gamma High Voltage source; FL, USA). 
The fibres were collected onto P(TMC-CL) solvent cast films covering a cylindrical drum (10 cm 
diameter, 15 cm of length, Yflow, Spain) rotating at 3000 rpm. The fibres were collected during 2.5 
hrs and subsequently the scaffolds were vacuum dried for 24 hrs. 6x5 mm bilayer scaffolds were 
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punched out and packed under vacuum after an argon purge. Samples were sterilized by gamma 
irradiation (25 kGy, 
60
Co source) prior further use.  
 
2.2. Scaffolds characterization 
The scaffolds were observed by scanning electron microscopy (SEM) using a FEI Quanta 
400FEG microscope (FEI, the Netherlands) after being sputter-coated with gold-palladium for 90 
seconds (SPI Supplies, PA, USA). Fibre diameter and alignment were quantified from SEM 
micrographs using Image analysis software (Image J, version 1.39, NIH, MD, USA). The fibre 
mean diameter was calculated from, at least, 100 measurements from 3 independent samples. To 
calculate fibre alignment, the preferential direction of the alignment was defined for each image 
and subsequently the angle formed between the fibres and this axis was measured. Results are 
presented as percentage relative to the total number of fibres measured from 3 independent 
samples. 
 
2.3. Drug release quantification 
The amount of ibuprofen released from P(TMC-CL) scaffolds was evaluated as follows. Samples 
were incubated at 37ºC and 120 rpm (Orbital Shaker Oven, IKA, Germany) in phosphate buffered 
saline (PBS) at the final concentration of 5 mg.ml
-1 
(mass of fibres/volume of PBS). At defined time 
points (0.5, 1, 2, 4, 6, 8, 24 and 48 hrs), the releasing medium was refreshed. The amount of 
ibuprofen released was quantified by high-pressure liquid chromatography (HPLC). In brief, the 
equipment used was an HPLC system (LaChrom Elite
®
, Hitachi Portugal) equipped with a variable 
wavelength diode array detector (L-2455). Separation was performed using a Lichrosorb RP-18 
column (5 μm, 12.5 x 0.4 cm, Merck) and a mobile phase consisting on a mixture of acetonitrile 
and ortho-phosphoric acid 0.015 M (45:55, (v/v), all supplied by Merck). Flow rate was set to 2.5 
ml.h
-1
 and separation occurred at 40ºC, whereas detection was performed at 25ºC. Ibuprofen was 
detected at 230 nm after 10 μl sample injection. Cumulative release was calculated relative to the 
theoretical maximum loading of 5% (w/w of polymer). 
 
2.4. Cell Culture 
ND7/23 cell line (mouse neuroblastoma (N18 tg 2) x rat dorsal root ganglion neuron hybrid) was 
obtained from ECACC (United Kingdom) and routinely cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) with Glutamax, supplemented with 10% (v/v) of heat inactivated (56ºC, 30 
minutes) foetal bovine serum (FBS) and 1% penicillin/streptomycin (PS, 10,000 units.ml
-1
 penicillin 
and 10,000 g.ml
-1
 streptomycin), all supplied by Gibco (Life technologies S.A., Spain).  
To test the effect of ibuprofen on these cells, ND7/23 cells were sub-cultured using supplemented 
DMEM at a cellular density of 2x10
4
 viable cells.cm
-2
. To promote cell differentiation, 24 hrs after 
seeding the cell culture medium was replaced by differentiation medium containing 0.5% FBS, 1% 
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PS, 200 nM nerve growth factor (NGF, Calbiochem, Merck), and 1 mM cyclic adenosine 
monophosphate (cAMP, Sigma-Aldrich). Cells were allowed to differentiate for 2 days before 
further treatment. 
 
2.5. Effect of ibuprofen on ND7/23 cell metabolic activity  
The effect of ibuprofen on ND7/23 cell metabolic activity was assessed by means of a resazurin-
based assay. In brief, different ibuprofen solutions in ethanol:water (7:3) were prepared and added 
(5 μl) to the cell culture medium (500 μl) in order to obtain a final drug concentration ranging from 
50 to 2000 μM. After a 24 hrs treatment, cells were incubated (4 hrs, 37 °C) with a resazurin 
(Sigma-Aldrich) solution (0.1 mg.ml
-1
, in PBS). Fluorescence (λex= 530 nm, λem= 590 nm) in the 
cell culture medium was measured (SynergyMx, Biotek, Portugal). Results are represented as 
percentage of cell metabolic activity relative to cells treated with equal volume of the ibuprofen 
solvent (5 μl).  
 
2.6. In vitro inhibition of RhoA activation by ibuprofen  
To investigate whether ibuprofen released from P(TMC-CL) scaffolds could influence RhoA 
activation in ND7/23 cells, extracts from the ibuprofen-loaded scaffolds (Ibuprofen scaffold) were 
firstly prepared as follows. Scaffolds were incubated in DMEM at 37ºC (80 rpm) during 72 hrs. The 
volume of DMEM used was adjusted according to the weight of scaffolds in order to achieve, after 
the total release of ibuprofen, a theoretical drug concentration of 500 µM. The concentration was 
selected based on a previous report showing ibuprofen-mediated inhibition of RhoA pathway in 
the PC12 cell line [7]. The obtained extracts were then tested on differentiated ND7/23 cells. In 
brief, after a starving period of 2 hrs in DMEM without serum, cell culture medium was replaced by 
the ibuprofen-containing extracts obtained from the P(TMC-CL) scaffolds. Ibuprofen solution (100x 
in ethanol:water (7:3)) was added to the cell culture media to a final concentration of 500 µM to 
serve as control (Ibuprofen soluble). After 30 minutes, the cells were activated with 45 µM of 
lysophosphatidic acid (LPA, Sigma-Aldrich) for 10 minutes. Non-treated cells were applied as 
negative control, and cells activated with LPA served as positive control for RhoA activation.  
RhoA activation was assessed using Rhotekin RBD-coupled beads (Millipore, MA, USA) 
according to manufacturer instructions. Cell lysates were prepared using Mg
2+
 lysis buffer (MLB) 
containing 25 mM HEPES, 1% Tergitol (v/v) and 10 mM MgCl2 (Sigma-Aldrich), and 150 mM 
NaCl, 1% (w/v) EDTA and 10% (v/v) glycerol from BDH-Prolabo (Portugal) and a protease 
inhibitors cocktail (Sigma-Aldrich). Lysates were clarified by centrifugation (20,000xg, 4ºC, 5 
minutes) and snap frozen prior further use. Total protein content was quantified using DC protein 
assay (Bio-Rad, Portugal). Lysates containing 1 mg of total protein were incubated with RBD-
coupled beads during 1 hr at 4ºC under slow rotation. After two washing steps, the beads were 
resuspended in 2x laemmli buffer (Bio-Rad) containing β-mercaptoethanol, boiled at 95ºC (10 
minutes) and filtered using Mobicol filters (35 µm, Mobitec, Germany). Bound GTP-RhoA along 
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with 25 µg of total lysate were separated in a 12% (w/v) SDS-polyacrilamide gel and detected by 
western blot. Briefly, gels were transferred to Hybond nitrocellulose ECL membrane (Amersham, 
GE Healthcare Europe GmbH, Portugal) and blocked in a 5% skim milk in PBS containing 0.1% 
(v/v) Tween-20 (PBS-T). The membranes were incubated overnight with a mouse anti-RhoA 
antibody (1:500, sc-418; Santa Cruz Biotechnology, CA, USA) followed by a 1 hr incubation with 
horseradish peroxidase-labelled sheep anti-mouse IgG (1:3,000, Amersham). After extensive 
washing the immunoreactive bands were detected using WesternBright Quantum 
Chemiluminescent Substrate (Advansta, CA, USA) and visualized by autoradiography on an 
Amersham Hyperfilm ECL (GE Healthcare Europe). The relative intensity of protein bands was 
analyzed using Quantity One (version 4.6) program (Bio-Rad). Results are expressed as the ratio 
between the activated protein form of RhoA (RhoA-GTP) and the total protein (RhoA). 
 
2.7. Preliminary in vivo testing – dorsal hemisection model 
All experiments involving animals and their care were conducted in compliance with institutional 
ethical guidelines and with the approval of Portuguese Veterinary Authorities – Direcção Geral de 
Veterinária (DGAV). Female adult Wistar rats (10 - 13 weeks) were anesthetized with 
ketamine/medetomidine (100 mg.kg
-1
 ketamine; 1 mg.kg
-1
 medetomidine). Laminectomies were 
performed at the 8 and 9 vertebrae and the spinal dura mater was incised to expose the spinal 
cord. Dorsal hemisection at the T9 level was performed using a micro-scissor. The scaffolds (6x5 
mm) were implanted underneath the dura, immediately after the lesion was carried out. The 
fibrous side of the scaffolds was placed in contact with the spinal cord, ensuring that fibres were 
longitudinally aligned with the axonal pathways. The surgery site was closed in layers using 
absorbable suture (Surgicryl, Smi, Belgium). Atipamezole (1 mg.kg
-1
) was administrated to 
counteract anaesthesia. The rats were kept in heating pads 24 hrs after surgery and abdominal 
massage was performed twice a day to help bladder evacuation. Butorphanol (1 mg.kg
-1
) was 
administrated twice a day during the first two days after surgery to manage pain. 
A total of twenty animals undergone surgery and were distributed in three experimental groups as 
follows: (A) non-treated (n=6); (B) P(TMC-CL) scaffold (n=7); (C) ibuprofen-loaded P(TMC-CL) 
scaffold (n=7). All the animals were subjected to dorsal hemisection as described above being that 
animals from group A were subjected to no further treatment, and animals from group B and C 
were implanted with P(TMC-CL) scaffolds, plain or loaded with ibuprofen, respectively. Five days 
after implantation, the animals were euthanized. The scaffold was removed and 1 cm of the spinal 
cord tissue centred at the lesion site was collected and divided sagitally. Part of the tissue was 
snap frozen in dry ice and stored at -80 ºC for posterior RhoA quantification. The second portion of 
the spinal cord, was fixed using 4% (w/v) paraformaldehyde at 4ºC (overnight). The samples were 
then transferred to a 30% (w/v) sucrose solution containing 0.1% (w/v) sodium azide for 
cryoprotection and stored at -20ºC before cryostat sectioning. 
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2.7.1. Histology and Immunohistochemistry  
Spinal cord tissue was embedded on optimum cutting medium (OCT, Thermo Scientific, Thermo 
Fisher Scientific, Portugal) and cut onto 16 µm thick sections using a cryostat (Thermo Scientific). 
Sections were mounted onto glass coverslips (Superfrost, VWR) and stored at -20ºC till further 
use.  
Sections were stained using haematoxilin and eosin according to standard procedures. 
For immunohistochemistry, cryostat sections were firstly incubated with 0.1% (w/v) sodium 
borohydride (5 minutes) and ammonium chloride (50 mM, 15 minutes). Afterwards, sections were 
incubated 1 hr at 37ºC with blocking buffer containing 5% (v/v) normal donkey serum (Sigma-
Aldrich) and 0.3% (v/v) Triton X-100 in PBS. The primary antibody for glial fibrillary acidic protein 
(GFAP, rabbit anti GFAP, Dako) was diluted in the blocking buffer (1:500) and incubated with the 
cryosections overnight at 4ºC. Subsequently, sections were incubated 1 hr at room temperature 
with Alexa 488-conjugated anti-rabbit secondary antibody (Invitrogen, 1:1,000). Afterwards, 
Hoechst solution (Invitrogen, 1:30,000) was applied (15 minutes at room temperature) in order to 
label cell nuclei. Stained sections were coverslipped using Fluoromount (Sigma-Aldrich) and kept 
at -20ºC until analysis. The immunolabelled tissue sections were analyzed using an inverted 
fluorescence microscope (Axiovert 200, Zeiss, Germany) . 
 
2.8. Statistical analysis  
Statistical analysis was performed using the Graphpad Prism 5.0 software (GraphPad, CA, USA). 
Statistical differences were calculated using one-way ANOVA followed by the Dunnett’s test for 
multiple comparisons. A p value lower than 0.05 was considered statistically significant. 
 
3. Results  
3.1. Scaffold morphology 
By combining solvent casting and electrospinning a bilayer scaffold was prepared. The obtained 
scaffolds were analysed by SEM and representative images are presented in Figure 1. The 
surface of the solvent cast flat outer layer reveals a spherulitic morphology, typical of a 
semicrystalline material [24] (Figure 1, A, C; E, G). The inner layer composed by electrospun 
fibres shows a preferentially longitudinally aligned fibrous structure (Figure 1, B, D, F, H). The 
presence of ibuprofen alters jet stability as denoted by the formation of bended fibres (Figure 1, F 
and H). Nonetheless, on the whole, the fibre mean diameter and alignment were not significantly 
altered as one can observe by comparing non-loaded and ibuprofen-loaded fibres. Fibre mean 
diameter was found to be 0.661 and 0.646 μm for non-loaded and ibuprofen-loaded fibres, 
respectively (Figure 1, K). 
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Figure 1. Characterization of the P(TMC-CL) scaffolds under investigation. Scanning electron microscopy 
photomicrographs of (A-D) non-loaded and (E-H) ibuprofen-loaded scaffolds. Images A, C, E and G show the 
outer layer of the scaffold composed by solvent cast films; images B, D, F and H shows the inner layer made 
of preferentially aligned fibres prepared by electrospinning. (I and J) Graphic representation of the 
quantification of fibre alignment for (I) non-loaded and (J) ibuprofen-loaded fibres. Bars represent average 
and error bars show standard deviation (n=3). (K) Fibre mean diameter as calculated from at least 100 
measurements (n=3). 
 
3.2. Drug release from P(TMC-CL) scaffolds 
The release of ibuprofen from P(TMC-CL) bilayer scaffolds was evaluated when in PBS at 37ºC. 
The percentage of cumulative release was calculated relative to a theoretical maximum loading of 
5% (w/w of polymer).  
Under the experimental conditions tested, ibuprofen was released from the P(TMC-CL) scaffolds 
within the first 24 hrs of incubation in PBS (37°C) (Figure 2). When fibres were incubated in PBS 
for longer period, none or residual amounts of ibuprofen were detected, being that the limit of 
quantitation of the applied experimental setup was determined to be 0.001 mg.ml
-1
. The scaffolds 
were analysed by SEM after drug release and the fibrous morphology was maintained (data not 
shown). 
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Figure 2. Cumulative release of ibuprofen from P(TMC-CL) scaffolds when incubated in PBS (37°C), as 
determined by HPLC. Average ± standard deviation are represented (n=7). 
 
3.3. Effect of ibuprofen on ND7/23 cell line 
3.3.1. Cell viability 
To determine whether ibuprofen can affect ND7/23 cells, cell metabolic activity was assessed as 
measure for cellular viability. The drug was added in its soluble form to the cell culture medium to 
a final concentration ranging from 50 to 2000 μM. Ibuprofen solvent (ethanol:water (7:3)) was 
used as reference and is represented as ibuprofen concentration 0 μM.  
The graph presented in Figure 3 shows that when cells are incubated during 24 hrs in the 
presence of ibuprofen at a final concentration higher than 500 μM, the cell metabolic activity is 
reduced in a concentration-dependent manner. No significant difference on cell metabolic activity 
was observed when cells were treated with ibuprofen up to 500 μM.  
 
 
Figure 3. Cell viability of ND7/23 differentiated cells after incubation with different concentrations of 
ibuprofen. Bars represent mean values and error bars show standard deviation (n=4). Percentage calculated 
relative to the cells treated with ibuprofen solvent (ethanol:water (7:3)). *p< 0.05; ***p<0.001 relative to 
control. 
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3.3.2. RhoA activation 
Pre-treatment of cells with ibuprofen has previously shown to limit RhoA-induced activation, 
namely by LPA [7]. To investigate if ibuprofen released from P(TMC-CL) bilayer scaffolds retains 
its bioactivity and can have an effect on the RhoA pathway, RhoA activation was assessed in 
treated ND7/23 cells after stimulation with LPA. The cells were pre-treated with extracts from 
P(TMC-CL) ibuprofen-loaded scaffolds, or with medium supplemented with ibuprofen solution. 
Non-activated cells (no LPA stimulation) and cells activated with LPA, but non-treated with 
ibuprofen were used as negative and positive control, respectively. 
 
Figure 4. RhoA activation on ND7/23 cells as determined by western blot after precipitation of the active form 
of RhoA (RhoA-GTP). Stimulation with LPA (45 µM, 10 minutes, 2-LPA) and pre-treatment with ibuprofen (3-
Ibuprofen soluble) or ibuprofen released from P(TMC-CL) scaffolds (4-Ibuprofen scaffold) were tested. The 
RhoA basal activation was also assessed (lane 1).  
The activated form of RhoA was not detected in non-stimulated ND7/23 cells. Treatment with LPA 
leads to an increase on RhoA activation as demonstrated by the detected high levels of RhoA-
GTP (Figure 4, lane 2). Similarly to the effect observed when cells were incubated with soluble 
ibuprofen, cells treated with extracts of the ibuprofen-loaded P(TMC-CL) scaffolds showed a 
significant reduction (approximately 5 times) of the LPA-mediated RhoA activation (Figure 4). 
 
3.4. Preliminary in vivo testing of ibuprofen-loaded P(TMC-CL) scaffolds 
The developed P(TMC-CL) bilayer scaffolds were tested in an in vivo situation by implantation in 
contact with a spinal cord immediately after dorsal hemisection (Figure 5). 
As shown in Figure 5, the P(TMC-CL) scaffolds were placed at the lesion site wrapping the spinal 
cord tissue. We found that the scaffolds bend properly to allow fixation in the bone and close 
contact with the spinal cord tissue. Five days after implantation, the retrieved scaffolds were found 
to be covered by fibrous tissue, and no signs of scaffold degradation were observed (Figure 5, C). 
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Figure 5. Photographs of the aspect of the bilayer P(TMC-CL) scaffold (A) prior implantation (gamma 
sterilized); (B) after implantation in an injured (dorsal hemisection) spinal cord; and (C) as collected after 
animal euthanasia (5 days post implantation). Arrows indicate the P(TMC-CL) scaffold. 
 
From the twenty animals used in this experiment, one, from group B, was excluded due to poor 
health at the day 5 of the experiment. This unique event was considered to be independent from 
the treatment, as animals with SCI are generally more susceptible to infections [25]. The 
implantation of ibuprofen-loaded P(TMC-CL) scaffolds did not compromise animal survival after 
SCI. 
 
Chapter V 
119 
 
Figure 6. Light microscopy images of the haematoxylin-eosin staining (A-C) and fluorescence microscopy 
images of GFAP (green) and DAPI (blue) immunolabelling (D-F) of cryosections from the spinal cord of (A 
and D) control animal dorsal hemisection and animals with implanted (B and E) P(TMC-CL) scaffold or (C 
and F) ibuprofen-loaded scaffold. Tissue was collected 5 days after implantation. The images show the 
region of the lesion (delimited in white). 
 
The histological evaluation of the tissues collected is ongoing. Figure 6 shows the preliminary 
analysis of one tissue from each experimental group. Figure 6 (A, B, C) shows the haemotoxilin-
eosin staining of the area of the lesion in tissues from group A (non-treated), group B (P(TMC-CL) 
scaffold) and group C (ibuprofen-loaded P(TMC-CL) scaffold), respectively. In the case of group 
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B, the region of the lesion is more difficult to demarcate, as it seems more spread than in the other 
tissues, where it is clearly identified. It is worthwhile mentioning that in the animals where P(TMC-
CL) scaffolds were implanted, the scaffold was separated from the spinal cord prior 
cryopreservation of the tissue. This process seems to have affected tissue cohesion and cause 
the appearance of additional debris in the stained sections (see Figure 6, B). Comparing the 
tissue from group A and C, the images from haemotoxilin-eosin staining suggest that the 
extension of the tissue damage is different among groups. When analysing the cryosections 
immunolabelleded for GFAP, it can be observed that on group B and C (Figure 6, E and F) a 
higher number of cells is found in the lesion site, suggesting significant cellular infiltration. 
Nevertheless, the number of GFAP positive cells in that region was found to be residual. This 
observation is not replicated in group A (Figure 6, D), where signs of astrogliosis (GFAP positive 
cells) are detected at the time of the evaluation. 
 
4. Discussion  
It is commonly accepted that a multi-target strategy will be required to tackle the challenge of 
promoting nerve regeneration after SCI [15]. Following the primary injury that interrupts axonal 
pathways, the rewiring of the system is limited due to the lack of physical support, the activation of 
inhibitory pathways, and, ultimately, due to the formation of a glial scar that physically halts axonal 
re-connection. In the present work, we describe the preparation of a bilayer scaffold that can 
provide physical support, guidance cues and can serve as vehicle for the in situ delivery of 
ibuprofen, a drug expected to be able to reduce the inhibitory environment at the lesion site.  
The use of aligned electrospun fibres to guide axonal growth has been previously explored in the 
literature both for the peripheral and the central nervous system regeneration (see [26] for a 
review). In the first report using aligned electrospun fibres in a SCI scenario, the authors claimed a 
robust rostral regeneration, four weeks after implantation of poly(L-lactide) longitudinally aligned 
fibres. The success of the strategy was ascribed to the anisotropy of the substrates as modest 
regeneration was observed when randomly oriented fibres or solvent cast films were implanted 
[19]. Here, we report the successful preparation of P(TMC-CL) preferentially aligned fibres. Fibre 
mean diameter was found to be around 650 nm, in accordance with that previously described for 
randomly oriented structures using the same solvent mixture [22]. The aligned fibres were 
collected onto solvent cast films in order to improve the final mechanical properties of the scaffold. 
Nanofibrous scaffolds have, in general, weaker mechanical properties than bulky structures [27], 
particularly when constituted by aligned fibres [28]. This can compromise the success of an 
implantable device, as demonstrated in a previous study showing that the folding of an 
electrospun fibrous fabric impaired nerve regeneration [29].  
The vectorization through scaffolds of molecules that have a positive effect on regeneration holds 
a great potential to become a therapeutic strategy for SCI. It was previously shown that the 
implantation after lesion of a nanofibrous patch with rolipram physically adsorbed to poly(L-
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lactide)-based electrospun fibres lead to an improved functional recovery from the third week on, 
comparing to non-loaded scaffolds that showed a similar result as non-treated animals [28]. In the 
present study, it is proposed the use of ibuprofen incorporated in a P(TMC-CL) scaffold, based on 
the reported inhibitory action of the drug on the RhoA pathway [7, 8]. Bilayer ibuprofen-loaded 
scaffolds were prepared by mixing the drug with the polymer solution prior to electrospinning and 
solvent casting, for the preparation of the inner and outer scaffold layer, respectively. It was 
observed that the drug released from the scaffolds is bioactive as confirmed by the hindrance of 
RhoA activation in a neuronal-like cell population challenged with LPA – a known RhoA activator. 
This result encouraged the testing of P(TMC-CL) bilayer scaffolds in an in vivo SCI model. 
The ibuprofen release profile from the P(TMC-CL) bilayer scaffolds conducted in sink conditions 
indicated that the majority of the drug is released within the first 24 hrs of incubation. When 
translating this data to an in vivo scenario, one can expect that this release will be delayed as in 
the conducted studies the media was completely refreshed at each evaluation time point, what 
favours the washing out of the drug from the scaffold. Moreover, we hypothesized that a 
significant release of ibuprofen in the initial stages of the tissue response after a lesion can also 
play a role on the early inflammatory response triggered, namely reducing microglia activation [10] 
and that this can positively contribute to regeneration in the aftermath of a SCI [30]. 
The results reported in this manuscript concerning the in vivo performance of the developed 
P(TMC-CL) scaffolds are still preliminary. This experiment aimed at constituting a proof-of-concept 
from the feasibility of using ibuprofen-loaded bilayer scaffolds for inhibiting RhoA activation. In that 
view, the study was designed to address the early response on the RhoA pathway and not 
attempt to assess axonal regeneration or achieve functional improvements. So far, we 
demonstrated that the implantation of P(TMC-CL) scaffolds can be successfully achieved and 
does not compromised animal survival rate. Although we were not expecting any deleterious 
effect caused by the implantation of P(TMC-CL) scaffolds, some concern existed about the drug 
loading applied. The published studies using ibuprofen for treatment of SCI report the 
subcutaneous administration of the drug at the dose of 60 mg.kg
-1
.day
-1
 [7, 8]. In the present study 
the drug loading in the P(TMC-CL) scaffolds was in average 500 µg.cm
-2
, corresponding to 
approximately 0.75 mg.kg
-1
. However, it must be noted that in the present study, the release of the 
drug occurs in situ, as the scaffold is in direct contact with the spinal cord tissue. A previous work 
using rolipram loaded patches implanted in contact with the spinal cord, showed that implantation 
of high drug doses (65 µg.cm
-2
) lead to an increase on animal mortality rate [31]. It should be 
mentioned however, that the effective dose of ibuprofen and rolipram are significantly different, 
and improvements on regeneration after SCI by the administration of rolipram are achieved by the 
subcutaneous administration of 1 mg.kg
-1
 of drug [32], 60 times less than that reported for 
ibuprofen [7, 8]. 
The preliminary histological characterization of the tissues collected from animals treated with 
ibuprofen-loaded P(TMC-CL) bilayer scaffolds showed that at the time of evaluation (5 days after 
the lesion) considerable cellular infiltration occurred at the lesion site, but no signs of astrogliosis 
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were identified so far. In comparison, the untreated animals showed already signs of the presence 
of a glial scar at the lesion site, as indicated by the presence of GFAP positive cells. The ongoing 
characterization of the infiltrated cells will shed light on the effect of the released ibuprofen on the 
modulation of the lesion microenvironment. Ultimately, the quantification of RhoA activation in 
tissues in contact with ibuprofen-loaded scaffolds will contribute for disclosing the potential of the 
proposed strategy in providing a more permissive milieu for axonal regeneration. 
 
5. Conclusion and Future Perspectives 
This study describes the successful preparation of bilayer P(TMC-CL) scaffolds containing 
longitudinally aligned P(TMC-CL) fibres, and loaded with ibuprofen. It is demonstrated that 
ibuprofen released from P(TMC-CL) scaffolds can effectively reduce RhoA activation in ND7/23 
cells putting forward these scaffolds to be applied in a SCI scenario.  
A preliminary in vivo experiment was performed and showed, so far, that the scaffolds can be 
implanted in the spinal cord after injury. No effect on animal survival was observed. The detailed 
histological characterization of the retrieved tissues is ongoing and will provide critical information 
on the success of the proposed strategy, bringing also new insights to future improvements on 
scaffold design. Drug loading, or the drug release profile are parameters that can be modulated in 
order to develop a scaffold that better supports cells in the hostile environment of SCI.  
To assess the effect of the strategy proposed in this study on axonal growth or functional recovery 
after SCI, it is necessary to perform an extended experiment in which the scaffolds are implanted 
for a longer period. This study is key to evaluate the effect of the early inhibition of RhoA pathway 
on regeneration and also the contribution of P(TMC-CL) and fibre alignment in the process. 
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Abstract  
Aim: Study the mechanism of transfection mediated by imidazole-grafted chitosan (CHimi) 
nanoparticles, to propose new strategies to control and improve the expression of a delivered 
gene in the context of Regenerative Medicine. Methods: Biochemical and microscopy methods 
were used to establish transfection efficiency and nanoparticle intracellular trafficking. The role of 
CHimi degree of N-acetylation (DA) on transfection was explored. Results: CHimi was found to 
promote the expression of a delivered gene during a minimum seven-day period. Additionally, the 
production of a protein of interest could be upheld by consecutive transfections, without 
compromising cell viability. Transfection was found to be a time dependent process, requiring 
CHimi-DNA complex disassembling. The DA was found to have an impact on transfection kinetics 
in line with the observation that the rate of lysozyme-mediated nanoparticle degradation increases 
with the polymer DA. Conclusions: The adjustment of the CH degradation rate can be used as a 
tool for tuning the expression of a gene delivered by CH-based nanoparticle systems. 
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1. Introduction  
The combination of gene delivery and tissue engineering strategies holds great promise in a 
regenerative medicine scenario, as a mean to promote the expression in loco of genes encoding 
for specific proteins that can play a role in regeneration [1]. This approach can overcome 
drawbacks associated with recombinant protein delivery, like short half-life and high cost of 
production [2]. Growth factors have been considered key elements due to their important role in 
regeneration. However, overexpression of these proteins could lead to abnormal cell behavior, 
since their action is commonly dose-dependent [3]. Therefore, control of gene delivery and its 
expression is of crucial importance. Accordingly, clinical application of strategies based on gene 
therapy and tissue engineering is strongly dependent on the development of vectors that can 
mediate the safe and effective delivery of genes, promoting a sustained and controlled expression 
of the encoded proteins. 
A number of synthetic molecules has been explored to serve as vehicles for genetic material, as 
the most extensively studied being based on the use of cationic lipids like 2,3-
bis[oleyl]oxipropyltrimethylammonium chloride (DOTMA) [4] or cationic polymers, such as 
poly(ethylene imine) (PEI) [5]. These systems can mediate promising transfection efficiencies and 
lead to transient expression of the transgene. However, the cytotoxicity and the lack of 
biodegradability of some of these vectors has been limiting their application in a regenerative 
medicine scenario [6-8].  
Chitosan (CH) is a natural polysaccharide widely explored for biomedical applications, particularly 
due to its well-known biocompatibility. CH is a copolymer composed by N-acetyl glucosamine and 
glucosamine moieties that can be cleaved by hydrolytic enzymes, such as lysozyme [9]. The in 
vivo biodegradability makes CH use very attractive in regenerative medicine applications [10]. 
Several reviews were recently published concerning CH application in gene delivery, highlighting 
its potential and versatility [11-13]. Our group has  previously showed that the incorporation of 
imidazole moieties into the CH backbone results in an increase of transfection efficiency 
comparing to the parental polymer [14]. The achieved improvement was found to be related to the 
higher buffering capacity of the modified CH, and consequent better escape of modified CH-DNA 
complexes from endosomal vesicles [14]. 
Foreseeing a regenerative medicine application, in this work we have performed a detailed and 
systematic study on the ability of imidazole-grafted CH-based vectors (CHimi) to mediate in vitro 
transfection under different experimental conditions. We focused on the evaluation of the reporter 
gene expression mediated by CHimi-based polymers as well as on the correlation of these 
observations with the intracellular trafficking of CHimi-DNA complexes in human embryonic kidney 
293T cells. The obtained results led us to hypothesize that CH degradation could be influencing 
the expression of the delivered gene. Taking into consideration the role of the degree of N-
acetylation (DA) on CH biodegradation [9], this hypothesis was explored by testing CHimi-based 
polymers with different DA. 
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2. Materials and Methods 
2.1. Materials 
Unless mentioned otherwise, all reagents were obtained from Sigma-Aldrich and were of 
analytical grade. 
Technical grade chitosan (Chimarin™, DA 13%, apparent viscosity 8 mPa.s, supplied by 
Medicarb, Sweden) was purified and characterized prior further use. The average weight 
molecular weight (  

M w), polydispersity, polydispersity index and DA of the purified polymer were 
found to be 1.2x10
5
,
 
2.1 and 16.4%, respectively (see below for experimental details) [14]. 
Endotoxin levels of CH extracts were found to be lower than 0.1 EU.ml
-1
 [14], respecting the US 
Department of Health and Human Services guidelines for implantable devices [15].  
Plasmids carrying β-galactosidase (pCMV-Sport β Gal, Invitrogen, 7.8 Kbp), green fluorescence 
protein (pCMV-GFP, 7.4 Kbp) or transthyretin (TTR) (pET-3a based plasmid, 4.9 Kbp) genes were 
used in this study. Plasmids were amplified in DH5 Escherichia coli (E. coli) and isolated using 
GENELUTE™ high performance endotoxin-free plasmid maxiprep kit according to the 
manufacturer instructions. Plasmid concentration and purity were determined 
spectrophotometrically (Beckman DU
®
650, USA). The ratio between optical density at 260 nm and 
280 nm was found to be higher than 1.7. 
 
2.2. Chemical modification of chitosan 
Chitosan deacetylation. CH with a low DA was prepared by heterogeneous deacetylation [16] of 
the purified polymer (CH16), under argon atmosphere. The deacetylated polymer (CH05) was 
precipitated by addition of a mixture of water/ammonia 7:3 (v:v) and recovered by centrifugation, 
neutralized by washing with deionized water, freeze dried (Labconco) and, subsequently, vacuum 
dried at 60°C for 24 hrs.  
Chitosan acetylation. CHs with different DA were obtained from re-acetylation of CH05 according 
to a previously described procedure [17]. The obtained polymers were purified as described 
above. 
Imidazole grafting of chitosan. CH05, CH10, CH16 and CH18 were modified with imidazole-4-
acetic acid sodium salt by amidation of the glucosamine residues using an EDC/NHS 
condensation system (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride – EDC; N-
hydroxysuccinimide – NHS) [14]. Polymer stock solutions (0.1% (w/v)) were prepared according to 
a previously described procedure [14], and stored at 4°C till further use. 
 
2.3. Polymer characterization 
Fourier Transform – Infrared Spectroscopy (FT-IR) was performed in Perkin-Elmer 2000 system. 
Samples were prepared as potassium bromide (KBr) discs by mixing 2 mg of the polymer 
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(vacuum dried 24 hrs at 60°C) with 200 mg of KBr (dried 24 hrs at 105°C). The IR spectra were 
recorded, after a 5-min purge of the sample chamber with N2, by accumulation of 200 
interferograms, at a 4 cm
-1
 spectral resolution. 
Size exclusion chromatography (SEC) was used to determine the molecular weight of CH05, 
CH10, CH16 and CH18. The modular system employed was composed by an isocratic pump (K-
1001 Knaeur), a vacuum degasser (K-5002 Knaeur), a viscometer/right angle laser light scattering 
(RALLS) dual detector (T60 Viscotek), and a refractive index detector (K-5002 Knaeur) operating 
at the same wavelength as the RALLS detector (670 nm). Separations were performed in a set of 
PL aquagel-OH mixed columns. 0.2 M NaCH3COO/0.5 M CH3COOH was used as eluent at a flow 
rate of 1ml.min
-1
 and the dn/dc used for molecular weight calculations was 0.205 ml.g
-1
 [18]. 
Sample concentration in a 0.1 to 0.2% (w/v) range and an injection volume of 100 µl were applied. 
All measurements were performed in triplicate, at room temperature (RT). 
 
2.4. CHimi-DNA particle preparation 
CHimi-DNA particles were prepared by mixing, while vortexing, equal volumes of a CHimi solution 
in 5 mM CH3COONa buffer pH 5.5 (0.1% (w/v)) and a plasmid DNA solution (in 25 mM Na2SO4), 
both previously heated at 55°C for 10 min. Complexes were allowed to form and stabilize for 15 
min at RT before further use. Unless mentioned otherwise, complexes were prepared at a molar 
ratio of CH primary amines to DNA phosphate group (N/P) of 18.  
 
2.5. CHimi-based particle characterization 
Complexes were prepared as described above, using 10 µg of pCMV-GFP and 150 µg of CHimi, 
independently of the polymer DA. After stabilization, complexes were diluted to a final volume of 1 
ml, using 5 mM CH3COONa buffer (pH 5.5). Complex size and zeta potential were assessed using 
a Zetasizer Nano Zs (Malvern, UK). The Smoluchowski model was applied for zeta potential 
determination and cumulant analysis was used for mean particle size determination. All 
measurements were performed in triplicate, at 25°C.  
 
2.6. Cell culture 
293T human embryonic kidney endothelial cells were cultured under standard conditions in 
Dulbecco's Modified Eagle's Medium (DMEM) high glucose (4500 mg.l
-1
) supplemented with 10% 
(v/v) heat-inactivated (56°C, 30 min) fetal bovine serum (FBS) and 1% (v/v) penicillin/streptomycin 
(10.000 U.ml
-1
 penicillin, 10.000 g.ml
-1
 streptomycin) (all supplied by Gibco). Cells were routinely 
tested for mycoplasma contamination by PCR [19, 20]. 
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2.7. Transfection 
293T cells were seeded (2.7x10
4
 viable cells.cm
-2
) on poly-D-Lysine hydrobromide (PDL) coated 
24-well tissue culture plates (Greiner Bio-one, CellStar), 24 hrs prior transfection. Cell culture 
medium was replaced for 500 μl of complete fresh medium 2 hrs before transfection. In all 
transfection experiments, complexes were added to the cells at a final DNA concentration of 1.3 
g.cm
-2
. Cell culture medium was refreshed everyday. 
 
2.8. In vitro gene expression studies 
In this set of studies the plasmid carrying the β-galactosidase (β-gal) reporter gene was used. 
The gene expression mediated by CHimi with a DA of 16% and two degrees of substitution with 
imidazole (13% - CH16imi1 and 22% - CH16imi2) was evaluated up to 168 hrs post-transfection. 
Cultures dilution was performed 72 hrs post-transfection. In brief, the cell monolayer was rinsed 
with pre-warmed phosphate buffered saline (PBS) and harvested by trypsinization (5 min, 37°C). 
Cells were re-suspended in supplemented DMEM (1 ml/well), diluted (7x) and re-seeded on PDL-
coated 24-well plates. 
The effect of multiple transfections on transfection activity (expressed as specific activity of -gal) 
and cell viability was assessed as follows: 72 hrs post-transfection cells were harvested by 
trypsinization, as described above, and re-seeded on PDL-coated 24-well plates at the initial cell 
density (2.7x10
4
 viable cells.cm
-2
). 24 hrs after plating, cells were subjected to a second 
transfection. This procedure was repeated once more. In total three transfection treatments were 
performed. Transfection activity was evaluated at 48 and 72 hrs after each transfection. At each 
time point, cells were processed for β-gal activity evaluation according to manufacturer 
instructions (β-gal assay kit, Invitrogen). Non-transfected cells were used as blank. The total 
protein was determined by the BCA assay (Pierce), following the manufacturer instructions.  
Cell viability was determined using a resazurin-based assay [21], as previously described [22]. 
Results are represented as percentage of metabolic activity of transfected cells relative to non-
transfected cells. 
 
2.9. Intracellular trafficking studies 
Fluorescence microscopy studies 
To allow the tracking of the CHimi-based particles inside cells, both polymer and plasmid DNA 
were fluorescently labeled. A rhodamine (λex=575 nm, λem=600 nm) activated derivative [5(6)-
Carboxy-X-rhodamine N-succinimidyl ester, ROX (Fluka)] was used to label CH16imi1. In brief, 10 
mg of CH16imi1 was dissolved overnight in 10 ml of a 1% (v/v) acetic acid solution and added to 
an equal volume ROX solution (0.13 mg.ml
-1
 in dehydrated methanol, Molecular Sieves, Merck). 
The reaction was let to occur for 3 hrs, under constant stirring, protected from light. The 
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fluorescently-labeled CH16imi1 (CHimiROX) was recovered by precipitation with 5 ml of 0.5 M 
NaOH. The precipitated polymer was washed with deionized water till no fluorescence was 
detected in the supernatant and, subsequently, freeze-dried. pCMV-GFP plasmid was 
fluorescently labeled using the commercial kit Label IT Cy5 (Mirus™) according to the 
manufacturer instructions. The fluorescently labeled DNA (DNACy5) was recovered by precipitation 
in ethanol and concentration was assessed by spectrophotometry (λ=260 nm) (Beckman DU
®
650, 
USA).  
Complexes prepared with the fluorescently labeled CHimiROX and DNACy5 were used to transfect 
cells 24 hrs after seeding on PDL-coated glass coverslips. The intracellular localization of the 
complexes was analyzed in both live and fixed cells as follows. Twenty four hrs after cell seeding, 
the cultures on PDL glass coverslips (2.5 cm
2
) were transferred into a closed chamber and 
incubated with L-15 medium (Gibco) supplemented with 10% (v/v) FBS and 1% (v/v) 
penicillin/streptomycin containing the complexes prepared with fluorescently labeled DNA and 
polymer. Cells were maintained at 37°C and images were acquired using an inverted 
epifluorescence microscope (Nikon eclipse TE2000-U) equipped with a Cool Snap HQ2 camera. 
Images were collected each hr during the first 6 hrs after transfection and at 24 hrs post-
transfection. A series of z-sections were collected in order to capture images in all cell depth. At 
least five different areas of the sample were followed in time, in three independent experiments. At 
48 hrs post-transfection images of GFP positive cells were collected. To prepare fixed cell 
samples, at defined time points (2, 4, 6, 24 and 48 hrs post-transfection), cultures on PDL glass 
coverslips (1.3 cm
2
) transfected with fluorescently labeled polymer and DNA were rinsed with pre-
warmed PBS and fixed for 15 min at 37°C with paraformaldehyde (4% (w/v), in PBS), 
supplemented with 2% (w/v) sucrose. After fixation, cell cytoskeleton and nuclei were stained. In 
brief, fixed cells were permeabilized according to a previously described procedure [23] and 
incubated with 1% (w/v) bovine serum albumin (BSA) for 1 hr. Cell nuclei were stained for 4 min 
with 4'-6-diamidino-2-phenylindole (DAPI, 0.1 g.ml
-1
 in PBS) and cell cytoskeleton filamentous 
actin (F-actin) was counterstained with Alexafluor 488-conjugated phalloidin (5 U.ml
-1
, in PBS with 
1% (w/v) BSA, 20 min, Molecular Probes). Samples were mounted in Vectashield (Vector) and 
observed by confocal laser scanning microscopy (CLSM, Leica Microsystems). Cytoskeleton 
staining was not performed in samples collected 48 hrs post-transfection in order to allow the 
detection of GFP positive cells. Cells were analyzed in depth by z-stacking. A minimum of 20 
fields per time point were collected, from three independent experiments. 
 
Cell-free gene expression assay 
The occurrence of reporter gene transcription and/or translation, when in a complex form with 
CHimi-based polymer, was evaluated using a TNT® Quick Coupled Transcription/Translation 
System (Promega). This system allows protein production from genes under a T7 promoter. A 
pET-3a based plasmid encoding for the TTR protein [22] was used in this experiment to complex 
with CH16imi1. Following the manufacturer instructions, 1 g of plasmid DNA was used in each 
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reaction. CHimi-based complexes were prepared by mixing 2 l of DNA solution (in 25 mM 
Na2SO4 solution) with 13.4 l  of CH16imi1. The complex suspension was added to the TNT mix. 
The modification in complex formation procedure, as well as the experimental conditions of the 
assay (complex formation procedure, medium pH, temperature and ionic strength) showed not to 
alter the polymer ability to retain DNA in an agarose gel electrophoresis (data not shown). Since 
the final volume of the reaction mixture containing the complex solution exceeds the 50 l 
recommended by the manufacturer, two controls were added to the experiment where the 
increase on the final reaction volume and the presence of CH3COONa buffer pH 5.5 (CH16imi 
solvent) were equated. The reaction was let to occur for 90 min at 30°C. The reaction products 
were resolved by an SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on a 15% (w/v) gel. 
The gel was dried and, since 35S[methionine] was included in the reaction mixture, the presence of 
TTR protein was analyzed by phosphorimaging (Typhoon 8600 variable mode imager; Molecular 
Dynamics), after an overnight exposure. The position within the gel of the TTR band was 
confirmed by running in the same gel a molecular weight marker and the recombinant human TTR 
protein (produced in E. Coli) (data not shown). 
 
2.10. DNase I protection assay CHimi-DNA particle stability and DNA protection 
To evaluate the stability in physiological media of CHimi-DNA particles prepared with CHimi with 
different degree of acetylation, DNA electrophoretic mobility and DNase I protection were 
assessed.  The electrophoretic mobility of DNA and CHimi-DNA complexes was analyzed in an 
agarose gel, as previously described [14]. Prior to running the gel, the complexes were prepared 
as described above and incubated for 20 minutes with equal volume of supplemented DMEM 
(10% FCS and 1% P/S). The gel was scanned using a Bio Rad Gel Doc
TM
 XR system. 
The ability of the polymer to protect DNA from DNase I degradation was assessed as follows. 
Complexes were suspended in buffer solution (10 mM Tris HCl, 150 mM NaCl, 1 mM MgCl2; pH 
7.4) and incubated with DNase I (1 U/μl, Fermentas) at 37ºC. Absorbance (260 nm) was recorded 
for 30 min, using a PowerWave™ Microplate Spectrophotometer (BioTek, USA).  
 
2.11. Extent of internalization and transfection efficiency 
The extent of internalization and transfection efficiency of complexes prepared with constant mass 
of pCMV-GFP and CHimi (independently of the polymer DA) were assessed by flow cytometry 
(FACSCalibur, BD Biosciences). For the internalization studies, pCMV-GFP was labeled with 
YoYo-1 (Invitrogen, 1:200 bp) prior to complex formation, according to the manufacturer 
instructions. After 2 hrs of contact with complexes, cells were processed for fluorescence 
activated cell sorting (FACS) analysis. Briefly, trypan blue (0.2% (w/v)) was added to the medium 
and incubated for 5 min in order to quench fluorescence external to cells [24]. Subsequently, the 
cells were washed with cold PBS, and harvested by trypsinization. After two washes with PBS, 
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cells were recovered in 100 µl of PBS containing 0.01% (w/v) of sodium azide. For transfection 
efficiency determination, cells were processed as described above, skipping the trypan blue 
incubation step. The number of cells expressing GFP was determined at 24, 48 and 72 hrs post-
transfection. The individual fluorescence of 10,000 cells was quantified and results were analyzed 
using the FlowJo software (version 8.3.7). Results are expressed as the percentage of labeled 
DNA (for extent of internalization) or GFP positive cells (for transfection efficiency). 
 
2.12. Enzymatic degradation of CHimi-based complexes 
To assess CH-based particle degradation, complexes were prepared using a constant CHimi-
pCMV-GFP mass ratio, independently of the polymer DA, and incubated with lysozyme in the 
presence of a fluorogenic substrate for the enzyme. In brief, 4-methylumbelliferyl β-D-N,N′,N′′-
triacetylchitotrioside (MU-[GlcNAc]3) was dissolved in CH3COONa (1M, pH=5.5):H2O:DMF (1:1:1) 
[25] and added to freshly prepared CHimi-DNA complexes. Equimolar solutions of MU-[GlcNAc]3 
and CHimi (4.45 µM) were applied. Subsequently, the mixture was incubated with lysozyme (from 
chicken egg white) at a final concentration of 0.5 mg.ml
-1
, at 37°C under constant stirring. After 1, 
2, 3 and 4 hrs of reaction, NaOH was added to a final concentration of 0.05 M to stop the reaction. 
The fluorescence resulting from the enzymatic degradation of the substrate was measured 
(λexc=360nm; λem=455nm – Spectra Max Gemini XS; Molecular Devices). For each DA, CHimi-
DNA complexes were incubated in the same conditions but without fluorogenic substrate, and 
used as blank.  
 
2.13. Statistical data analysis 
Data are presented as average ± standard deviation (SD). The statistical analysis of the results 
was performed using the non-parametric Mann-Whitney U-test. For multiple comparisons, 
homogeneity of variances was assessed by the Bartlett’s test. If homogeneity of variances could 
be assumed the post-hoc Bonferroni test was performed, otherwise, the Dunnett T3 test was 
applied. Results were considered statistically significant when p<0.05. Calculations were 
performed using SPSS
®
 software for Windows (version 16.0). 
 
3. Results 
3.1. In vitro gene expression study  
In a previous work we have optimized CHimi mediated transfection [14] . It was found that the best 
transfection results are attained when CHimi-DNA complexes are prepared with CHimi containing 
13% (CH16imi1) or 22% (CH16imi2) of the primary amines substituted with imidazole moieties, at 
an N/P molar ratio of 18. These two formulations were selected to be further studied in the present 
work. To follow CHimi-mediated gene expression over time, β-gal activity was evaluated during 7 
days after transfection (Figure 1).  
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Figure 1. (A) Transfection activity as function of time for 293T cultures treated with CH16imi1- and 
CH16imi2-based vectors (N/P=18). Cells were trypsinized and diluted (7x) at 72 hrs post-transfection. (B) 
Independent plotting of -gal activity and respective total cell protein content. Representative experiment out 
of the three performed (average ± SD; n=3). 
 
Under the experimental conditions used, a transfection activity maximum is reached 72 hrs post-
transfection for both polymers tested. After trypsinization, a significant decrease on β-gal specific 
activity was observed (Figure 1 (A)), in accordance to a previously published report [26]. 
Nevertheless, when the enzymatic activity (nmolONPG.min
-1
) and the total cell protein content are 
plotted separately (Figure 1 (B)), one can observe that the decrease in enzymatic activity is of the 
same magnitude of the dilution performed (7x dilution) rather than resulting from an effective 
decrease in the production of the reporter protein. Furthermore, β-gal production remained stable 
in the period between 96 and 168 hrs post-transfection. Cell viability was monitored at the same 
time points. No significant alteration was found in terms of metabolic activity of cells transfected 
with CHimi-based polymers relative to non-transfected cells (Figure S1, supplementary material). 
The possibility of performing successive transfection treatments using CHimi-based polymers, 
without compromising cell viability, was addressed in vitro. In terms of transfection activity the 
results show that cells can be re-transfected, maintaining high levels of the reporter gene 
expression (Figure 1 (A)). One should refer that a burst increase in transfection efficiency was 
observed at times, as illustrated in Figure 2 (A). This could be resulting from the series of 
trypsinization steps introduced every 3 days of culture that could not be circumvented in the 
implementation of this study. Even so, independently of the polymer system tested, cell viability 
relative to untreated cells remained above 80% after every treatment (see Figure 2 (B) for an 
example).  
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Figure 2. (A) Transfection activity and (B) relative cell viability of 293T cells after consecutive transfections 
with CH16imi-based vectors. Representative experiment out of the three performed (average ± SD; n=3). 
 
3.2. Intracellular trafficking studies 
In order to monitor the intracellular route of CHimi-DNA complexes after transfection, both 
CH16imi1 and DNA were covalently labeled with fluorescent tracers (rhodamine and Cy5, 
respectively). The ability of the labeled polymer to form complexes with DNA was confirmed by 
assessing the physical properties of the resulting particles. No significant differences were found 
in terms of complex size and zeta potential, comparing to those prepared with the non-labeled 
polymer (Table S1, supplementary material). 
 
Live cell imaging 
To follow fluorescently-labeled complexes (CHimiROX-DNACy5) in live cells, a number of regions of 
the cell monolayer were monitored over time. Differential-interference contrast (DIC) combined 
with fluorescence images were acquired at different z-planes aiming at defining the localization of 
complexes inside the cell. A representative region of a sample at the first hrs after transfection is 
presented in Figure 3. 
 
Chitosan-mediated gene delivery 
138 
 
Figure 3. Fluorescence images combined with DIC images of 293T live cells at (A) 1, (B) 2, and (C) 6 hrs 
after transfection with complexes prepared with fluorescently labeled polymer and DNA. Images correspond 
to one central section from the z-stack acquired and the x-z and y-z section is presented. An amplification of 
the cells for each condition (A1, B1, and C1) and the correspondent fluorescence images (A2, B2, C2) is 
presented for each time point. The signal corresponding to CHimiROX is shown in red and DNACy5 in green. 
Arrows indicate the location of CHimiROX-DNACy5 complexes. Scale bar = 10 µm. 
 
Complexes could be detected bound to the cell membrane and also in the cell cytoplasm from the 
first hr post-transfection, up to 6 hrs post-transfection (Figure 3). The same scenario was found 
after 24 hrs post-transfection.  
At 48 hrs post-transfection, fluorescently labeled complexes were still detected inside the cell 
cytoplasm, as well as bound to the cell membrane, both in GFP positive (Figure 4) and negative 
cells. The fluorescence signals from CHimiROX and DNACy5 were found not to co-localize in some 
cases, although being detected in close proximity (see Figure 4 (3)). 
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Figure 4. Z-section and the correspondent x-z and x-y section of 293T cells expressing GFP captured at 48 
hrs post-transfection. The amplification of the fluorescence images corresponding to the area within the 
rectangle is shown in 1-4. The individual signals of (1) CHimiROX and (2) DNACy5 are presented. (3) shows the 
merged image of CHimiROX (in red) and DNACy5 (in blue). (4) combines also the GFP signal. Arrows indicate 
the location of CHimiROX-DNACy5 complexes within the GFP expressing cell. Scale bar = 10 µm. 
 
Fixed cells analysis 
The CHimiROX-DNACy5 complexes distribution was analyzed in fixed cells by CLSM at the same 
time points: 2, 6, and 48hrs after transfection. Representative images of each time point are 
presented in Figure 6. 
 
Figure 5. CLSM images captured at (A) 2, (B) 6, and (C) 48 hrs after transfection of 293T cells with 
CHimiROX-DNACy5 complexes. Images correspond to one central section from the z-stack acquired. The insert 
corresponds to an amplification of the specific area indicated in the original image. The fluorescence signal 
corresponding to CHimiROX is shown in red and DNACy5 in gray. Cells were stained with DAPI (genomic DNA, 
blue) and phalloidin (filamentous actin, green; A-B). (C) Cells are shown in green due to GFP expression. 
Arrows indicate the location of CHimiROX-DNACy5 complexes. Scale bar = 10 µm. The images of each of the 
fluorescence channels are presented in supplementary material (Figure S2). 
Chitosan-mediated gene delivery 
140 
 
The analysis of the images obtained by CLSM showed that complexes can be found bound to the 
cell membrane as well as in the cytoplasm for all of the tested time points (see Figure 5 (A) for an 
illustration) and also in GFP positive cells (see Figure 5 (C)). CHimiROX and DNACy5 signals were 
always co-localized.  
In both studies, with live and fixed cells, it was not possible to localize a significant number of 
complexes inside the cell nucleus.  
 
3.3. Cell-free gene expression assay 
The importance of CHimi-DNA complex disassembling to the expression of the delivered gene 
was investigated through an in vitro transcription/translation assay. A pET-3a based plasmid 
encoding for the TTR protein was used to form complexes with CH16imi1.  
 
 
Figure 6. Phosphor imaging of the in vitro transcription/translation assay reaction products. 
 
Four different reactions were performed and the resulting radioactive products can be visualized in 
the gel presented in Figure 6. TTR protein was not detected when pTTR was complexed with 
CHimi-based polymer (lane 4), whereas in all the controls performed (lane 1-3) the radioactive 
signal corresponding to TTR is identified. 
 
3.4. Degree of acetylation role on CH-based nanoparticle transfection efficiency and 
degradation  
Polymer Characterization 
Through deacetylation of CH16 and posterior acetylation, three polymers with a range of DA were 
prepared, as determined by FT-IR spectra (Figure S4 supplementary material) according to 
Brugnerotto et. al. [27] (see Table 1). The molecular weight and the polydispersity index ( wM /
nM ) of the resulting polymers were determined by SEC. No statistically significant variation was 
found when comparing the respective average number molecular weight ( nM ) of the obtained 
polymers and the starting CH (CH16, see Table 1). Subsequently, both deacetylated and 
acetylated polymers were grafted with imidazole moieties following a previously described 
Chapter VI 
141 
procedure [14]. Briefly, grafting of the starting materials was explored with a molar ratio of 
imidazole-4-acetic acid sodium salt to glucosamine residues of 0.30. The obtained degree of 
substitution of each grafted polymer was assessed by FT-IR [14] (spectra in Figure S5 
supplementary material) and it is presented in the Table 1. For the polymers with lower DA (CH16 
and CH18) the obtained degree of substitution was lower than the expected value of 30% of 
imidazole moieties per mol of primary amino groups (22.1 and 23.4%, respectively). A possible 
explanation is that the lower polymer solubility could be limiting the reaction efficiency, as 
previously discussed [14]. 
 
Table 1. Degree of N-acetylation, percentage of the average number molecular weight (  

M w) relative to the 
initial polymer (CH16), polydispersity index ( nMwM ) and degree of substitution of primary amines of CH 
with imidazole moieties (imi) of the resulting polymers (average ± SD; n=3). 
 
 
CHimi-based particle characterization 
The physical properties of the CHimi-DNA complexes prepared with a constant polymer to DNA 
mass ratio, using CHimi with different DA were determined. No significant variations in terms of 
particle size and zeta potential were detected between complexes prepared with the different 
polymers. Particle zeta potential was found to be around +20 mV, whereas the mean particle size 
ranged between 244 and 331 nm (Table 2).  
 
Table 2. Zeta potential, average size (Z-Average), and polydispersity index (PdI) of CHimi-DNA complexes 
prepared with the pCMV-GFP plasmid and CHimi with different DA (average ± SD; n=3). 
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CHimi-DNA particle stability and DNA protection 
The ability of CHimi with variable DA to form stable particles with DNA and to protect the plasmid 
from nuclease degradation in physiological conditions was assessed. Results show that only 
naked DNA is able to migrate under an electrophoretic field, demonstrating that, independently of 
the CHimi DA, the complexes are stable in the presence of supplemented cell culture medium 
(Figure S3, supplementary material (A)). Furthermore, CHimi-based polymers  are able to protect 
DNA from DNase I degradation. The performed assay is based on the fact that intact DNA 
molecules possess hypochromicity and that the absorbance at 260 nm increases upon enzymatic 
digestion [26]. The results show that naked DNA is fully degraded by DNase I following a 30 min 
incubation period, whereas for DNA complexed with CHimi-based polymers, the absorbance at 
260 nm does not significantly increases upon incubation with the enzyme (Figure S3, 
supplementary material (B)). 
 
Extent of internalization and transfection efficiency  
The percentage of YoYo-1 positive cells was determined after 2 hrs of incubation of the cells with 
complexes based on CHimi with different DA. As shown in Figure 7 (A), internalization of 
complexes based in CH05imi, CH10imi or CH16imi was observed in approximately 30% of 293T 
cells. However, a significant lower extent of internalization was observed for CH18imi-based 
complexes.  
Transfection efficiency mediated by CHimi-based complexes with variable DA was assessed for 
up to 72 hrs post-transfection (Figure 7 (B)). As can be observed, CH16imi is the most efficient 
polymer among the various CHs tested, being able to transfect over 40% of the cell population (at 
72 hrs post-transfection). Although CH18imi-based complexes are able to be internalized by the 
cells, a significantly lower transfection efficiency is attained, in comparison to the other three 
polymers. The rate of internalization of CH18imi-DNA complexes is similar to the one obtained 
when naked DNA is added to cells (see representative histogram plots in Figure S6 
supplementary material), being the later also ineffective transfecting cells [14]. For CH05imi-, 
CH10imi- and CH16imi-based complexes, transfection efficiency increased over time, in 
accordance to what was previously described in section 3.1. For CH10imi and CH16imi, the most 
significant increase of transfection occurred from 24 to 48 hrs post-transfection. However, in the 
case of CH05imi this effect was observed from 48 to 72 hrs post-transfection. A commercial 
formulation of PEI (Escort V
®
 – Sigma) was used as a control for transfection experiments, and 
transfection efficiency was found to be above 80% at all the time points tested. A more detailed 
comparison between CHimi and PEI can be found in a previous publication [14]. 
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Figure 7. (A) Percentage of 293T cells positive for YoYo-1 after 2 hrs of incubation with CHimi-based 
complexes with variable DA. (B) Percentage of 293T cells expressing GFP at 24, 48 and 72 hrs post-
transfection with CHimi-based complexes with variable DA. The increase in the percentage of GFP positive 
cells over time for each polymer is presented. Representative experiment out of the three performed 
(average ± SD; n=3). * denotes statistical significant differences relative to CH05imi, CH10imi and CH16imi 
(p<0.05). Representative histogram plots and mean fluorescence intensity data are presented in Figure S6, 
Figure S7 and Figure S8 of supplementary material. 
 
Enzymatic degradation of CHimi-based nanoparticles 
To evaluate the effect of the DA of CHimi on the degradation of CHimi-based complexes, a 
competition assay was setup using lysozyme as a model enzyme for CH intracellular degradation 
[9, 28-31]. The assay is based on the competition for lysozyme between a fluorogenic substrate 
(MU-[GlcNAc]3) [25] and CHimi-based complexes. It is expected that a reduction on the 
fluorescence produced is observed when CHimi is competing with the fluorogenic substrate, since 
less substrate will be degraded.  
 
Figure 8. Extent of MU-[GlcNAc]3 hydrolysis after 4 hrs of incubation with lysozyme in the absence or 
presence of CHimi-DNA complexes. Complexes were prepared with pCMV-GFP and CHimi with different 
DA. The insert shows the fluorescence produced as a function of time.  Representative experiment out of the 
three performed (average ± SD; n=3). 
 
As seen in Figure 8, a reduction in fluorescence can be observed as CHimi DA increases. The 
decrease on fluorescence results from less substrate being degraded, indicating that more 
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polymer degradation has occurred. This difference is identified also at earlier time points (insert of 
Figure 8), although being more evident as incubation time increases.  
 
4. Discussion 
The application of gene delivery strategies in regenerative medicine has been proposed as a 
promising approach to induce the production in loco of proteins that can play a role in tissue 
regeneration. In a previous study we showed that by grafting CH with imidazole moieties, 
transfection efficiency mediated by this polymer can be improved, without impairing cell viability 
[14]. In the present work, we aim at investigating the mechanism of transfection mediated by 
CHimi-based vectors, with the final objective of finding new avenues to further improve the system 
and tune the expression of a delivered gene. 
It has been proposed that gene delivery mediated by CH is a time dependent process [32]; 
however, most of the related publications in this field report transfection efficiency in the 3 to 4 
days after transfection [33-36]. Transfection experiments are usually conducted at high initial cell 
densities (>50% cell confluence), which may be considered a limiting factor regarding the 
maximum time period to render such evaluation feasible. Li and co-workers studied CH-mediated 
transfection up to 15 days post-transfection [37], but the cell culture conditions applied in that 
study were not described in detail. In the present work we introduced a trypsinization step 72 hrs 
post-transfection, as an experimental strategy to extend the time period for evaluation of 
transfection activity and cell viability, while maintaining cells in exponential growth conditions. Two 
CHs with a degree of substitution of primary amine with imidazole moieties of 13% (CH16imi1) 
and 22% (CH16imi2) were tested, as in previous studies in our laboratory these were found to be 
the most effective in mediating cell transfection [14]. The obtained results showed that both 
polymers could mediate a sustained expression of a reporter gene for the time period of the study 
- up to 7 days post-transfection. Additionally, successive transfections with CHimi-based carriers 
could be performed to uphold the levels of gene expression, without a significant reduction on cell 
viability.  
The understanding of the intracellular mechanisms occurring during transfection is considered a 
valuable tool in the design of efficient and functional gene delivery systems [38, 39]. A number of 
intracellular trafficking studies has been conducted so far [40-45], nevertheless the importance of 
complex disassembling on transfection is yet to be established for the cationic polymer-based 
gene delivery systems, as recently discussed [46]. Some authors suggested that DNA can be 
transcribed while complexed with PEI [42], whereas in other studies it was hypothesized that the 
release of DNA from CH is the limiting step for an efficient in vitro transfection [47]. In an attempt 
to clarify whether disassembling of CHimi-DNA complex occurs and to better define the 
intracellular localization of such process, fluorescence microscopy studies were performed in live 
and fixed cells, using complexes prepared with fluorescently labeled CHimi and DNA. In both 
conditions CHimiROX-DNACy5 complexes could be detected inside 293T cells from the first hrs post-
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transfection up to 48 hrs post-transfection, including in GFP expressing cells. In the process of 
assessing the occurrence of complex disassembling by fluorescent signal co-localization, an 
important difference was noted between conditions. In live cells the signal from CHimiROX and 
DNACy5 did not always overlap, whereas in CLSM images of fixed cells CHimiROX and DNACy5 
were found to co-localize at all time periods. The disparity in the observations suggested that 
cell/complex movement could be responsible for the separation of signals observed during 
acquisition in live cells. By fast time-lapse consecutive acquisition of individual fluorescence 
channels, we were able to confirm that particles change position in the time frame of the image 
collection (data not shown). This artifact is not observed when using CLSM for live cell imaging, 
because different wavelengths are acquired simultaneously (see Figure S9 of supplementary 
material). Therefore, fluorescent microscopy studies were not able to clearly demonstrate complex 
disassembling; nonetheless these studies highlighted the importance of a cautious analysis of 
fluorescence images on intracellular trafficking studies. In our attempt to establish complex 
disassembling, we proposed an innovative assay in gene delivery studies. By an in vitro 
transcription/translation assay we were able to show that the production of the reporter protein is 
impaired when DNA is complexed with CHimi, clearly suggesting that disassembling is required 
for gene expression to occur. 
The observed sustained gene expression profile combined with the fact that CHimi-DNA 
complexes could be found in cell cytoplasm up to 48 hrs post-transfection, indicate that gene 
expression mediated by CHimi is a time dependent process, as previously hypothesized for CH 
based gene delivery systems [32]. Furthermore, DNA transcription and/or translation were found 
to be impaired in the presence of the polymer, pointing out the importance of DNA release for the 
expression of the delivered gene. Being CH established as a biodegradable polymer [9, 48], we 
hypothesized that the complex disassembling process could be dependent on CH degradation, 
and, consequently, closely dependent on the polymer DA [9]. To address this question, 
transfection mediated by CHimi with different DA was explored. By the deacetylation of CH16 and 
posterior homogeneous acetylation [17], three polymers with a DA of 5, 10 and 18% were 
produced, while maintaining unchanged the initial molecular weight of the polymer. Imidazole 
moieties were subsequently grafted to each of the prepared CHs. The variation of CH DA neither 
did affect the CHimi-DNA complex physical properties, in accordance to a previous report [49], nor 
the CHimi ability to form stable complexes with DNA in the serum supplemented culture medium 
and to protect it from DNase I-mediated degradation under physiologic conditions. Nonetheless, 
significant differences were found in terms of complex internalization in 293T cells, as well as on 
transfection efficiency. Internalization of CH18imi-based complexes was found to be significantly 
lower than the other nanoparticle formulations. Furthermore, the internalized CH18imi-based 
nanoparticles showed a limited ability to transfect cells, comparing to the other tested systems. 
These results suggest that other factors rather than the extent of internalization are contributing to 
the observed transfection outcome. There is evidence in the open literature that a small difference 
on chitosan degree of acetylation can lead to significant changes on polymer properties [29], 
being the distribution of the acetylated monomers in the polymer chain one of the contributors to 
Chitosan-mediated gene delivery 
146 
this effect [9]. The effect of the DA on CH enzymatic degradation has been previously described 
namely for CH films [29] and scaffolds [31]. The data concerning CH degradation, when the 
polymer is incorporated in nanoparticles is limited and inconclusive, though. Campos et al. [30] 
had shown a slight decrease of CH-tri-polyphosphate nanoparticle size (DA 16%) after 4 hrs of 
incubation with lysozyme. Similar results were reported by Bernkop-Schnurch and colleagues 
using thiolated CH [50]. By applying an assay in which CHimi-based complexes compete with a 
fluorogenic substrate for lysozyme, we showed that as CHimi DA increases, less fluorescence is 
produced, indicating that the polymer present in the particles is being more extensively degraded. 
According to this result, CH18imi was found to be the polymer under investigation that degrades 
at the fastest rate, what can justify its low efficiency as a gene delivery vector. Upon 
internalization, the polymer may be readily degraded leading to a premature release of DNA, 
therefore compromising the plasmid DNA protection intracellularly and, consequently, impairing 
transfection. On the other hand, only a small decrease on fluorescence was observed when 
CH05imi-based particles competed for lysozyme, suggesting that the degradation of this polymer 
was limited. The slower degradation could justify the delayed expression of the reporter gene 
mediated by CH05imi, when in comparison to CH10imi and CH16imi. In the former case the boost 
on transfection efficiency occurs only after 48 hrs post-transfection. Additional indication of CHimi 
degradation was obtained by CLSM in an experiment where a CHimiROX-DNACy5 complex 
entrapped in a vesicle within the cell cytoplasm was followed by live imaging (time lapse video 
supplied in supporting info. For experimental details see caption of Figure S9, supplementary 
material). The fluorescence emitted by CHimiROX was clearly reduced during the experiment, 
whereas the one emitted by DNACy5 is not altered (Figure S10, Supplementary material). The 
results provide experimental evidence for CH-based complexes degradation both in vitro and 
intracellularly, putting forward CH degradation rate as a parameter influencing transfection 
efficiency mediated by CHimi. 
 
5. Conclusion 
The opportunity to tune gene expression as a function of CHimi biodegradability, and the fact that 
this polymer promotes a sustained gene expression that can be upheld by successive 
transfections, emphasizes the potential of CHimi-based polymers as gene vectors in vivo in a 
regenerative medicine scenario. Therefore, our group is currently exploring different possibilities to 
incorporate CHimi-based polymers in the design of targeted nanoparticles aiming at cell-specific 
gene delivery to the peripheral nervous system [51]. 
 
Executive summary 
In vitro gene expression study  
CHimi-based vectors show appropriate properties to be used in a regenerative medicine scenario, 
being able to mediate a transient, and sustained expression of a delivered gene without cytotoxic 
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effects. Successive transfections with CHimi-based vectors can be carried out to uphold the levels 
of expression of a therapeutic protein without compromising cell viability. 
Intracellular trafficking studies 
The sustained gene expression is consistent with the fact that complexes are detected inside the 
cells up to 48hrs after transfection. 
Cell-free gene expression assay 
Complex disassembling is a critical step for the transcription and/or translation of the delivered 
gene. The in vitro transcription/translation assay proved to be a valuable tool in gene delivery 
studies to disclose the role of complex disassembling on gene expression. 
Degree of acetylation role on CH-based nanoparticle transfection efficiency and degradation 
CHimi, when complexed with DNA, can be enzymatically degraded. The degradation rate is 
directly dependent on the chitosan degree of acetylation. Gene expression kinetics can be related 
to the CHimi degradation.  
Conclusion 
CHimi-based polymers have high potential as gene vectors for an in vivo application in a 
regenerative medicine scenario. Tuning their degradation rate could be used as a strategy to 
adapt the overall expression process of a transgene to fulfill the therapeutic end. 
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Supporting information  
 
Figure S1. Cell viability as a function of post-transfection time. Relative viability was defined as the 
percentage of metabolic activity of transfected cells relative to non-transfected cells. Representative 
experiment out of the three performed (average ± SD; n=6).  
 
Table S1. Zeta potential, average size (Z-Average) and polydispersity index (PdI) of CHimi1-DNA based 
complexes. Measurements were performed in acetate buffer 5 mM (pH 5.5) at 25C. Zeta potential was 
calculated according to the Smoluchowski model. CHimiROX indicates the fluorescent labeled polymer 
(average ± SD; n=3). 
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Figure S2. CLSM images obtained at 2, 6, and 48 hrs after transfecting 293T cells with CHimiROX-DNACy5 
complexes. Merged and individual signals are presented. In merged images CHimiROX is shown in red, 
DNACy5 in gray, genomic DNA is stained in blue and phalloidin (filamentous F-actin) is in green.  At 48 hrs 
post-transfection GFP positive cells are depicted in green. White arrows indicate CHimiROX-DNACy5 
complexes. Scale bar: 10 µm. 
 
 
 
Figure S3. CHimi-DNA particle stability and protection. Complexes were prepared with the same polymer 
mass, independently of the DA. Naked DNA was used as control. (A) Agarose gel electrophoresis of naked 
DNA and CHimi–DNA complexes in the presence/absence  of supplemented DMEM (10% FCS and 1% PS). 
(B) Variation of absorbance values at 260 nm (t-t0) as a function of time after addition of DNase I (pH 7.4, 
37°C).  
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Figure S4. FT-IR spectra of chitosan with different degree of acetylation prepared in this study. 
 
 
Figure S5. FT-IR spectra of imidazole-grafted chitosan obtained from chitosan with different degree of 
acetylation. 
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Figure S6.: Representative histogram plot of the extent of  internalization in 293T cells of DNA or complexes 
prepared with CHimi with different degree of acetylation.  
 
 
 
Figure S7. Representative histogram plot of GFP expression by 293T cells 24, 48 and 72 hrs after being 
transfected with CHimi-based complexes with variable degree of acetylation. 
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Figure S8. Mean fluorescence intensity of 293T cells that incorporated YoYo-1 (A) or express GFP (B) as 
determined by FACS.    
 
 
 
Figure S9. Time-lapse images obtained by CLSM. The experiment started at 2h30min and finished at 
5h45min post-transfection. Acquisitions were performed each 15 min. The video can be found in 
http://www.futuremedicine.com/loi/nnm. It shows the degradation of a CHimiROX-DNACy5 complex inside a 
vesicle in the cell cytoplasm. The vesicle (region of interest – ROI) is delimited by a white circle in the video. 
Complexes were entrapped in the vesicle during the all course of the experiment. CHimiROX signal is shown 
in red and DNACy5 in green. Scale bar: 10µm. Changes in the gamma settings were performed in order to 
allow the better visualization of CHimiROX. 
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Figure S10.: Mean fluorescence of CHimiROX (A) and DNACy5 (B) measured in the region of interest (ROI) 
depicted in the Figure S4. It can be noticed that DNACy5 mean fluorescence values are higher than the ones 
for CHimiROX. This occurs because Cy5 is a much brighter fluorophore than rhodamine. 
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APPENDIX I 
Preliminary results on the incorporation of chitosan-based 
nanoparticles in poly(trimethylene carbonate-co-ε-caprolactone) 
electrospun fibres 
 
 
1. Introduction  
The combination of gene therapy-based strategies with tissue engineering scaffolds holds the 
promise of providing both physical support for cell adhesion and growth, and genetic material to 
tune specific cellular processes [1]. Nucleic acids have been directly incorporated into the 
matrices [2-5], or vectorized through virus [6, 7] or nanoparticles formed by interaction with lipids 
[3] or cationic polymers, such as poly(ethylene imine) (PEI) [8] and chitosan [9]. 
In the context of spinal cord injury, the use of this combined strategy has already showed 
promising results in vivo. The implantation of a multiple channel bridge loaded with lipid-DNA 
nanoparticles promoted the expression of a reporter gene during at least 3 weeks [3]. More 
recently, Yao and co-workers reported the sustained expression of a growth factor - neurotrophin-
3 (NT-3) - at the lesion site after implantation of a collagen conduit loaded with polymeric particles 
containing the NT-3 gene. While a statistically significant functional improvement was not 
achieved in the time frame of the study (4 weeks), an increased number of axons was found 
crossing the conduit at the time of evaluation [10]. 
Currently, electrospinning is being actively investigated for the preparation of tissue engineering 
scaffolds since it allows the formation of fibres at the nano/micrometer scale, mimicking the 
extracellular matrix [11, 12]. Furthermore, alignment of these fibrous structures can be achieved, 
by applying a rotating target. The use of aligned fibres is very promising in the field of nerve 
regeneration as these can provide physical guidance for axonal regrowth [13, 14]. Although the 
scientific publications concerning the incorporation of genetic material into electrospun fibres in 
the context of nerve regeneration is still in its infancy, this combined strategy was already 
investigated in vitro using DNA [15, 16], siRNA [17, 18] or nanocomplexes with nucleic acids [16, 
18-20]. Furthermore, positive results were already reported in vivo [16, 21], namely in a diabetic 
ulcer model [16].  
The application of electrospun-based scaffolds for the delivery of genetic material into a SCI can 
combine topographic guidance with the delivery of gene vectors that mediate the sustained 
expression of therapeutic molecules (such as growth factors) or that can block the expression of 
specific inhibitory factors, leading, ultimately, to an enhancement on the process of nerve 
regeneration. In this study, we aim at incorporating chitosan-based nanoparticles in 
poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] electrospun fibres, in order to create 
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a device for the delivery of genes to the SCI site. P(TMC-CL) is a synthetic polymer that has 
previously showed interesting properties to assist nerve regeneration both in the peripheral [22, 
23] and the central nervous system [24]. Our group has recently described the preparation of 
P(TMC-CL) fibres by electrospinning and its application in vitro as drug delivery platform [25]. 
Additionally, we have previously studied chitosan chemical modification [26, 27] and its 
intracellular trafficking [28] getting hold of relevant cues for the optimization of gene delivery 
mediated by chitosan-based nanoparticles. Taking advantage of this previously obtained know-
how, the present communication reports preliminary results on the efforts made to combine 
nanoparticles with electrospun fibres, foreseeing the development of a combinatorial strategy to 
promote nerve regeneration. 
 
Results and Discussion 
Electrospinning of nanoparticle containing solutions: solvent screening 
In order to incorporate chitosan-based nanoparticles within P(TMC-CL) fibres during the 
electrospinning process, it was firstly necessary to find a solvent mixture compatible with both the 
chitosan-based nanoparticles and the P(TMC-CL) copolymer. P(TMC-CL) and chitosan (CH) differ 
significantly on their nature and solubility. P(TMC-CL) is a synthetic polyester, mainly soluble in 
organic solvents; whereas CH is a natural polycation, soluble in slight acidic solutions. 
Considering that to assure the fibre formation by electrospinning from this mixture the major 
component - P(TMC-CL) - needs to be well solubilised, the compatibility of CH or CH-DNA 
nanoparticles with solvents commonly used to dissolve P(TMC-CL) was tested (see Table 1). 
CH solutions prepared in sodium acetate buffer (pH 5.5) [26, 28] were found to be immiscible with 
the organic solvents tested, namely chloroform or dichloromethane. CH-DNA nanoparticles (in 
suspension in acetate buffer pH 5.5 [26]) when added to these solvents tend to precipitate. If 
added to dimethylformamide (DMF), nanoparticles tend to aggregate, but do not precipitate. 
However, when formed it was not possible to re-disperse these aggregates. 
 
Table 1. Solvent mixtures tested.  
Solvent P(TMC-CL) CH 
CH-DNA 
nanoparticles 
Chloroform Soluble Immiscible  
Dichloromethane Soluble Immiscible  
Dimethylformamide Soluble  Aggregate 
Acetone Soluble  Precipitate 
Dioxane Soluble  Precipitate 
CH-chitosan (Mw: 121000, DDA:84.6%);P(TMC-CL): poly(trimethylene carbonate-co--caprolactone)  
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In view of the results summarized in Table 1, it was considered that to efficiently suspend CH-
based nanoparticles in a polymeric organic solution required the stabilization of the nanoparticles. 
 
Electrospinning of P(TMC-CL) fibres containing TriM-CH based nanoparticles  
Our group is currently investigating the use of the CH derivative trimethyl chitosan (TriM-CH). The 
quaternization of the primary amine groups of CH with methyl groups has been found to 
considerably improve CH solubility, rendering it soluble in a wider range of pHs, including at 
physiological pH. The group has tested TriM-CH of different molecular weights and degrees of 
quaternization, as these parameters can significantly affect the polymer properties, and, 
ultimately, transfection. In general, in comparison to CH, TriM-CH forms by electrostatic 
interaction with plasmid DNA nanoparticles with smaller diameter and with an improved 
complexation stability in different dispersants [29]. In particular, it was found that TriM-CH-based 
nanoparticles have an improved stability, comparing to CH-based ones, after freezing or freeze-
drying process [29]. 
In the present work, we tested two modified CHs with similar degree of quaternization (< 30%), but 
different molecular weights - high (110,000, TriM-CH(H)) and low molecular weight (30,000, TriM-
CH(L)). The detailed description of polymer characterization is supplied in the experimental 
section (Table 3). Taking advantage of the described stability to the freeze-drying process, we 
explored the possibility of resuspending these nanoparticles in an organic solvent – DMF – to, 
subsequently, mix it with P(TMC-CL) solution. DMF has been commonly applied in electrospinning 
solutions as a mean to increase solution conductivity [30]. Particularly, it showed to improve 
P(TMC-CL) fibre morphology and homogeneity, decreasing mean fibre diameter [25].  
In the preparation of the TriM-CH-DNA complexes for transfection, we have been employing TriM-
CH polymer solutions in glucose 5% (w/v), pH 7.4 (Aida Moreira, unpublished data). In order to 
avoid interference of glucose in the electrospinning process, the stability of the TriM-CH based 
nanoparticles to the freeze-drying process when in a water solution (MilliQ grade) was firstly 
investigated. 
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Figure 1. Size distribution graph for TriM-CH(H)-DNA nanoparticles (N/P molar ratio = 4) prepared in water 
(MilliQ grade). The table shows the z-average and polydispersity index (PDI) of the prepared nanoparticles 
(n=3). 
 
TriM-CH(H) prepared in glucose solution (5% (w/v)) yielded nanoparticles with a mean diameter 
around 320 nm. However, when TriM-CH(H) nanoparticles are prepared in water, mean diameter 
decreases to 200 nm, suggesting that polymer-DNA condensation is affected by the presence of 
glucose. Nevertheless, when the TriM-CH(H) particles were freeze-dried and subsequently 
resuspended in water, the formation of large aggregates is denoted. This process hindered a valid 
characterization of nanoparticle in terms of mean diameter and suggests that the presence of 
glucose in solution is critical for nanoparticle stability to the freeze-drying process. The tendency 
to form aggregates was also observed when the nanoparticles were resuspended in DMF. 
Nonetheless, the mixture was added to a P(TMC-CL) solution in dichloromethane (DCM) and 
stirred overnight to be subsequently, electrospun. The final solvent mixture was 3:1 DCM:DMF 
and DNA concentration was set to 0.02% (w/w of polymer). After overnight mixing,  
TriM-CH(H)–DNA nanoparticles and P(TMC-CL) yield an apparently homogeneous suspension. 
As shown in Figure 2, homogeneous fibres were formed, being the fibre mean diameter 0.37 ± 
0.11 μm. The mean fibre diameter was found to be significantly decreased comparing to the 
diameter of P(TMC-CL) fibres obtained using a similar electrospinning setup found to be 0.67 ± 
0.12 μm [25].  
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Figure 2. SEM micrographs of the fibres obtained after electrospinning of a P(TMC-CL) solution containing 
TriM-CH(H)–DNA nanoparticles using a 3:1 DCM:DMF solution.(A) Low and (B) high magnification images 
are presented. 
 
The differences found in terms of fibre mean diameter suggest that the presence of nanoparticles 
alter the conductivity of the electrospun solution and, therefore, fibre diameter. To obtain evidence 
on the presence of DNA incorporated in the fibres, an electrophoresis was performed, after 
dissolving the obtained fibrous mesh. Results are presented in Figure 3.  
 
 
Figure 3. Gel electrophoresis of P(TMC-CL) fibres containing TriM-CH(H)-DNA nanoparticles after 
dissolution in dioxane (lane 4). Plasmid DNA solutions in H2O and dioxane were used as control (lanes 2 and 
3, respectively).  
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Gel electrophoresis of the fibrous mesh solution was performed along with a DNA solution in 
water or in the same solvent used to dissolve the fibrous mesh. Figure 3 shows that dioxane 
interferes with the plasmid DNA run, but does not hamper its detection (Figure 3, lane 3). When 
analysing the run of the fibrous mesh solution (lane 4), one should take into account that P(TMC-
CL) fibres were prepared with a DNA loading of 0.02% (w/w of polymer). Consequently, in this 
particular experiment, the maximum amount of DNA present in the fibres and therefore, loaded in 
the gel, was 70 ng, corresponding to approximately 15 times less than the control (1 µg, lane 3). 
Figure 3 (lane 4) shows a band that although significantly smaller in comparison to control, 
suggests the presence of DNA that has been retained near the loading well. This result points to 
the presence of TriM-CH and that the positive charge from the polymer is hindering the DNA to 
move electrophoretically. Although suggesting that both DNA and polymer are present, the result 
obtained in this assay cannot assure that in the fibre both are still complexed in the form of 
nanoparticles.  
 
To prove the presence of the nanoparticles in the fibres we prepared fluorescently-labelled 
nanoparticles, by labelling TriM-CH(L) with rhodamine (TriM-CH(L)ROX) as previously described for 
chitosan [28]. We proceeded these studies with TriM-CH(L) with a lower molecular weight (see 
Table 3) as in the course of this work this polymer was found to be more efficient in terms of 
stability to storage and transfection efficiency than TriM-CH(H) (Aida Moreira, unpublished data). 
The nanoparticles prepared using TriM-CH(L)ROX dissolved in water (MilliQ grade) were 
characterized in terms of size as prepared and after freeze-drying and resuspension (Table 2).  
 
Table 2. Characterization in terms of Z-average diameter (nm) and polydispersity index (PDI) of 
nanoparticles prepared with TriM-CH(L)ROX (n=3) at an N/P molar ratio of 2. 
Nanoparticles Z-average (nm) PDI 
TriM-CH(L)ROX–DNA 136 ± 31 0.248 ± 0.02 
TriM-CH(L)ROX–DNA (freeze dryed) 349 ± 29 0.349 ± 0.02 
Z-ave (nm): Z-average nanoparticle diameter; PDI: polydispersity index. 
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Figure 4. Size distribution graph of fluorescently-labelled TriM-CH(L)ROX-DNA nanoparticles (N/P molar 
ratio= 2) prepared in water, before and after freeze-drying process.  
 
Nanoparticles prepared using the fluorescently-labelled TriM-CH(L)ROX show a mean diameter 
around 136 nm. After freeze-drying and resuspension, particle diameter increases above 300 nm, 
being observed the formation of a small population of particles of larger diameter. These effects 
may be caused by the use of water as solvent, as mentioned above for TriM-CH(H). The use of 
water as dispersant for nanoparticles does not favour stability to the freeze-drying process, 
comparing to glucose solutions. Indeed, glucose and other sugars have been previously applied 
as cryopreservatives [31]. Nonetheless, it was observed that nanoparticles based on TriM-
CH(L)ROX can be easily suspended after freeze-drying without forming aggregates. 
To prepare nanoparticle-loaded P(TMC-CL) fibres, TriM-CH(L)ROX–DNA nanoparticles were 
resuspended in DMF and added to a P(TMC-CL) solution. The mixture showed a light pink colour, 
indicating the presence of the fluorochrome. The fibres obtained after electrospinning of this 
mixture are presented in Figure 5. 
The fibre formation was found not to be homogeneous and two distinct regions of deposition were 
obtained. In the main region, fibres are formed (Figure 5, A-B), being the fibre mean diameter 
found to be 1.04 ± 0.38 μm. In the second region some fibres are deposited, as well as drops of 
the suspension (Figure 5, C). Since the two deposition areas were independent, fibres collected in 
the first area were considered for the posterior analyses.  
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Figure 5. SEM micrographs of the fibres obtained after electrospinning of a P(TMC-CL) solution containing 
TriM-CH(L)ROX–DNA nanoparticles using a 3:1 DCM:DMF solution. (A) Low and (B) high magnification 
images are presented. (C) Secondary region of deposition where both fibres and polymer drops were 
deposited . Images presented are representative from three independent experiments. 
 
Since fluorescently-labelled TriM-CH was applied for the preparation of these fibres, the 
fluorescence of the prepared mesh was analysed by fluorescence microscopy (Figure 6). The 
images suggest that a large amount of nanoparticles is present in the fibres, due to high intensity 
signal in the rhodamine fluorescence channel (Figure 6, A). When combining fluorescence and 
bright field, the image (Figure 6, B) suggests the presence of fluorescently-labelled polymer within 
the fibres.  
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Figure 6. (A) Fluorescence images (B) combined with bright field image of the P(TMC-CL) fibres containing 
TriM-CH(L)ROX nanoparticles. Amplification image suggests that fluorescence from TriM-CH(L)ROX co-localize 
with the fibre as indicated by the arrows.  
 
To investigate if the TriM-CH(L)ROX were present in the P(TMC-CL) fibres and can be released 
when incubated in phosphate buffered saline (PBS), the fluorescence of the releasing medium 
was followed during 23 days (Figure 7).  
 
 
Figure 7. Cumulative release of fluorescent particles (λex=575nm, λex=605nm) to the releasing medium when 
P(TMC-CL) fibres containing TriM-CH(L)ROX nanoparticles were incubated with PBS at 37°C. RFU: relative 
fluorescence units. 
 
The results presented in Figure 7 show that there is a gradual release of fluorescent particles to 
the medium (PBS) over time, suggesting that TriM-CH(L)ROX based nanoparticles are being 
released from P(TMC-CL) fibres. The fluorescence intensity of the prepared fibres was mapped 
using the area scan functionality of the fluorometer before and after incubation in PBS.  
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Figure 8. Area scan of fluorescence (λex=575 nm, λex=605 nm) found in P(TMC-CL) fibres containing TriM-
CH(L)ROX–DNA nanoparticles before (A) and after (B) incubation in PBS during 23 days. 
 
The mapping of the fluorescence of P(TMC-CL) fibres demonstrates that fluorescence intensity 
decreases after incubation with PBS in all the sample. Since some fluorescence can still be found, 
this suggests that the majority of the nanoparticles were released from the P(TMC-CL) fibres 
during the 23 days of incubation, but some can still be entrapped within the polymer mesh. 
 
In a very preliminary experiment, ND7/23 cells were seeded on top of P(TMC-CL) fibres loaded 
with TriM-CH(L)ROX nanoparticles. As shown in Figure 9 a significant amount of cells are found 
adhered to the fibres, suggesting that these can be a good substrate for cell growth. Additionally, 
the presence of fluorescence signal in the rhodamine channel (shown in red) suggests that the 
fluorescent polymer is present in the fibrous mesh. In this experiment a plasmid DNA encoding for 
green fluorescence protein (GFP) was applied, in order to identify transfected cells by their green 
fluorescence. However, no GFP signal was observed, indicating that transfection was not efficient 
in the time frame of the experiment (72 hrs). This result could be caused by the limited period of 
incubation with the fibres. The sustained/delayed release of the nanoparticles from the fibrous 
mesh may limit the amount of nanoparticles available to be internalized by the cells, and 
consequently can limit transfection. Previous reports using polymeric nanoparticles based on PEI 
incorporated on electrospun fibres showed that transfection efficiency increases up to day 7 after 
seeding [16, 19]. Alternatively, we hypothesize that the amount of plasmid DNA available to be 
delivered in this experiment can be insufficient. since the prepared fibres were loaded with 0.02% 
(w/w of polymer) DNA whereas others report the use of 0.1% (w/w of polymer) DNA loading [19]. 
A quantification of the actual amount of DNA that is released over time is necessary to adjust DNA 
loading in the P(TMC-CL) fibres and also to establish appropriate cell culture time-points. 
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Figure 9. Fluorescence image of ND7/23 cells seeded on top of P(TMC-CL) electrospun fibre loaded with 
TriM-CH(L)ROX-DNA nanoparticles. The nanoparticles are shown in red and cell nucleus is shown in blue. 
The auto-fluorescence of the P(TMC-CL) fibres allows its identification below the cells. 
 
4. Conclusion and future directions 
The results presented in this section, although preliminary, provide important insights for a 
successful preparation of electrospun fibres containing chitosan-based nanoparticles. 
We found that nanoparticles based on TriM-CH are appropriate to combine with P(TMC-CL) 
electrospun fibres. Their stability to freeze-drying process allowed resuspension in a organic 
solvent, favouring fibre formation process. Our preliminary results suggest that nanoparticles 
prepared with TriM-CH(H), though tending to form aggregates after freeze-drying, can be 
homogeneously dispersed in the P(TMC-CL) solution, yielding more homogeneous electrospun 
fibres. Conversely, TriM-CH(L)ROX based nanoparticles dispersed in P(TMC-CL) solution fibres 
yield higher diameter fibres and a less homogeneous mesh. The higher molecular weight of TriM-
CH(H) can better fit in the electrospinning requirements. Future efforts will be focused on the 
preparation of homogeneous solutions in order to avoid the formation of droplets during 
electrospinning, effect that we were not able to circumvent when using TriM-CH(L)ROX, so far. 
The presented results also highlight the importance of using labelled nanoparticles to allow its 
identification within the fibrous mesh. The fluorescent labelling was explored in this study but, 
although the presence of fluorescence signal in the fibres suggests the presence of particles, one 
cannot exclude that some unbound fluorochrome exists. Furthermore, it is important to figure out if 
the fluorescence signal corresponds to nanoparticles (polymer and DNA) or only to TriM-CH 
entrapped in the P(TMC-CL) mesh. Double fluorescent-labelling of DNA and TriM-CH can address 
this issue. Alternative labelling methods using quantum dots or gold nanoparticles can improve 
sensibility of detection. The use of chemical characterization techniques, like confocal-Raman 
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should be taken into consideration, as it can also provide information on the nanoparticle 
distribution within the mesh. 
Future work on this project will certainly include the investigation of DNA bioactivity in transfection 
experiments in order to clarify if electrospinning process alters DNA or if CH-based nanoparticles 
maintain their ability to deliver DNA. The quantitative evaluation of the amount of DNA released 
over time will be paramount for establishing appropriate time-points for cell culture studies on 
transfection efficiency. 
 
Experimental section 
Materials 
Poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] was synthesized as previously 
described [25, 32] using trimethylene carbonate as received (Boehringer Ingelheim, Germany) 
and ε-caprolactone (Merck, Germany) distilled before co-polymerization reaction. The synthesized 
polymer was purified by precipitation into a tenfold volume of ethanol (96%, v/v; AGA, Portugal). 
The purified polymer contains 11% mol of TMC; the number weight molecular weight was found to 
be 8.2x10
4
 and the polydispersity index was 1.61 [25]. 
Technical grade chitosan (CH) (Chimarin™, degree of deacetylation (DDA) 87%, apparent 
viscosity 8 mPa.s, supplied by Medicarb, Sweden) was purified as previously described [26]. The 
average weight molecular weight (  

M w), polydispersity index and DDA of the purified polymer were 
found to be 1.2x10
5
,
 
2.1 and 84.6%, respectively [26] (Table 3). Chitosan stock solutions (0.1% 
(w/v)) were prepared in acetate buffer solution (5 mM, pH 5.5) and stored at 4°C till further use. 
Trimethylchitosan (TriM-CH) of fungal origin was obtained from Kitozyme (Belgium). Two TriM-CH 
of different molecular weight were tested in these experiments. The characterization of the 
polymers under investigation is presented in Table 3. TriM-CH solutions were prepared by 
dissolving the polymer overnight in water (MilliQ grade) at a final concentration of 0.1% (w/v).  
 
Table 3. Characterization of the polymers tested in this study.  
 Mw x 10
3
 DQ (%) DDA (%) 
CH 121  84.6 
TriM-CH(L) 30 22 88.8 
TriM-CH(H) 110 29 77.7 
Mw: average weight molecular weight; DQ: degree of quaternization; DDA: degree of deacetylation; 
 
Plasmid DNA encoding for GFP (pCMV-GFP, 7.4 kbp) was used in this study to prepare 
nanoparticles with CH or TriM-CH. Plasmid was amplified in DH5 Escherichia coli (E. coli) and 
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isolated using GENELUTE™ high performance endotoxin-free plasmid Gigaprep kit according to 
the manufacturer instructions (Sigma-Aldrich). Plasmid concentration and purity were determined 
spectrophotometrically (NanoDrop, Thermo Scientific). The ratio between optical density at 260 
nm and 280 nm was found to be higher than 1.7. 
Preparation of nanoparticles 
To prepare nanoparticles, equal volumes of pre-heated (55°C, 10 minutes) CH or TriM-CH and 
DNA (in MilliQ-grade water) solutions were mixed by adding the DNA solution dropwise to the 
polymer solution, under vortex. Nanoparticles were allowed to form and stabilize for 15 minutes at 
RT before further use. 
Taking into consideration the transfection activity results previously obtained [26, 28], CH-DNA 
complexes were prepared at a molar ratio of chitosan primary amines to DNA phosphate groups 
(N/P) of 18. For TriM-CH-based complexes, N/P molar ratio is expressed in terms of moles of 
quaternized amine groups of the polymer (-N-(CH3)3), to moles of phosphate groups of DNA. The 
N/P molar ratios applied in this study were 4 and 2, respectively for TriM-CH(H) and Tri-CH(L). 
For electrospinning experiments, TriM-CH-based nanoparticles were prepared containing 20 μg of 
plasmid DNA, freeze-dried (-80ºC, 0.008 mBar, 48 hrs, Labconco, USA) and stored at room 
temperature till further use.  
Solvent screening 
The compatibility of P(TMC-CL) and CH or CH-DNA nanoparticles with different solvents was 
investigated. Solvents tested include dichloromethane (DCM), dimethylformamide (DMF), 
chloroform, acetone, and dioxane. Visual analysis was performed. 
Chitosan-based nanoparticle characterization 
Nanoparticles prepared as previously mentioned were characterized in terms of size using a 
Zetasizer Nano Zs (Malvern, UK). Cumulant analysis was used for mean particle size 
determination. All measurements were performed in triplicate, at 25°C.  
Trimethyl chitosan fluorescent labelling 
Fluorescent labelling of TriM-CH was performed based on the previous described procedure [28] 
with minor modifications. In brief, TriM-CH(L) was dissolved overnight in MilliQ water (1% (w/v)). 
5(6)-Carboxy-X-rhodamine N-succinimidyl ester (ROX, Fluka) was dissolved in dimethylsulfoxide 
(7.5 mg.ml
-1
) and added dropwise to the polymer solution, under stirring. The reaction occurred 
during 3 hrs at room temperature, under constant agitation. The labelled polymer was washed 
with distilled water using Amicon
®
 ultra centrifugal filters (3,000 kDa, Millipore), till no significant 
fluorescence was detected in the supernatant (λex 575 nm, λem 605 nm). The polymer solution was 
collected and freeze dried. Stock solutions of the fluorescently-labelled polymer (TriM-CH(L)ROX) 
were prepared in water (MilliQ grade) at a final concentration of 0.1% (w/v). 
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Preparation of electrospun P(TMC-CL) fibres loaded with nanoparticles 
To prepare P(TMC-CL) fibres loaded with TriM-CH nanoparticles, P(TMC-CL) was dissolved 
overnight in DCM. Lyophilized TriM-CH-based nanoparticles were resuspended in DMF and 
stirred at 1,400 rpm overnight (Thermomixer, Eppendorf Iberica, Spain). Nanoparticle suspension 
was added dropwise to the P(TMC-CL) solution and the mixture was under magnetic agitation for 
additional 4 hrs. The final concentration of P(TMC-CL) was 10% (w/v) and the solvent mixture 
corresponds to a 3:1 DCM:DMF ratio. DNA loading tested was 0.02% (w/w of polymer), 
corresponding to 20 μg of DNA per each 100 mg of P(TMC-CL). 
Although variations in the electrospinning parameters were tested, the prepared solution was 
electrospun using similar electrospinning setup as described in previous work [25]. In brief, using 
a vertical configuration of electrospinning, solutions were dispensed at a controlled flow rate of 1 
ml.h
-1
 using a syringe pump (Ugo Basille, Italy). An electric field of 1 kV.cm
-1
 was created (Gamma 
High Voltage source, USA) between the spinneret (inner diameter 0.8 mm) and the flat collector 
(15x15 cm) covered with aluminium foil. Fibres were collected during 30-40 minutes and 
subsequently, vacuum dried during 24 hrs.  
Fibre morphology analysis 
The morphology of the P(TMC-CL) fibres was observed by scanning electron microscopy (SEM, 
FEI Quanta 400FEG, FEI, the Netherlands) after being sputter-coated with gold-palladium for 90 
seconds (SPI Supplies, USA). Fibre diameter was quantified from SEM micrographs using an 
image analysis software (Image J, version 1.39). 
Gel electrophoresis 
P(TMC-CL) fibres containing TriM-CH–DNA nanoparticles were dissolved in dioxane (18  
mg.ml
-1
) overnight at room temperature. 20 μl of this solution were loaded along with 5 μl of 
loading buffer (Fermentas) in a 1% (w/v) agarose gel containing 0.05 μg.ml
-1
 of ethidium bromide 
(Q-BioGene, USA). 1 μg of plasmid DNA was used as control. The electrophoresis was run at 100 
V for 45 minutes. The gel was visualized using a Gel Doc™ system (Bio-Rad, Portugal). 
Evaluation of nanoparticle release from P(TMC-CL) electrospun fibres 
To investigate the release of fluorescently-labelled nanoparticles the prepared fibres were 
incubated in PBS at 37ºC and at day 1, 2, 5, 8, 12, 16 and 23 of incubation, the releasing medium 
was completely refreshed. Fluorescence (λex=575nm, λex=605nm) of the collected medium was 
analyzed using a SynergyMax (Biotek, Portugal) fluorometer. The fluorescence of P(TMC-CL) 
fibres was mapped using the functionality of area scan of this equipment. 
Preliminary transfection experiment using ND7/23 cell line 
ND7/23 cell line (mouse neuroblastoma (N18 tg 2) x rat dorsal root ganglion neuron hybrid) was 
obtained from ECACC (UK) and routinely cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
with Glutamax, supplemented with 10% (w/v) foetal bovine serum (FBS) (heat-inactivated at 56ºC 
for 30 minutes) and 1% penicillin/streptomycin (PS, 10,000 units.ml
-1
 penicillin and 10,000 μg.ml
-1
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streptomycin), all supplied by Gibco (Life Technologies S.A., Spain). The cells were seeded 
(4x10
4
 viable cells.cm
-2
) on top of P(TMC-CL) fibres loaded with TriM-CH(L)ROX–DNA 
nanoparticles. After 72 hrs of incubation, the cells were fixed in 4% (w/v) paraformaldehyde and 
incubated with 4’,6-diamidino-2-phenylindole (DAPI, Vector Laboratories) for 10 minutes, to allow 
nucleus fluorescent labelling. The cells were observed under an inverted fluorescence microscope 
(Axiovert 200, Zeiss, Germany). 
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After the primary insult that leads to the interruption of the axonal pathways, a lesion to the spinal 
cord is followed by the activation of a number of inhibitory mechanisms and a protracted period of 
tissue destruction. Axonal regeneration fails in this hostile environment and the process ends up 
with the formation of a cavity surrounded by scar tissue [1]. In order to promote regeneration in 
such inhibitory scenery, it is well accepted that a multi-targeted approach is required [2]. In this 
context, the ultimate goal of the work described in this thesis is to propose a scaffold to be 
implanted in the spinal cord after a lesion, that provides physical support, guidance and 
biochemical cues, constituting, utterly, a permissive substrate for axonal regrowth. Each of the 
presented experimental chapters were sought to contribute to the design of such a structure.  
 
Poly(trimethylene carbonate-co-ε-caprolactone) [P(TMC-CL)] was chosen as starting material for 
the development of this scaffold, based on previous reports showing the interesting properties of 
the polymer in the context of peripheral [3, 4], and central nervous system regeneration [5].  
The use of electrospinning for the preparation of scaffolds for tissue engineering has been largely 
investigated due to the characteristics of the resulting fibrous structure that emulates the features 
of the extracellular matrix [6, 7]. Herein we report the preparation of P(TMC-CL) fibres by 
electrospinning. Taking into consideration the importance of microglia, the resident immune cells 
on the central nervous system (CNS), in triggering the response to injury, we described for the first 
time the effect of electrospun fibres on primary microglia cells in comparison to flat solvent cast 
films. In line with what is described in the open literature for other cell types, we showed that 
microglia morphology is remarkably affected by the topography of the surface. It was shown that 
the fibrous structure favours microglia cytoplasm elongation, and, surprisingly, the release of the 
pro-inflammatory cytokine - TNFα. The classical classification of microglia ascribes a pro-
inflammatory phenotype to cells with an amoeboid morphology [8]. Moreover, in macrophages, an 
elongated cell shape has been associated with an anti-inflammatory phenotype [9]. Our study 
highlights the importance of specifically addressing the response of microglia in the context of 
CNS regeneration. Indeed, although sharing important lineage features with macrophages, 
microglia can respond differently to stimuli. This study also showed that the P(TMC-CL) surfaces 
under investigation do not significantly activate microglia, as astrogliosis markers were not 
exacerbated when astrocytes were in contact with microglia conditioned media. Furthermore, it 
was demonstrated that microglia seeded on P(TMC-CL) fibres or solvent cast films was able to 
actively contribute in myelin phagocytosis, a critical step on the progress of regeneration as myelin 
debris accumulation after injury leads to the release/exposure of molecules inhibitory to axonal 
regrowth. These results put forward the P(TMC-CL) surfaces as contributors for the CNS 
regeneration process, modulating microglia towards a pro-regenerative activity. 
 
Another contribute to the design of a multi-target strategy to promote axonal regeneration in the 
aftermath of a spinal cord injury (SCI) is to convert these three-dimensional (3D) structures into 
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drug delivery devices. By adding a drug to the electrospinning solution, drug-loaded fibres can be 
obtained. To tame the inflammatory response at the spinal cord lesion site, we explored the 
incorporation of a non-steroidal anti-inflammatory drug – ibuprofen – in P(TMC-CL) fibres. 
Ibuprofen-loaded P(TMC-CL) fibres were successfully prepared. The fibre formation process was 
optimized and by adjusting solvent mixture applied in the electrospun solution, it was 
demonstrated that fibre mean diameter can be tuned. The release of ibuprofen in vitro in sink 
conditions occurred in the first 24 hrs, being the released drug able to reduce the secretion of 
prostaglandin E2 by human-derived macrophages, pointing out that the drug bioactivity is 
maintained after the process. Furthermore, this study shows that ibuprofen-loaded P(TMC-CL) 
fibres can be applied as structures with anti-inflammatory properties.  
 
The use of ibuprofen in scaffolds to implant after a SCI enclosed, however, a double target 
strategy. If on the one hand, ibuprofen can reduce cyclooxygenase activity at the lesion site and 
consequently, might contribute to tame the inflammatory response [10]; on the other hand, 
ibuprofen has been described to limit RhoA-mediated axonal growth inhibition, improving 
functional recovery after SCI [11-13]. Consequently, we explored the effect of ibuprofen released 
from drug loaded P(TMC-CL) fibre on the RhoA pathway in neuronal cells. Foreseeing an 
application in vivo, we firstly created an ibuprofen-loaded bilayer scaffold composed by an outer 
layer based on a P(TMC-CL) solvent cast film and an inner layer made of preferentially aligned 
electrospun fibres to provide physical guidance cues for axonal regrowth. Here we report the 
preparation of the scaffold and its assessment both in vitro and in vivo. It was demonstrated that 
ibuprofen released from these bilayer P(TMC-CL) scaffolds is able to limit RhoA activation in 
neuronal cells when these are stimulated with lysophosphatidic acid. This result encouraged the in 
vivo testing of the prepared scaffolds. As proof-of-concept of the effect of ibuprofen released from 
the implanted scaffold on the RhoA pathway, a preliminary study using a dorsal hemisection SCI 
model was conducted. The ibuprofen-loaded P(TMC-CL) scaffolds were implanted immediately 
after the lesion and maintained during five days. So far, it was observed that the scaffold is 
suitable for implantation at the lesion site, wrapping the spinal cord tissue. No harmful effects were 
detected; particularly, the implantation of ibuprofen-loaded scaffolds showed to have no impact on 
animal survival rate. The analysis of the results of this study is currently in progress and will be 
paramount to determine whether this strategy can move forward to an extended study in order to 
understand if the early effects can have a consequence in axonal growth and functional outcome 
and to assess the contribution of P(TMC-CL) and fibre alignment in the process.  
 
An alternative to load scaffolds with biochemical cues is to use gene therapy-based strategies. 
The premise is that the release of nanoparticles containing genetic material can guarantee the 
long-term expression of proteins of interest in the spinal cord lesion site. Chitosan-based vectors 
were previously proposed as gene delivery vectors [14, 15]. In this regard, we firstly performed an 
extensive in vitro work on the characterization of chitosan-based vectors gene delivery, namely its 
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intracellular trafficking, degradation and time window of gene expression. We showed that these 
vectors mediate a long-term gene expression that can be modulated by adjusting chitosan 
degradation rate. 
 
In order to translate these knowledge into a 3D scaffold, we tested the incorporation of chitosan-
based nanoparticles in P(TMC-CL) fibres during the electrospinning process. However, it was not 
possible to obtain a homogeneous polymer solution that could allow the formation of fibres. As 
alternative, we proposed the use of trimethylated-chitosan based nanoparticles. This polymer has 
higher solubility and nanoparticle stability is improved. In preliminary tests we showed that 
P(TMC-CL) fibres containing nanoparticles can be obtained. The nanoparticle release profile and 
the bioactivity of the delivered gene wait for a more detailed study. Still, the preliminary tests 
presented in this thesis are encouraging indicating the feasibility of incorporating such 
nanoparticles as vectors for nucleic acid delivery within electrospun polymeric fibres. 
 
Overall, the work described in this thesis provides relevant knowledge that contributes to the 
design of a multi-target scaffold to be used as a therapeutic strategy in the context of a SCI. 
Engineering a permissive substrate for axonal regrowth by means of combining topography, 
ibuprofen and trimethyl-chitosan-based nanoparticles for gene delivery might constitute a 
successful approach towards nerve regeneration in the CNS.  
 
 
While this thesis reports major findings, some questions remain to be answered as well as 
additional ones can be raised. The more relevant points that remain to be addressed are 
described below. 
 
The detailed analysis of the tissues collected in the preliminary in vivo study performed is critical 
to determine the significance of the proposed strategy in a SCI scenario. The evaluation of RhoA 
activity in the tissues, and the characterization of the cellular populations at the lesion site can 
also provide new insights for future improvements on scaffold design. In particular, the drug 
loading or the drug release profile can be adjusted accordingly. The short-term study (5 days) 
performed only addresses the early effect of the released drug. To assess the contribution of 
P(TMC-CL) or fibre alignment on axonal growth and, ultimately, on functional recovery, the 
implantation of ibuprofen-loaded scaffolds for a longer period will be of remarkable importance.   
The second question that comes up from the reported work is whether one can prepare a scaffold 
that combines chitosan-based nanoparticles (vectorizing a therapeutic gene) with P(TMC-CL) 
fibres already loaded with ibuprofen. The combination of both gene and drug delivery strategies 
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would be a major achievement, and to tune timely the release of each, would certainly constitute 
the major challenge.  
 
Additionally, of remarkable interest in the context of this thesis is to investigate the effect of 
ibuprofen loaded P(TMC-CL) fibres on microglia, and to figure out how microglia response can be 
altered when using surfaces based on aligned fibres. 
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